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Preface 
 
This thesis is the compilation of published and unpublished work on the effects of HIV-1 
Nef on cellular trafficking pathways.  Nef removes a number of host proteins from the 
cell surface, interfering with antigen presentation and immune cell activation, resulting in 
evasion of the host immune system.  Nef directly promotes HIV-1 pathogenesis and is 
therefore an appealing target for therapeutic intervention. 
 
Chapter 1 is a discussion of the biological properties of HIV-1 Nef and Nef’s impact on 
HIV-1 pathogenesis.  We compare two competing models for the mechanism by which 
Nef reduces the surface expression of MHC-I and discuss the current evidence for the 
downmodulation of a variety of host factors by Nef.   
 
In Chapter 2, we analyze a panel of putative cellular targets of Nef.  We compare the 
relative impact of Nef on expression of each of these targets and assess the contribution 
of cellular trafficking machinery.  This work has been published as Leonard JA, Filzen T, 
Carter CC, Schaefer M, Collins KL.  “HIV-1 Nef Disrupts Intracellular Trafficking of 
Major Histocompatibility Complex Class I, CD4, CD8, and CD28 by Distinct Pathways 
That Share Common Elements.” J Virol. (2011) Jul;85(14):6867-81.  
 
In Chapter 3, we present data assessing the relative contribution of ARF-1 and ARF-6 in 
Nef-induced downmodulation of MHC-I.  Expression of a constitutively GTP-bound 
ARF-1 mutant revealed a requirement for ARF-1 in Nef-dependant MHC-I trafficking.  
 v 
 
Conversely, ARF-6 was found to be dispensable for the effects of Nef on MHC-I, as 
demonstrated in experiments with ARF-6 mutants or ARF-6 depletion.  These data have 
been submitted for publication and are currently in revision. 
 
In Chapter 4 we describe methods for a live cell flow-cytometric screen to identify 
chemical inhibitors of Nef-mediated MHC-I downmodulation.  We present preliminary 
findings from a screen of approximately 100,000 small molecules, in which we identified 
a small pool of Nef inhibitors for further development. 
  
Finally, Chapter 5 is a discussion of impact of the data presented in the previous chapters, 
as well as proposed future directions for additional mechanistic studies of Nef and for 
developing small molecule inhibitors of Nef for clinical use. 
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ABSTRACT 
 
Mechanisms by which HIV-1 Nef disrupts the intracellular trafficking of host 
proteins  
by 
Jolie A. Leonard 
Chair: Kathleen L. Collins 
The Nef protein is an important HIV virulence factor that promotes
 
the degradation of 
host proteins to augment virus production
 
and facilitate immune evasion. The best-
characterized targets
 
of Nef are major histocompatibility complex class I (MHC-I)
 
and 
CD4, but Nef also has been reported to target several other
 proteins, including CD8β, 
CD28, CD80, CD86, and CD1d. To
 
compare and contrast the effects of Nef on each 
protein, we
 
constructed a panel of chimeric proteins in which the extracellular
 
and 
transmembrane regions of the MHC-I allele HLA-A2 were fused
 
to the cytoplasmic tails 
of CD4, CD28, CD8β, CD80, CD86, and CD1d. We found that Nef coprecipitated with 
and disrupted
 
the expression of molecules with cytoplasmic tails from MHC-I
 
HLA-A2, 
CD4, CD8β, and CD28, but Nef did not bind to or alter the expression of molecules with 
cytoplasmic tails from
 
CD80, CD86, and CD1d. In addition, we used short interfering
 
RNA (siRNA) knockdown and coprecipitation experiments to implicate
 
adaptor protein-1 
(AP-1) as a cellular cofactor for Nef in the downmodulation of
 both CD28 and CD8β. 
The interaction with AP-1 required
 for CD28 and CD8β differed from the AP-1 
interaction required
 
for MHC-I downmodulation in that it was mediated through the
 
 xvii 
 
dileucine motif within Nef (LL164,165AA) and did not require
 
the tyrosine binding pocket 
of the AP-1 µ subunit. In
 
addition, we demonstrated a requirement for COP-I coatomer 
subunit β-COP as a cellular cofactor for Nef that was necessary for the degradation of 
targeted
 
molecules HLA-A2, CD4, and CD8. Additionally, we expressed ADP-
ribosylation factor (ARF) mutants to demonstrate a requirement for ARF-1, but not ARF-
6, in Nef-dependent downmodulation of MHC-I.  Finally, we developed cell-based, flow 
cytometric high throughput screening methods to identify a select group of chemical 
compounds which may be potent inhibitors of MHC-I downmodulation by Nef.  These 
studies provide important
 
new information on the similarities and differences between the 
ways in which
 
Nef affects intracellular trafficking of different host proteins and help 
focus future
 
research on the best potential pharmaceutical targets. 
1 
 
Chapter 1 
 
The effects of HIV-1 Nef on cellular proteins important for immune responses 
 
1.1. Overview 
This dissertation primarily pertains to HIV-1 Nef function.  Nef removes a variety of host 
proteins from the cell surface, disregulating immune signaling and activation.  However, 
conflicting reports exist regarding which proteins are targeted by Nef, and what 
mechanisms are involved.  In this chapter, the relevant background and current 
understanding of Nef function will be discussed.  Subsequent chapters will describe the 
development and employment of tools to directly compare the relative effects of Nef on 
various putative target proteins, and investigate trafficking factors and adaptor protein 
involvement.  Furthermore, this dissertation will explore methods for identifying 
chemical inhibitors of Nef, an appealing drug target due to the importance of Nef for 
HIV-1 pathogenesis.  
 
1.2. Summary of the HIV pandemic 
Despite major advances in research and treatment, the human immunodeficiency virus 
(HIV) continues to persist as a pandemic.  In 2009, an estimated 33.4 million people were 
living with HIV, including 2.1 million children.  There were 2.7 million new infections 
2 
 
and  2 million people died of acquired immunodeficiency syndrome (AIDS) (194). While 
great progress has been made in drug therapies that dramatically decrease mortality and 
prevent mother to child transmission, a cure for the disease remains an elusive goal and 
an effective, prophylactic vaccine is not yet in hand.   
 
1.3. Natural history of the untreated disease 
Following initial infection by HIV, a partially effective immune response reduces the 
viral load to an equilibrium level, or set point, the magnitude of which has prognostic 
significance with respect to how rapidly disease progression occurs  (137).  During a 
period of clinical latency, HIV preferentially infects and destroys activated CD4
+
 T 
lymphocytes, including those T cells that are HIV-specific, which eventually leads to a 
defective anti-HIV immune response (54).  Once the total CD4
+
 T cell count reaches 
<200 cells per microliter of blood, the clinical definition of AIDS, the immune system is 
functionally impaired  and HIV infected individuals  become susceptible to opportunistic 
infections, which are the primary cause of death from AIDS.   
 
1.4. The virus 
HIV-I is a retrovirus of the genus Lentivirus, a group of viruses that characteristically 
cause a chronic infection with a long incubation period and have the ability to replicate in 
nondividing cells.  Like all retroviruses, HIV-1 reverse transcribes its single-stranded  
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Figure 1.1.  HIV-1 Genome and Nef structure.  Schematic of HIV-1 genome. HIV-
1reading frames are shown to reveal HIV-1 genes and their relative genome locations. 
Open reading frames are shown as rectangular boxes. The spliced reading frames, tat and 
rev, are shown as boxes connected by lines.  Adapted from (205).  
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RNA (ssRNA) genome into a DNA intermediate prior to integration into the host cell 
genomic DNA.  Also typical of retroviruses, HIV encodes group-specific antigen (gag), 
polymerase (pol), and envelope (env) (Figure 1.1). (for review see (68), (86)).  Gag 
polyprotein is the major structural component of the viral capsid, and is necessary and 
sufficient for virus-like particle assembly (71).  Gag is processed into matrix, capsid, and 
nucleocapsid by the viral protease within nascent virions in the process of particle 
maturation.  Pol is also initially expressed as a polyprotein that is cleaved within newly 
budding virions into functional enzymes reverse transcriptase (RT), integrase, and 
protease.  Envelope (Env) is likewise expressed as a 160 kilodalton (kDa) polyprotein 
(gp160), which is cleaved by the viral protease into gp41 and gp120 within the Golgi of 
the infected cell.  gp120 directly interacts with CD4, the viral receptor, while gp41 is 
required for virus fusion with the host cell (115).  Additionally, HIV-1 Env has been 
demonstrated to directly reduce the surface expression of CD4 in order to prevent viral 
superinfection and enable viral particle assembly and release (17, 88, 113, 167). 
 
1.4.1 HIV-1 replication 
The HIV-1 lifecycle begins with binding of Env to the viral receptor, CD4, and co-
receptors, typically CCR5 or CXCR4 (Figure 1.2) (3, 44, 48, 64).  This ligation event 
induces a conformation change in Env and allows fusion with the cell membrane and 
release of the viral capsid into the cytoplasm (172).  In the cytoplasm, RT accesses the 
viral genome and begins transcribing the RNA into double-stranded DNA (11).  This 
DNA genome, along with RT, Vpu, matrix, and integrase form a pre-integration complex  
5 
 
 
 
 
 
Figure 1.2.  HIV Life Cycle.  1.  HIV Envelope binds to CD4 and co-receptor CXCR4 
or CCR5.  The virion fuses with the plasma membrane of the target cell and releases the 
RNA-containing capsid into the cytoplasm.  2.  The viral reverse transcriptase (RT) 
transcribes the single-stranded RNA (ssRNA) genome into double-stranded DNA 
(dsDNA).  3. The dsDNA genome is transported into the nucleus through a nuclear pore, 
where integrase mediates integration of provirus into the cellular genome.  The provirus 
may remain latent indefinitely.  4. Active infection results from the expression of viral 
mRNA and proteins.  5.  Viral proteins, along with two strands of viral ssRNA, assemble 
at sites of Gag multimerization at the plasma membrane.  The nascent virion buds and is 
then released from the plasma membrane.  6. Protease cleaves HIV polyproteins within 
the immature virion, inducing maturation into fully infectious HIV. 
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Figure 1.2.  HIV Life Cycle   
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(PIC) (23, 61, 62, 98, 100).  The PIC is translocated into the nucleus of the cell through a 
nuclear pore, where integrase mediates the insertion of viral DNA into the cellular 
genome, forming a provirus (22, 58).  Here, the provirus may remain latent in the absence 
of viral gene expression, or may engage in active infection.  During active infection, viral 
genes are transcribed into RNA for incorporation into virions as full-length viral 
genomes, or processed for subsequent translation of viral proteins.  Virion assembly 
occurs through the accumulation of HIV structural proteins Env and Gag at the plasma 
membrane, where Gag also associates with nascent RNA genomes (34, 95, 121, 170).  
Gag multimerization induces virion budding from the plasma membrane (191).  After 
scission of immature virions from producer cells, the HIV protease enzyme cleaves 
polyproteins Gag and Pol, which then reassemble into a mature, fully infectious virion 
(196). 
 
1.4.2 Accessory genes 
HIV is unique among retroviruses in that it has acquired accessory genes tat, rev, vif, vpr, 
vpu, and nef, which encode proteins that optimize viral fitness and spread in the host.  
HIV tat and rev promote transcription of the viral genome and nuclear export of viral 
RNA, respectively (for review see (146, 155)).  Tat binds to trans-activating response 
element (TAR) in the LTR to promote transcription elongation (99).  Rev binds to Rev 
Response Elements (RRE) in viral RNA transcripts to promote nuclear export and RNA 
stability and utilization.  The Vif protein counteracts the intrinsic antiviral factor 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G), a 
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cellular cytosine deaminase which hypermutates the viral genome during reverse 
transcription, resulting in attenuated or non-infectious virus.  Vif associates with a 
cellular ubiquitin ligase complex in order to target APOBEC3G for degradation (179).  
Similarly, Vpu also utilizes a cellular ubiquitin ligase complex to degrade cellular targets, 
including the viral receptor CD4 and the intrinsic antiviral protein tetherin.  Degradation 
of these targets allows more efficient budding of nascent virions (145).  The role of Vpr 
is not entirely clear, but it is known that Vpr induces a G2 mitotic arrest in infected cells 
(12), a state which favors transcription from the HIV-1 LTR (73).  Recent data indicate 
that Vpr associates with a cellular ubiquitin ligase complex to degrade cellular factors 
that may otherwise inhibit viral infection and/or spread in the host (for review see (55, 
110)).  Finally, the viral accessory protein Nef is a multifunctional protein that disrupts 
intracellular signaling and trafficking pathways to favor viral infection and spread.  Nef 
has the well-characterized ability to alter the intracellular trafficking of major 
histocompatibility complex proteins class I and II (MHC-I and MHC-II) and CD4, and 
has also been reported to affect the trafficking of a variety of other cellular proteins, such 
as CD28, and CD8 (69, 120, 178, 183, 184, 187).  Nef is important for viral fitness and 
persistence, and mediates immune evasion by HIV (139, 140). 
 
1.5 HIV-I Nef 
The importance of Nef in viral pathogenesis is highlighted by a cohort of blood 
transfusion recipients exposed to an HIV-I strain that contained a large deletion within 
the nef gene as well as the long terminal repeat (LTR), but not affecting any of the major 
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promoter elements in the LTR (47, 118).   Three decades after exposure, and in the 
absence of anti-retroviral treatment, half of the patients demonstrated delayed progression 
to CD4 T cell loss or AIDS (19).  These patients are termed long term non-progressors 
(LTNPs), while the other patients in the cohort maintain undetectable viral loads and are 
categorized as elite controllers (74, 75).  Thus, Nef is required for maximal pathogenic 
potential. 
 
More direct evidence for the requirement for Nef in HIV-induced immune collapse has 
been revealed through non-human primate research.  Rhesus macaques infected with a 
Nef-deleted ( nef) strain of simian immunodeficiency virus (SIV) did not progress to 
AIDS (105).  The combination of non-human primate research and longitudinal patient 
cohort studies has revealed the requirement for Nef in progression from HIV disease to 
AIDS.   
 
Nef is a multifunctional adaptor protein which is known to disrupt intracellular 
trafficking of host proteins, activate cellular kinases, and enhance virion infectivity.  As 
mentioned, one of the primary physiological roles of this protein is the downregulation of 
cell surface receptors such as MHC-I and CD4 from the cell surface.  Nef accomplishes 
this by interacting with a multitude of endogenous trafficking and signaling proteins.  
This dissertation will focus on the effects of Nef on the trafficking and expression of a 
variety of cellular proteins significant to immune recognition and signaling. 
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1.6 Nef disrupts antigen presentation to cytotoxic T lymphocytes 
CD8
+
 cytotoxic T lymphocytes (CTLs) are important for the control of chronic viral 
infections.  The T cell receptor (TCR) in conjunction with CD8, another reported target 
of Nef downmodulation, is capable of distinguishing between “self” and “non-self” 
peptide antigens presented by MHC-I on the cell surface (Figure 1.3).  Normal cellular 
peptides typically do not activate a CTL response.  However, in a virally infected cell, 
MHC-I molecules also present peptides derived from viral proteins (“non-self” peptides).  
In response to the recognition of  a “non-self” signal presented by MHC-I, the CTL 
releases perforins and granzymes that kill the virally infected cell, preventing further 
spread of the virus (reviewed in (18)).   
 
There is a great deal of evidence that CTLs play an important role in the control of HIV 
infection (for review see (38)).  For example, individuals mounting a Gag-specific CTL 
response have improved parameters with regard to controlling disease (70, 106).  Despite 
the efficacy with which CTLs control viral load early in infection, in most individuals, 
anti-HIV CTLs ultimately fail to prevent progression of disease. There is evidence that 
antigenic variation, viral effects on CTL differentiation, viability, proliferative capacity 
and function influence the ability of CTLs to control HIV infection.  However, this 
chapter will focus on the effect of HIV Nef on the trafficking of cellular proteins that 
influence CTL activation. 
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Figure 1.3. Presentation of Antigen to Cytotoxic T Lymphocytes.  Intracellular 
peptide antigens are generated through protealytic cleavage and transported into the 
endoplasmic reticulum (ER) through transporter associated with antigen processing 
(TAP).  Immature MHC-I is loaded with peptide antigen within the ER and then proceeds 
through the Golgi to the plasma membrane (PM).  There, peptide-loaded MHC-I will 
bind to the T cell receptor (TCR) of CD8+ cytotoxic T lymphocytes (CTLs) for 
recognition of self or non-self antigen.  Foreign antigen in the context of MHC-I will 
activate the cognate CTL to lyse the presenting cell.  Adapted from (205). 
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While Nef expression is required for viral spread and pathogenesis in vivo, it is not 
necessary for production of infectious virus in vitro and, in fact, is quickly lost in culture.  
Therefore, it is clear that Nef functions to antagonize the host immune response.  It was 
first observed that MHC-I cell surface expression is reduced in HIV-1-infected cells, and 
this activity was subsequently attributed to HIV-1 Nef (178).   Functional significance 
was provided by a study which demonstrated that HIV-1-infected peripheral blood 
mononuclear cells (PBMC) expressing Nef were rescued from anti-HIV CTL lysis as 
compared to PBMC infected with a nef variant of HIV-1 (39).  This work was the first 
to directly demonstrate that Nef downmodulates MHC-I molecules to allow HIV-1-
infected cells to evade detection and lysis by CTLs. 
 
Additional studies in which killing of HIV-infected cells was directly compared plus or 
minus Nef expression have supported the conclusion that Nef protects infected cells from 
CTL-mediated lysis (37, 122, 189, 207).  Nef has been shown to protect HIV-infected 
primary T cells from CTL lysis using flow cytometric killing assays (37, 122), CTL co-
culture assays (207) and chromium release assays (189).  Although Nef limits the ability 
of CTLs to recognize and kill infected cells, it does not appear to abrogate the capacity of 
CTLs to produce inhibitory cytokines in response to infected cells (189).  Recent in vivo 
evidence supports the hypothesis that CTLs may control HIV infection in vivo primarily 
by the elaboration of inhibitory cytokines, but fail to eradicate the infection because the 
CTLs cannot efficiently lyse the infected cell source of new virions (206). 
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Based on in vivo studies, it is known that progression to AIDS is delayed in the absence 
of an intact nef gene in most humans and monkeys (46, 105, 111). However, Nef has 
multiple functions including CD4 downmodulation and kinase activation; therefore these 
studies do not prove an important role for Nef-mediated MHC-I downmodulation 
specifically in vivo.  To address this point, several studies have used SIV systems to 
demonstrate that the capacity to downmodulate MHC-I is selected for in vivo (26, 142, 
186).    In addition, it was recently demonstrated that the ability of in vivo-derived Nef to 
down-regulate MHC-I predicted the resistance of HIV-1 to suppression by CTL in vitro 
(123).  Taken together, these data demonstrate that the ability of Nef to down-regulate 
MHC-I in vivo is maintained by the selective pressure for HIV-1 to evade  the antiviral 
CTL response. 
 
1.6.1 Natural killer cells 
Many viruses, HIV-1 included, have evolved strategies to reduce MHC-I expression in 
order to evade CTL recognition by their hosts.  As a countermeasure, host natural killer 
(NK) cells monitor the overall surface levels of MHC-I.  Low expression of MHC-I can 
activate NK cells to lyse target cells.  In order to evade NK cell detection, Nef selectively 
downmodulates some MHC-I allotypes, while allowing others to remain on the cell 
surface. 
 
There are three classical MHC-I genes expressed by all nucleated cells in humans; HLA-
A, HLA-B and HLA-C.   These genes are highly polymorphic and hundreds of alleles of 
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each have been identified.   HLA-A and HLA-B are the primary allotypes that present 
antigens to CTLs, whereas HLA-C may function primarily to regulate NK cell function.   
In addition, a non-classical MHC-I called HLA-E, which does not commonly present 
antigens to CTLs also inhibits NK cell function (reviewed in (144)).   
 
Nef has been shown to directly interact with an amino acid sequence (Y320SQAASS326) 
present in the cytoplasmic domain of HLA-A and HLA-B molecules (203).   This 
interaction is necessary for Nef-dependent downmodulation of MHC-I molecules (35, 
117, 203). In contrast, HLA-C and HLA-E have amino acid variations within this domain 
(35, 117, 203) and thus remain unaffected by Nef.  It has therefore been proposed that 
Nef selectively downmodulates a subset of MHC-I molecules to evade CTL killing 
without activating NK cell lysis.  However, recent evidence demonstrating that HLA-C is 
expressed at very low levels on primary T cells suggests that additional mechanisms may 
be necessary to fully explain HIV evasion of NK cells (175). 
 
1.6.2. Functional domains required for Nef to downmodulate MHC-I 
Though small (25 kDa), Nef is structurally complex, containing numerous protein-protein 
interaction domains that mediate associations with a variety of host proteins (Figure 1.4).  
Nef can be divided into the N-terminal anchor domain, the core domain, and the C-
terminal flexible loop.  The N-terminal anchor domain and C-terminal flexible loop are 
relatively disordered, making structural analysis of the full length protein difficult.  
However, structures have been solved separately for the core domain by X-ray  
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Figure 1.4.  Functionally important Nef domains.  (A) Domains in Nef that are 
pertinent to reducing the surface expression of cellular targets.  Adapted from (205).  (B) 
Table of Nef domains that are required for the downmodulation of the indicated 
molecules.  A “+” indicates that a domain is required, while a “-” indicates that a domain 
is dispensible. 
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crystallography and nuclear magnetic resonance (NMR), and for the N-terminal anchor 
with NMR spectroscopy (7, 67, 79, 119). These structural data were combined to 
assemble a model for the conformation of full length Nef.  The result predicts that the 
flexibility of Nef allows for exposure of numerous protein-protein interaction domains, 
regulated by multiple conformations that may depend on intracellular localization and 
binding partners (7). 
 
Two sites in Nef are required for most of the functions of Nef.  First, Nef is myristoylated 
at the glycine residue at position 2, which allows Nef to bind the inner leaflet of the 
plasma membrane (60). In addition, an aspartic acid at position 123 (D123) is required to 
form homodimers of Nef (126).  If either of these sites is mutated (G2A or D123G), Nef is 
inactive for nearly all of its functions.   
 
The three structural elements of Nef that are required for MHC-I downmodulation are 
contained within the N terminal anchor or core domains.  They are an N-terminal a-
helical domain (R17ERM20RRAEPA26 and specifically M20) (2, 133), an acidic cluster 
(E62-65) , and a polyproline repeat (P72/75/78).  These motifs are required for Nef to bind to 
the cytoplasmic tail of MHC-I (202) and for Nef to downmodulate MHC-I  (77, 133).   
The C-terminal loop of Nef contains a number of trafficking signals capable of binding 
adaptor proteins, a coatomer protein, and a vacuolar ATPase (for review see (164)).  
However, the C-terminal loop of Nef is only active against other Nef targets, such as 
CD4 (133), suggesting that there are structural constraints that limit the ability of the C-
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terminal loop to recruit trafficking factors when Nef is bound to MHC-I with its natural 
conformation. 
 
1.6.3 Candidate host factors that partner with Nef to downmodulate MHC-I 
 
1.6.3.1. Adaptor protein complexes 
Nef is reported to interact with a variety of cellular trafficking factors, including the 
clathrin-associated adaptor proteins.  Clathrin-coated vesicles transport cargo from the 
trans-Golgi network (TGN), plasma membrane, or endosomal network.  Clathrin-
associated adaptor proteins (APs) are composed of four subunits: two large subunits ( 1 
or 2 and AP-1 , AP-2 , or AP-3 ), one medium subunit ( ), and one small subunit ( ) 
(161, 162, 190).  The four subunits combine to function as a heterotetrameric adaptor 
complex that recognizes Yxx  (Y, tyrosine; , bulky hydrophobic amino acid; x, any 
amino acid) and [D/E]xxxLL (D, aspartic acid; E, glutamic acid; L, leucine) sorting 
signals and recruits clathrin coats.  AP-1 transports proteins between the trans-Golgi 
network and endosomes (52, 112, 197).  AP-2 localizes to the plasma membrane and is 
necessary for internalization of some types of cargo into endosomes (190).  AP-3 
localizes to endosomes and is thought to transport proteins into acidic, degradative 
compartments (151).   
 
Recent structural studies have provided confirmation that clathrin adaptor proteins have 
physically separate signal-recognition sites for Yxx and [D/E]xxxLL motifs.  The μ 
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subunit contains a tyrosine binding pocket (TBP) and a hydrophobic binding pocket, 
which recognize Yxx  signals (149).   In contrast, a hydrophobic pocket in the 2 subunit 
plus a positively charged patch made from residues in both the 2 and  subunits 
combine to form the recognition site for  [D/E]xxxLL motifs (104).   
 
Yeast two-hybrid assays initially revealed that HIV Nef’s C-terminal dileucine motif 
(LL164,165) interacts with the subunit of AP-1 and AP-3 (21, 40, 42, 59, 76, 90, 92, 117, 
152).  However, consistent with the structural analysis described above, a much more 
robust interaction occurs between Nef’s dileucine motif and hemicomplexes composed of 
 and  or subunits (30, 53, 92).  Recent data suggest that a robust interaction 
between the  subunit of AP-1 and Nef also occurs, but only when Nef is bound to the 
MHC-I cytoplasmic tail.  In this case, the MHC-I cytoplasmic tail provides the tyrosine 
residue necessary for binding to the AP-1 1 subunit tyrosine binding pocket (147, 165, 
181, 204). 
 
1.6.3.2. ADP-ribosylation factors 
In addition to the clathrin-associated adaptor proteins, the small GTPases, ADP-
ribosylation factors (ARFs), are important for cellular control of assembly and 
disassembly of various intracellular trafficking complexes (10, 97).  ARFs are important 
for clathrin dependent (50, 148, 150, 163) and clathrin independent (188, 198) trafficking 
pathways.  ARF activation and recruitment to cellular membranes is regulated by its 
guanine nucleotide exchange factors (GEFs), which are required for the recruitment of 
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GTP to ARF and are necessary for the maintenance of overall Golgi structure ((85, 89) 
and reviewed in (51)). Conversely, GTPase-activation proteins (GAPs) promote GTP 
hydrolysis, thus inactivating ARFs (193).  
 
ARF-1 is a clathrin regulatory protein that recruits AP-1 or coat protein complex-I (COP-
I) coatomers (9). In studying AP-1 involvement in Nef biology, it was observed that 
functional ARF-1 is required for recruitment of AP-1 by Nef (36).  Additionally, an 
interaction between Nef and -COP, which promotes degradation of internalized CD4, 
also requires ARF-1. Interestingly ARF-1 does not need to be in the activated GTP bound 
state for this interaction to occur (63). 
 
There is also evidence that activation of ARF-6, a regulator of clathrin independent 
trafficking, by a Nef-dependent multi-kinase cascade induces MHC-I endocytosis (Figure 
1.5) (20, 28, 87).  This is consistent with normal ARF-6 biology, as ARF-6 localizes to 
the plasma membrane and is involved in clathrin-independent endocytosis and recycling 
(158).  ARF-6 is regulated by ARF nucleotide binding site opener (ARNO), an ARF-6 
GEF that is activated and recruited to the plasma membrane by PI3-kinase (195).  There 
is evidence that overexpression of ARF-6 and ARNO mutants alters the intracellular 
localization of MHC-I in Nef-expressing HeLa cells (20). This mechanism is discussed in 
detail below.  
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Figure 1.5.  Endocytic model of MHC-I downmodulation by Nef.  Nef binds to 
PACS-2 resulting in translocation to the trans-Golgi network (TGN).  At the TGN, Nef 
activates a Src family kinase (SFK), which in turn phosphorylates ZAP-70.  This 
signaling event activates phosphoinositide-3-kinase (PI3K), resulting the generation of 
PIP3.  PIP3 recruits and activates a guanine exchange factor, ARNO, which subsequently 
recruits and activates ARF-6, inducing clathrin-independent endocytosis of MHC-I.  Nef 
then binds to AP-1, and this interaction is responsible for transporting MHC-I from 
endosomes to the TGN.  Adapted from (205). 
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1.6.3.3. -COP 
-COP is a component of COP-I coatomer complexes.  COP-I and COP-2 coatomers are 
involved in normal protein trafficking within the Golgi and ER (169, 176) and have also 
been found associated with low pH endosomes in an ARF-1-dependent manner (5, 82). 
These COP-I coatomers are implicated in recycling endosome function (45) and in 
transport from the endolysosomal network into multivesicular bodies (81).   
 
The interaction of Nef with -COP was also discovered using a yeast two-hybrid screen 
(15).  This interaction was found to require the diacidic motif (EE155, 156) in the C-
terminal loop domain of Nef and to result in targeting internalized CD4 to degradative 
compartments. (63, 153, 174).  RNAi directed against -COP, as well as another member 
of the COP-I complex, -COP, was reported to inhibit CD4 downmodulation and 
degradation by Nef, further supporting the involvement of the COP-I complex in Nef-
dependent trafficking (30, 174).   
 
1.6.4.  Downmodulation of MHC-I:  endocytic mechanism 
Although Nef-dependent downmodulation of MHC-I has long been the subject of intense 
study, the mechanism by which this occurs is not entirely clear.  In fact, two competing 
models have been proposed; in the first, Nef stimulates endocytosis of MHC-I at the 
plasma membrane.  In the second model, Nef inhibits the transport of newly synthesized 
MHC-I.  Both models are evaluated here. 
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Initial studies examining the effects of Nef on MHC-I trafficking in T cell lines revealed 
that the rate of MHC-I synthesis and trafficking through the ER and cis-Golgi is 
unaffected by Nef, but that MHC-I stability over time is decreased through lysosomal 
degradation (cited as data not shown (177).  Furthermore, Nef causes an accumulation of 
MHC-I in juxtanuclear and endosomal compartments and enhances the rate of 
endocytosis in some cell types (for review see (164)). Normally, T lymphocytes and 
macrophages spontaneously internalize and recycle MHC-I back to the plasma membrane 
at high rates in an AP-2 dependent manner (131, 192).  However, in Nef-expressing cell 
lines, over-expression of a dominant negative dynamin, a protein that mediates scission 
of clathrin vesicles, (29, 116, 185) or a dominant negative mutant subunit of AP-2 (20) 
did not affect Nef-induced MHC-I endocytosis suggesting this process could be clathrin 
and AP-2 independent.  It has also been demonstrated that Nef does not affect the rate of 
MHC-I recycling in HeLa cells or CEM SS T cells (101). More recently it was shown 
that a dominant negative dynamin reduced Nef-induced MHC-I downmodulation in 
primary T cells from about 50% in this assay system to approximately 25% (208) 
indicating that clathrin-dependent endocytosis cannot fully account for MHC-1 
downmodulation. Furthermore, Greenberg et al determined that MHC-I co-localizes with 
AP-1, but not AP-2 in Nef-expressing cells (77), arguing against an AP-2-dependent 
internalization pathway.   
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Alternatively, there is evidence for an ARF-6-dependent, clathrin-independent pathway 
by which Nef affects MHC-I in some cell types (Figure 1.5).  This mechanism relies on 
an interaction between the acidic cluster E62-65 in Nef and phosphofurin acidic cluster 
sorting proteins (PACS-1 and PACS-2) (154).  Antisense to hPACS-1a increases steady 
state MHC-I surface expression in Nef-expressing cells by about 20% and redistributes 
the intracellular localization of MHC-I in A7 astrocytic cells.  Another group confirmed 
that knockdown of PACS-1 inhibited Nef-induced MHC-I downmodulation in HeLa cells 
(but not Jurkat T cells) (208).   Based on these data a model was proposed in which Nef 
physically recruits MHC-I and links it to a PACS-1 based TGN retrieval pathway (154). 
This model was later modified to indicate that PACS-2 was more important for 
translocation of Nef to the TGN (8).  Once at the TGN, Nef is proposed to bind to and 
activate a src family kinase (SFK), such as Hck, through Nef’s polyproline motif, 
P72/75/78, which is a Src homology 3 (SH3)-binding domain.  The active SFK then triggers 
a signaling cascade by binding to and phosphorylating tyrosine kinase ZAP70, which in 
turn enables ZAP70 to activate phosphoinositide 3-kinase (PI3K) (87).  PI3K activity 
generates phosphatidylinositol (3,4,5)-triphosphate (PIP3), which results in ARNO 
recruitment to the plasma membrane and activation.  There is evidence that 
overexpression of ARF-6 and ARNO mutants alters the intracellular localization of 
MHC-I in Nef-expressing HeLa cells and that overexpression of Nef and PACS-1 in A7 
cells increases PI3-kinase-dependent GTP loading of ARF (20). A relatively small effect 
(approximately two fold) of a dominant negative ARF-6 mutant was noted in primary T 
cells when pan-MHC-I antibodies were used (208).  These antibodies recognize all 
MHC-I allotypes, including those that are unaffected by Nef and thus small effects of Nef 
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are usually detected.  ARF-6 activation is proposed to result in clathrin-independent 
endocytosis of MHC-I and accumulation in the Golgi in a mechanism that depends upon 
AP-1 and M20 within the alpha helical region of Nef (20, 28). 
 
1.6.5 Evidence against an endocytic mechanism 
Arguing against an important role for PACS proteins are data from investigators who 
reported no effect of knocking down PACS-1 on Nef-induced downregulation of MHC-I 
HLA-A2, or on the localization of other proteins containing acidic cluster motifs, in 
HeLa cells (127). Additionally, Baugh et al were unable to demonstrate a significant 
interaction between the acidic cluster in Nef and the PACS-1 furin binding region (13), 
and mutating three of the four glutamates in the acidic cluster decreased Nef’s effects on 
MHC-I by only 50% (13).  Chemical inhibitors of SFKs, Src knockdown, and expression 
of dominant negative Src all failed to inhibit Nef-dependent downmodulation of MHC-I 
in U937 monocytic cells, arguing against an important role for SFKs in this pathway (29).  
Overexpression of a GTP-locked ARF-6 mutant (ARF-6 Q67L) is reported to alter the 
intracellular localization of MHC-I in Nef-expressing HeLa cells (20).  However, 
mutation of an additional residue in ARF-6 (ARF-6 N48I,Q67L) prevents phospholipase D 
activation, an effector required for endosomal membrane recycling (96), but had no effect 
on MHC-I downmodulation  in Jurkat T cells (114).   Furthermore, inhibition of PI3-
kinase, had no effect on the internalization step in U373mg astrocytoma cells (114).  
Instead, other investigators provided evidence that PI3-kinase inhibitors affected 
localization of intracellular MHC-I to the TGN in Nef-expressing U373mg astrocytoma 
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cells (114, 185).  Therefore, an alternative mechanism of MHC-1 downregulation by Nef 
has been proposed, as discussed below. 
.  
1.6.6. Downmodulation of MHC-I: evidence for targeting of newly synthesized 
protein in the secretory pathway 
1.6.6.1. Disruption of MHC-I transport 
A dramatic effect of Nef on MHC-I is required for HIV-infected primary T cells to 
effectively evade anti-HIV CTLs (up to a 300-fold reduction (cited as data not shown 
(37)). The degree of MHC-I downmodulation in HeLa cells (2-4 fold reduction (20) is 
small relative to the effect of Nef on an endogenous MHC-I allotype (HLA-A2) in HIV-
infected primary T lymphocytes (37).  Thus, the internalization pathways described 
mainly in HeLa cells may not fully explain the intracellular trafficking required for the 
maximal effect of Nef necessary for HIV immune evasion in T cells. Indeed, direct 
comparison of Nef activity in HeLa versus T cell lines revealed striking differences in the 
degree of MHC-I downmodulation (101).   
 
Most viruses that disrupt antigen presentation target newly synthesized MHC-I rather 
than “old” MHC-I at the cell surface because the newly synthesized molecules harbor 
viral antigens present at the time of infection.  For example, Herpes Simplex Virus, 
Human Cytomegalovirus, Epstein-Barr Virus, and Adenovirus all encode proteins that 
block peptide translocation into the ER, target nascent MHC-I for degradation, induce ER 
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retention of peptide-loaded MHC-I, or  prevent transport of MHC-I to the plasma 
membrane (for review see (83)).  Older MHC-I molecules are likely to be presenting 
cellular antigens, which are present prior to infection, and therefore would not be a threat 
to the virus.  In fact, MHC-I loaded with cellular antigens would be protective against 
NK cell recognition.   
 
In Nef-expressing cells, reports of MHC-I localizing to the trans-Golgi and AP-1-
containing vesicles suggested that Nef could be directly disrupting MHC-I trafficking at 
the trans-Golgi network to prevent nascent MHC-1 from presenting new antigens rather 
than only affecting MHC-I after it had reached the cell surface (Figure 1.6).  The first 
study supporting this model examined the effect of Nef on an HLA-A2-GFP fusion 
protein in U373mg astrocytoma cells (185). In this series of experiments investigators 
utilized a temperature block (20
o
C )  to prevent TGN exit and to allow accumulation of 
MHC-I in the TGN. When cells were subsequently shifted to 37
o
C, MHC-I could be 
detected by microscopy at the cell surface within 15 minutes, whereas in Nef-expressing 
cells MHC-I remained within a juxtanuclear compartment (185).  Biochemical 
experiments examining the transport of newly synthesized MHC-I to the cell surface in T 
cell lines confirmed that there was a dramatic effect of Nef on the transport of MHC-I to 
the cell surface.  Moreover, the effect of Nef on transport of newly synthesized MHC-I 
was much greater than its effect on MHC-I internalization (101).   An effect of Nef on 
intracellular transport of endogenous MHC-I HLA-A2 was confirmed in HIV-infected 
primary T cells (101).   PI3-kinase inhibitors did not reduce the ability of Nef to disrupt  
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Figure 1.6.  Newly synthesized MHC-I is targeted for degradation by Nef. Nef binds 
to the cytoplasmic tail domain of MHC-I in the Golgi network.   Nef recruits AP-1 to the 
complex at the TGN, resulting in routing of MHC-I into endocytic compartments.  
Subsequent recruitment of -COP targets MHC-I into endolysosomal compartments.  Nef 
binds to the cytoplasmic tail of CD4 at the plasma membrane and recruits AP-2, inducing 
rapid CD4 internalization.  Subsequent recruitment of -COP results in the convergence 
of MHC-I and CD4 into Rab7
+
 late endosomes or multivesicular bodies (MVBs) for 
eventual lysosomal degradation.  Adapted from (205). 
 
 
 
  
28 
 
 
 
 
 
Figure 1.6.  Newly synthesized MHC-I is targeted for degradation by Nef 
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MHC-I transport to the cell surface as measured by a one hour biochemical assay but the 
investigators could not rule out an effect of PI3-kinase on the intracellular localization of  
retained MHC-I molecules (101) as was subsequently proposed (114).   
 
Additional evidence in favor of a transport block are studies in which Nef was found to 
associate with immature forms of MHC-I (102).  The HLA-A2 cytoplasmic tail is 
phosphorylated at specific serines upon exiting the TGN (57).  Interestingly, Nef 
preferentially binds immature, hypophosphorylated forms of HLA-A2 and inhibits 
phosphorylation of the MHC-I cytoplasmic tail (102).  Based on these data it was 
proposed that Nef binds MHC-I very early in the secretory pathway (102).  In support of 
this model, a recent study was able to observe a Nef-CFP fusion protein in complex with 
a subset of HLA-A2-Venus in the ER as well as in the Golgi and at the plasma membrane 
of HeLa cells using two photon two color fluorescence cross correlation spectroscopy 
(208).  However, there was no detectable effect of Nef on MHC-I transport until MHC-I 
reached the trans-Golgi apparatus, thus binding to Nef was not sufficient for disruption of 
MHC-I trafficking (102, 165) (Figure 1.6). 
 
1.6.6.2. AP-1 is required for disruption of antigen presentation by HIV Nef 
Because AP-1 is a clathrin adaptor protein that acts at the TGN and because Nef had been 
reported to interact with AP-1, it was hypothesized that Nef might disrupt post-TGN 
transport of MHC-I by promoting an interaction between MHC-I and AP-1. Indeed, 
RNAi directed against the AP-1 1 subunit inhibited downmodulation of endogenous 
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HLA-A2 in U373mg astrocytoma cells and exogenous HLA-A2 expressed in CEM-SS T 
cells (120, 165, 174, 204).  Furthermore, siRNA directed against AP-1 1 also inhibited 
Nef-induced downmodulation of MHC-I in HeLa and Jurkat cell lines, as well as in 
primary T lymphocytes (208). 
 
Consistent with these observations, AP-1 co-precipitated with Nef and endogenous HLA-
A2 from lysates made from HIV infected primary T cells  (165).  In contrast, complexes 
of Nef-MHC-I and AP-1 were not detected in HeLa cells unless the cells were incubated 
at room temperature overnight.  Further experiments revealed that temperature reduction 
decreased the rate of MHC-I trafficking sufficiently to allow the Nef-MHC-I-AP-1 
complex to form.  For unclear reasons, T cells naturally traffic MHC-I at slower rates and 
lower incubation temperatures do not change the ability of Nef to form this complex 
(102).   These data help explain why investigators that focused on non-T cell lines did not 
detect this pathway.  
 
1.6.6.2.1. Nef stabilizes an interaction between the AP-1 tyrosine binding pocket and 
the MHC-I cytoplasmic tail  
Yeast two-hybrid interaction assays and microscopic analyses provided evidence that 
interactions between Nef and the adaptor proteins AP-1 and AP-3 depend on Nef’s 
dileucine motif (21, 40, 42, 59, 76, 90, 92, 152).  In contrast, MHC-I downmodulation 
and AP-1 recruitment in T cell systems do not require these amino acids   (77, 165, 202).  
Thus, the complex between Nef-MHC-I and AP-1 most likely occurred independently of 
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the dileucine motif and involved a separate AP-1 binding domain.  Indeed, it was 
demonstrated that the MHC-I cytoplasmic tail mediates a key interaction between the 
Nef-MHC-I complex and AP-1 (165).  The tyrosine in the MHC-I cytoplasmic tail does 
not form a canonical Yxx  AP-1 sorting signal and does not bind AP-1 in T cells in the 
absence of Nef.  Remarkably , Nef binding to the cytoplasmic tail provides the necessary 
elements for this non-canonical tyrosine signal to function as a potent AP-1 binding motif 
(165).  Providing further support for the model that Nef stabilizes an interaction between 
the AP-1  tyrosine-binding pocket (TBP) and the tyrosine residue in the MHC-I 
cytoplasmic tail, it was shown that a dominant negative mutant of AP-1 1 that had two 
amino acid substitutions in the tyrosine binding pocket (TBPM) dramatically and 
specifically inhibited Nef-mediated  MHC-I downmodulation (204).  
 
1.6.6.2.2. Nef domains and AP-1-dependent MHC-I trafficking 
All of the domains of Nef  that are  required for MHC-I downmodulation are also 
required for Nef to interact with the MHC-I cytoplasmic tail (202).  To determine 
whether some of these domains might also be important for recruitment of AP-1, a fusion 
protein between MHC-I and Nef was examined (165).  These studies confirmed that the 
MHC-I cytoplasmic tail tyrosine was required for AP-1 recruitment and that Nef’s 
dileucine motif was dispensable for this interaction (165, 204). In this system, the acidic 
cluster (E62-65) and  polyproline helix (P72/75/78) of Nef were dispensable for AP-1 
recruitment as long as a chemical crosslinker was used (165). However, when a digitonin 
detergent based buffer that lacked crosslinker was substituted, a requirement for these 
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domains to optimally stabilize the interaction between AP-1 and MHC-I was noted (204). 
In addition, the N-terminal -helix and specifically M20, were required for AP-1 
recruitment under all conditions tested (165, 204).   
 
Experiments using purified Nef-MHC-I cytoplasmic tail fusion proteins and either whole 
AP-1 complexes from crude lysates or purified 1 subunit support the conclusion that 
Nef stabilizes an interaction between the MHC-I cytoplasmic tail and the AP-1 1 
subunit. Moreover, these experiments provide evidence that the polyproline helix and the 
acidic domain within Nef are needed for Nef to stabilize the interaction between the AP-1 
-1 subunit and the MHC-I cytoplasmic tail domain.  In the pure protein system, 
formation of a complex between the Nef-MHC-I cytoplasmic tail fusion protein and the 
AP-1 1 subunit also required an intact tyrosine binding pocket in the AP-1 1 subunit.  
However, no role for Nef M20 was identified and thus this amino acid, although required 
for Nef-induced MHC-I downmodulation, may not be directly involved in protein-protein 
interactions but may serve another role in intact cells (181).  Therefore, at least three Nef 
domains are required for AP-1 recruitment and subsequent downmodulation of MHC-I in 
Nef expressing cells (165, 204). 
 
1.6.6.3.  A role for -COP in disruption of antigen presentation by Nef 
Although the experiments described above provide evidence that Nef recruits AP-1 to 
reroute MHC-I into the endosomal network (165) (Figure 1.6), it remained unclear how 
33 
 
Nef promoted accelerated degradation of MHC-I (165, 177).  However, prior reports had 
determined that Nef accelerated the degradation of internalized CD4 through an 
interaction between Nef and -COP.  Interestingly, MHC-I and internalized CD4 co-
localize in Rab7
+ 
late endosomes in Nef-expressing cells (174, 208) and RNAi against -
COP disrupts Nef-dependent degradation of both MHC-I and CD4 (174).  Recent studies 
have shown that two distinct domains in Nef recruit -COP, thus clearing up 
discrepancies in binding data found in previously published literature (63, 91, 124, 153).  
An arginine rich domain in the N-terminal alpha helix of Nef (R17XR19) mediates -COP 
binding and MHC-I degradation, whereas a diacidic motif (EE155, 156) in the C-terminal 
flexible loop of Nef mediates -COP binding and CD4 degradation. (153, 174).  The 
inability of Nef to utilize sequences within the C-terminal loop to affect MHC-I 
downmodulation or to use sequences within the N-terminal alpha helix to affect CD4 
downmodulation support the notion that there are important structural differences 
between Nef molecules bound to the MHC-I cytoplasmic tail and Nef bound to the CD4 
tail.   
 
1.6.7. Summary of MHC-I downmodulation 
In sum, a consensus is starting to emerge regarding which host factors are required for 
Nef to disrupt antigen presentation in HIV infected cells.   There is broad agreement 
among investigators that the cellular clathrin adaptor protein AP-1 is necessary for Nef to 
disrupt MHC-I trafficking in a wide variety of cell types (49, 127, 165, 174, 204, 208).   
Additionally, there is agreement that three Nef domains are required (acidic, polyproline 
and N-terminal alpha helix, including M20A) for Nef-induced MHC-I downmodulation 
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(20, 77, 133, 147, 165, 181, 202, 204).  There are data from two separate groups 
indicating that a three-way complex forms, which contains Nef, MHC-I and AP-1 
proteins and that this complex can be detected in lysates from HIV infected primary T 
cells and in purified protein reactions (165, 181).  At least two of the three required Nef 
domains plus the MHC-I cytoplasmic tail, including the tyrosine at position 320, are 
directly needed for formation of the Nef-MHC-I-AP-1 complex (147, 165, 181, 204).  
Moreover, there is a consensus that a functional tyrosine binding pocket in the AP-1 1 
subunit is needed for formation of the Nef, AP-1, MHC-I complex and for Nef to disrupt 
MHC-I antigen presentation (181, 204).  Finally, a number of groups have noted that PI3-
kinase inhibitors reduce the effect of Nef on steady state surface levels of MHC-I, 
although the exact role of PI3-kinase is debated (20, 87, 114, 185).   
 
1.7. Nef downmodulates CD4 
In addition to reducing MHC-I surface expression, Nef also targets the HIV-1 receptor 
CD4 for endocytosis and degradation (69, 135).  CD4 downmodulation promotes viral 
spread, as CD4 on the surface of producer cells would bind to Env and inhibit the release 
of nascent virions (6, 113, 128, 167).  Downmodulation of CD4 also prevents 
superinfection (199).  Interestingly, HIV encodes two accessory proteins to antagonize 
CD4 expression.  Nef is an early viral gene product which downmodulates mature CD4 
early in infection (1, 160).  In contrast, late viral gene product Vpu reduces newly 
synthesized CD4 expression through an endoplasmic reticulum associated protein 
degradation (ERAD) pathway (56, 200, 201).  Additionally, the HIV-1 structural protein 
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Env has also been demonstrated to associate with CD4 in the endoplasmic reticulum (ER) 
and inhibit CD4 transport (43, 88).  That HIV has evolved three proteins to achieve CD4 
downmodulation by complimentary mechanisms suggests that this function is essential to 
HIV-1 pathogenesis.  
 
1.7.1 In vivo evidence for the importance of CD4 downmodulation 
The existence of a long term non-progressor with a unique Nef mutation provides direct 
evidence for the importance of CD4 downmodulation in HIV-1 pathogenesis.  The virus 
from this patient had a deletion of amino acids 26-37 within Nef that abrogated MHC-I 
and CD4 downmodulation, as well as enhancement of virion infectivity.  However, a 
compensatory duplication of amino acids 43-53 restored the ability of this Nef variant to 
downmodulate MHC-I and enhance virion infectivity, but not to downmodulate CD4.  
This patient demonstrated relatively high viral loads but no decline in CD4+ T cell counts 
(25).  This single example suggests that HIV-1 requires Nef-induced CD4 
downmodulation to maintain maximal pathogenic potential.   
 
1.7.2. Functional domains required for Nef to downmodulate CD4 
A number of motifs within the C-terminal loop of Nef have been implicated in CD4 
downmodulation (Figure 1.4).  These sites within Nef mediate binding directly to the 
cytoplasmic domain of CD4, as well as recruitment of cellular adaptor proteins.  Nef has 
been demonstrated to interact directly with the cytoplasmic domain of CD4 by a number 
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of investigators using a variety of methods including: yeast-2 hybrid (168), in vitro 
binding (84, 156), immunoprecipitation (94, 120), and fluorescence resonance energy 
transfer (FRET).  NMR and fluorescence spectroscopy analyses have identified residues 
57-59, 95, 97, 106, and 110 of Nef as forming the binding interface between Nef and 
CD4 (80, 156).  Specifically, mutation of WL57-58 abrogates CD4 downmodulation by Nef 
(133).   This Nef interface binds to a membrane proximal sequence (QIKRLLSEKKT) 
within the CD4 cytoplasmic domain; the two leucines within this sequence are required 
for binding to Nef (Figure 1.7) (80).   
 
Additional structural motifs within Nef required for CD4 downmodulation are a dileucine 
motif (ENNSLL160-165) and a diacidic motif (D/ED174-175), which mediate the association 
of Nef with cellular adaptor proteins (31, 41, 124).  Another motif, EE154-155, was 
reported by some investigators to be required for Nef-induced CD4 trafficking to acidic 
compartments, while others found this motif to be dispensable for the Nef-dependent 
reduction in CD4 surface expression (63, 91, 124, 153). This controversy was addressed 
by a recent study in which it was observed that the di-glutamic acid motif in Nef was 
dispensable for surface downmodulation and intracellular accumulation of CD4, but was 
required for subsequent CD4 degradation through a -COP-dependent pathway (174).  
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Figure 1.7.  Cellular proteins targeted by Nef participate in immune activation and 
signaling.  (A)  An interaction between an antigen presenting cell (APC) and a T 
lymphocyte.  The T cell receptor (TCR) and either CD4 or CD8 bind to MHC-II or 
MHC-I, respectively.  Activation of the T cell requires a second signal which is provided 
through ligation of CD28 by CD80 or CD86.  (B)  The cytoplasmic tail domains of Nef 
target proteins do not share significant homology.  Sequence comparison of the 
cytoplasmic regions of cellular proteins targeted by Nef.  Regions reported to be involved 
in Nef-binding or Nef-induced downmodulation are underlined, while critical residues 
are highlighted in red. 
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Figure 1.7.  Cellular proteins targeted by Nef participate in immune activation and 
signaling. 
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1.7.3 Nef downmodulates CD4 by an endocytic mechanism 
The mechanism by which Nef affects CD4 surface expression is quite distinct from the 
mechanism of MHC-I downmodulation by Nef (Figure 1.6).  Furthermore, the 
understanding of Nef-induced CD4 downmodulation within the field is less controversial.  
It has long been known that Nef associates with CD4 at the plasma membrane, 
connecting CD4 to cellular endocytic machinery and inducing an increased rate of CD4 
endocytosis (1, 66, 72, 78, 101, 124, 132, 138, 152, 153, 183).  Consistent with an 
endocytic model, Nef-induced downmodulation of CD4 was found to be inhibited by 
dominant negative dynamin expression (93, 116), as well as by chemical inhibitors of 
clathrin-mediated endocytosis (129).  Additionally, microscopic analysis revealed that 
Nef increases the number of CD4-containing clathrin pits (66), and RNAi knockdown of 
the clathrin heavy and light chains inhibited Nef-induced downmodulation of CD4 (30).  
Thus, downmodulation of CD4 by Nef depends on clathrin-associated endocytic 
machinery. 
 
1.7.4 Host factors that partner with Nef to induce CD4 downmodulation and 
degradation 
1.7.4.1.  AP-2 mediates CD4 downmodulation by Nef 
Nef links CD4 to cellular endocytic machinery through clathrin associated adaptor 
protein 2 (AP-2) (Figure 1.6).  An early study used fluorescence microscopy to observe 
colocalization between Nef and the  subunit of AP-2 at the plasma membrane.  It was 
soon noted that Nef contains a canonical dileucine trafficking signal, (ENNSLL160-165), 
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and that this domain was not only required for CD4 downmodulation but was also 
capable of interacting with both AP-1 and AP-2 (21, 41, 76).  AP-2 is known to mediate 
clathrin-mediated endocytosis at the plasma membrane and this protein seemed the 
likeliest candidate for the Nef-induced increase in CD4 turnover.  RNAi knockdown of 
the 2 subunit of AP-2 provided evidence for AP-2 involvement in CD4 
downmodulation.  While 2 knockdown alone did not impair Nef-induced 
downregulation of CD4, co-expression of the siRNA with a dominant negative mutant of 
an AP-2 accessory protein involved in clathrin-mediated endocytosis, Eps15 (16, 24), 
reduced Nef-specific CD4 downmodulation (93).  Subsequent reports of AP-2 
knockdown have been conflicting, with some investigators observing a partial 
requirement for AP-2 in CD4 downmodulation by Nef (30, 183), while others have not 
(120, 166). This may depend in part on which subunit of AP-2 is targeted, as in one study 
AP-2  knockdown inhibited downmodulation by approximately 50% in HeLa and S2 
insect cells, but AP-2  knockdown did not (30).   
 
Though AP-2 knockdown has been controversial, studies taking a different experimental 
approach have provided ample evidence of an interaction between Nef and AP-2 in vitro.  
Yeast 3-hybrid analyses identified an interaction between Nef and AP-2  
hemicomplexes that required both the dileucine motif and D/ED174-175 diacidic motif 
within Nef, and this interaction was confirmed with GST pulldown experiments (30, 
124).  This observation is consistent with a recent study which mapped the dileucine 
binding site within AP-2 to an interface between the  and  subunits, as discussed 
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above (104).  Interestingly, the requirement for Nef’s D/ED174-175 diacidic motif in 
addition to the dileucine motif appears to represent an extended AP-2 binding site as 
compared to other AP-2-cargo interactions.  Yeast 3-hybrid experiments and mutational 
analysis of AP-2  recently identified a patch of arginine and lysine residues which are 
responsible for the interaction with the diacidic motif of Nef.  Furthermore, Yeast 4-
hybrid analysis provided direct evidence for a tripartite complex between CD4, Nef, and 
the  hemicomplex (31). Taken together, this evidence supports the conclusion that 
Nef utilizes AP-2 to connect CD4 to the endocytic machinery 
 
1.7.4.2.  -COP is required for Nef-induced CD4 degradation 
In addition to decreasing CD4 surface expression through increased internalization, Nef 
also induces degradation of CD4 (1, 63, 107, 124, 129, 153, 160, 171).  Inhibition of 
lysosomal acidification prevents Nef-induced CD4 degradation but does not restore CD4 
surface expression, indicating that CD4 internalization and degradation are separable 
functions of Nef (129, 159, 171).  CD4 targeting to late endosomal and lysosomal 
compartments requires an association between EE154-155 in Nef and the cellular adaptor 
protein -COP, as discussed above (Figure 1.6) (63, 153, 174).   
 
1.8 Nef is reported to disrupt trafficking of a variety of cellular proteins 
In addition to the effects of Nef on MHC-I and CD4 trafficking, there are a number of 
recent reports that Nef downmodulates a variety of other cell surface signaling proteins, 
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including CD28, CD8, CD80, CD86, and CD1d (Figure 1.7).  Relative to MHC-I and 
CD4 downmodulation, these functions of Nef are not well understood.  These proteins 
are all immunologically important molecules, but their cytoplasmic tail domains share no 
obvious sequence homology (Figure 1.7).  Therefore, it is surprising that Nef would be 
able to affect the trafficking of so many different targets. 
 
1.8.1. Nef downmodulates CD28  
Like MHC-I and CD4, CD28 is a molecule of tremendous importance in T cell biology.  
Ligation of CD28 in conjunction with T cell Receptor (TCR)-MHC interactions provides 
a potent co-stimulatory signal that is required for T cell activation (Figure 1.7).  Early 
studies reporting CD28 downmodulation by Nef were primarily performed with SIV Nef, 
although some investigators observed an effect of HIV-1 Nef as well, albeit of smaller 
magnitude (14, 187).   Both SIV and HIV-1 Nef were found to increase the rate of 
endocytosis of CD28 in Jurkat and SupT1 T cell lines, similar to the effect of Nef on CD4 
surface expression (14, 183, 187).  Also similar to CD4, downmodulation of CD28 by 
Nef was found to require the dileucine motif in Nef (14, 183, 187).  Further mutational 
analyses of Nef also implicated the myristoylation site (G2), the dileucine motif 
(ENNSLL160-165), the diacidic motif (E/DD174-175), WL57-58, and acidic cluster (EEEE62-65) 
of Nef in CD28 downmodulation (183, 187).  As discussed above, WL57-58 residues are 
involved in Nef binding to CD4, while the dileucine and E/DD174-175 diacidic motifs are 
required for Nef to interact with AP-2.  Interestingly, the EEEE62-65 acidic cluster is 
required for Nef-induced downmodulation of MHC-I, but not CD4 (Figure 1.4).  Whether 
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any these residues contribute to Nef-CD28 binding is unclear, as attempts to detect an 
interaction between SIV Nef and CD28 by yeast two-hybrid analysis or co-
immunoprecipitation were not successful (14).  However, fluorescence microscopy 
experiments in IMR90 fibroblasts did reveal colocalization of Nef and CD28, as well as 
colocalization of CD28 and AP-2 in cells expressing Nef (187).  Therefore, it has been 
proposed that Nef induces rapid CD28 endocytosis in an AP-2 dependent mechanism, 
similar to the manner by which Nef induces CD4 downmodulation.  However, neither an 
association of Nef with CD28 nor adaptor protein involvement in Nef-induced CD28 
downmodulation has been directly demonstrated. 
 
1.8.2 Evidence for downmodulation of CD8 by Nef 
CD8, like CD4, is a T cell co-receptor, but CD8 is expressed on CTLs while CD4 is 
expressed on helper T lymphocytes.  CD8 ligation to MHC I is required for efficient 
signaling through the TCR, resulting in antigen recognition and increased avidity of 
TCR-antigen interactions (Figure 1.7).  Therefore, a lack of CD8 surface expression 
would likely impair activation of anti-HIV CTLs.  However, as CD4 is the viral receptor, 
HIV infects CD4-expressing cells, not CTLs.  Thus it is not clear under what 
circumstances HIV-1 Nef might encounter CD8. 
CD8 is a dimer classically formed by one  and one  subunit, although  
homodimers do occur in some cell types, such as NK cells.  HIV-1 Nef was reported to 
downmodulate CD8 in the SupT1 T cell line as well as in primary T lymphocytes.  
Specifically, Nef downmodulated CD8 /  and CD8 /  homodimers, but not CD8  
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homodimers.  This indicated that Nef downmodulates CD8 by acting on the  subunit 
(183).   
 
Similar to several other Nef targets, CD8 downmodulation by Nef was determined to be 
due to an increased rate of internalization.   In order to assess the involvement of 
endocytic machinery, investigators used RNAi to knock down expression of the clathrin 
heavy chain, dynamin, and AP-2  in the Daudi B cell lymphoma cell line.  Dynamin and 
AP-2 depletion each inhibited Nef-induced downmodulation of CD8, as well as CD4, by 
approximately half.  Though clathrin heavy chain knockdown had no effect on CD8 or 
CD4 downmodulation, treatment with ikarugamycin, a chemical inhibitor of clathrin-
mediated endocytosis, inhibited Nef-induced internalization of CD8, indicating that Nef-
dependent endocytosis of CD8 is likely mediated by clathrin (183).   Mutational analysis 
of Nef revealed that downmodulation of CD8 requires the myristoylation site (G2), the 
CD4 binding site (WL57-58) the dileucine motif (LL154-155) and diacidic motif (E/DD174-
175) of Nef (183).  Each of these Nef domains has also been implicated in CD4 and CD28 
downmodulation, suggesting that common molecular interactions mediate these 
mechanisms (Figure 1.4).  All together, this evidence is consistent with the conclusion 
that HIV-1 Nef uses a common mechanism by which it downmodulates CD4, CD28, and 
CD8.   
 
The CD8  cytoplasmic tail is short, only 15 amino acids, and, unlike the CD4 
cytoplasmic tail, it contains no known protein-protein interaction motifs.  Furthermore, 
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CD8  shares no obvious sequence homology with the CD4 and CD28 cytoplasmic 
domains (Figure 1.7).  Mutational analysis of the CD8  sequence revealed that amino 
acids FMK204-206 of the cytoplasmic domain were required for Nef-dependent 
downmodulation (183).  This motif does not resemble the dileucine signal that forms the 
Nef-binding site within CD4, nor does it correspond to any motif within CD28.  
Therefore, it is unclear how Nef can affect these targets by similar mechanisms, mediated 
through dissimilar protein domains.  Therefore, further studies are needed to clarify the 
mechanism by which Nef affects CD8 and how CD8 is a physiologically relevant target 
for Nef. 
 
1.8.3. Evidence for CD1d downmodulation by HIV-1 
Antigen-presenting molecule CD1d is structurally similar to MHC-I and presents lipid, as 
opposed to peptide, antigens to Natural Killer T Cells (NKT cells).  CD1d has long been 
known to be capable of presenting the model antigen galactosylceramide (aGalCer), a 
marine sponge-derived lipid (103, 143).  Recently, CD1d has also been found to present 
lipid antigens from microbial pathogens such as Sphingomonas, Borrelia burgdorferi, 
Leishmania, and Mycobacteria (4, 65, 108, 109, 136, 182).  It is not clear whether an 
HIV-associated lipid antigen exists. It is also unknown whether CD1d-restricted NKT 
cells have any antiviral activity against HIV and whether CD1d expression influences 
HIV pathogenesis.  The literature regarding CD1d downmodulation by HIV-1 is 
conflicting.  Two groups have reported downmodulation of CD1d by HIV-1 Nef but 
report conflicting mechanisms (32, 33), while another group attributes this function to 
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Vpu (141).  Other groups reported controversial CD80/86 or CD1a downmodulation, but 
failed to observe CD1d downmodulation by HIV in primary human APCs (27, 180).  
 
1.8.3.1 Reports of CD1d downmodulation by Nef 
CD1d was first observed to be downmodulated in human Jurkat T cells infected with 
NL4-3 HIV-1.  Downmodulation of transiently expressed CD1d was observed when 
NL4-3 Nef was expressed in human T2 cells.  The authors state (as data not shown) that 
HIV accessory protein Vpu had no effect on CD1d expression.  In this study, the 
magnitude of Nef-induced CD1d downmodulation always exceeded that of MHC-I or 
CD4.  Co-immunprecipitation experiments detected Nef in complex with CD1d, although 
the interaction was described as weak or transient due to the necessity of using a 
chemical crosslinker to observe co-precipitation.  This interaction was dependent upon 
the CD1d cytoplasmic domain, but was independent of a tyrosine trafficking motif in 
CD1d (33). 
 
Another group also demonstrated reduced CD1d expression on Jurkat cells infected with 
NL4-3 HIV as compared to those infected with NL4-3 HIV nef.  In contrast to the 
previous study, these investigators reported moderate effects of Nef on CD1d expression 
(approximately 30%) as compared to MHC-I (50%) and CD4 (70%).  Transient 
transfection of Nef alone resulted in decreased CD1d expression, although not to the 
same extent as whole HIV, suggesting the involvement of other viral proteins.  This study 
attributed CD1d downmodulation to an increased rate of endocytosis in the presence of 
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Nef, though the rate increase, measured as the percent of labeled-CD1d unaffected by an 
acid wash, was not observed at time points earlier than 45 minutes, at which time 
recycling defects confound endocytosis measurements.  Microscopic analysis of HeLa 
cells revealed that CD1d colocalized with a Nef-GFP fusion protein and accumulated in 
the TGN.  The investigators observed a requirement for the tyrosine motif within the 
CD1d cytoplasmic domain for Nef-induced downmodulation (Figure 1.7).  Mutational 
analysis of Nef provided evidence for a requirement for the myristoylation site (G2) as 
well as a partial dependence upon CD4-downmodulation domains LL164-165 and DD174-175, 
and MHC-I downmodulation domains PxxP72/75 and EEEE62-65, but not M20 (Figure 1.4) 
(32).  Therefore it is not apparent that CD1d downmodulation by Nef occurs by a 
mechanism shared with MHC-I or CD4 downmodulation. 
 
Interestingly, although differing binding domain requirements were reported, both studies 
reported that Nef-expressing APCs demonstrated reduced capacity to activate CD1d-
restricted NKT cells through GalCer presentation as compared to cells expressing CD1d 
in the absence of Nef (32, 33).  This observation supports the potential functional 
significance of HIV-dependent CD1d downmodulation.  
 
1.8.3.2. Evidence for CD1d downmodulation by HIV-1 Vpu 
Though in agreement with previous studies that HIV-1 induces downmodulation of 
CD1d, a recent report has identified Vpu as the HIV accessory protein responsible for 
this activity.  As in previous reports, functional assays demonstrated impaired activation 
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of CD1d-restricted NKT cells by HIV-1-infected primary human monocyte-derived 
dendritic cells (MDDC).  However, in this system HIV-1 Vpu expression was sufficient 
to induce CD1d downmodulation (141).  Vpu did not affect CD1d internalization 
between 0 and 30 minutes, but recycling of CD1d was impaired in cells expressing Vpu.  
Fluorescence microscopy revealed colocalization of CD1d and a Vpu-GFP fusion protein 
within EEA1-positive early endosomal compartments.  CD1d, but not Vpu, could also be 
found in LAMP-1-positive late endosomes/lysosomes in Vpu-expressing cells (141).   
 
Interestingly, HIV-1 vpu or nef each demonstrated a reduced ability to affect CD1d 
surface expression in human MDDCs, while inactivation of both Nef and Vpu 
synergistically abrogated CD1d downmodulation by HIV (141).  This observation 
indicates that HIV-1 Nef and Vpu may both impair CD1d surface expression by distinct 
pathways, similar to the redundant abilities of Nef and Vpu to induce CD4 degradation 
(69, 200).  Additionally, HIV-1 Vpu downmodulates viral restriction factor BST-
2/tetherin, a function that is performed by Nef in primate lentiviruses which lack Vpu, 
such as SIVsmm, SIVmac, SIVsyk, and SIVagm (173).  Therefore, perhaps Nef and Vpu 
functions frequently overlap, and both may acquire the ability to downregulate CD1d, 
depending upon the evolution of each virus strain. 
 
1.8.4. Evidence for downmodulation of CD80 and CD86 by HIV-1 Nef 
Like CD1d, CD80 and CD86 are expressed on APCs, though the latter two are not 
antigen-presenting molecules.  Indeed, CD80 and CD86, previously known jointly as B7, 
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are ligands for CD28, providing the critical co-stimulatory signal for T cell activation 
(125).  It is likely that a Nef-induced reduction in surface expression of these molecules 
would prevent the activation of anti-HIV T lymphocytes.  However, the literature on 
CD80/86 downmodulation by Nef is conflicting; several groups report no change in 
expression of these molecules in the presence of Nef (130, 157, 180), while other reports 
describe a detailed mechanism by which Nef affects these molecules (27, 134).   
 
CD80 and CD86 downmodulation by Nef was first reported in a mouse dendritic cell 
(DC) line in a study characterizing the effects of Nef on immature DC function (134).  
However, it is notable that every marker stained for, including CD40 and inter-cellular 
adhesion molecule-1 (ICAM-I), was similarly downmodulated and the isotype 
background was also highly reduced in the Nef-expressing cells.  It is also important to 
consider the ramifications of utilizing cell lines that stably express Nef, a cytotoxic 
protein.  Indeed, the authors observed changes in cell morphology such as smaller size 
and loss of dendrites, as well as reduced antigen presentation and an inability to respond 
to stimulation (134).  An additional caveat is the use of a murine cell line.  Nef has 
reduced ability to downmodulate murine MHC-I allotypes, and Nef-induced 
downmodulation of human MHC-I is impaired in murine cells, indicating that Nef may 
not be able to bind to cellular cofactors in murine cells (33).  
 
Other investigators did not observe downmodulation of CD86 or ICAM-I by Nef, but did 
observe CD4 downmodulation, indicating that Nef was active in this experiment (130).  
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Additional studies detected Nef-induced downmodulation of MHC-I by Nef in primary 
human DCs, but failed to detect CD86 or CD40 downmodulation (157, 180).  Still other 
experiments performed in primary monocytes did report Nef-dependent downmodulation 
of CD80 and CD86 (27).  Hence, differences in experimental systems must influence the 
observed effects of Nef on CD80/86. 
 
1.8.4.1 Proposed mechanism of CD80/86 downmodulation 
Despite the controversy, one group has extensively studied CD80/86 downmodulation by 
HIV-1 Nef in human APCs, thoroughly detailing a mechanism for this proposed Nef 
function.  They report robust downmodulation of endogenous CD80 and CD86, but not 
CD1d, in U937 monocytic cells infected with NL43 HIV, as well as in primary human 
monocytes infected with Ada HIV (27).  Transfection of Indian subtype F2 Nef into a 
mouse myeloid cell line or primary murine DCs and macrophages produced a similar 
result.  Surprisingly, the investigators did not observe degradation of CD80, CD86, or 
MHC-I in the presence of Nef.  Also unexpected was the observation that mutation of a 
number of functional domains within Nef (WL56,57, E62-65, R77, P72/75/78, D86, R106, I109, 
F121, P130, EE154-155, and LL164-165) did not inhibit CD80/86 downmodulation.  Only 
elimination of the myristoylation site in Nef (G2A) or truncation of Nef at amino acid 100 
reduced downmodulation of CD80/86 (27).  Despite a failure to identify responsible Nef 
domains, the authors were able to  provide evidence for a direct association of Nef with 
CD80 and CD86 using microscopy and co-immunoprecipitation assays, as well as yeast-
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2-hybrid methods (27).  They later reported high affinity interactions between Nef and 
the cytoplasmic tail domains of CD80 and CD86 (29). 
 
In a subsequent study, the investigators reported that F2 Nef increased the rate of 
endocytosis of CD80 and CD86, as well as MHC-I, based on measurements collected 
over 10 hours.  This is an unusual time course for an endocytosis assay, as recycling and 
newly synthesized protein also contribute to surface expression after approximately 15 
minutes.  The investigators next used a series of chemical inhibitors and dominant 
negative proteins to propose a cellular mechanism.  Like MHC-I downmodulation by 
Nef, Nef-dependent CD80 and CD86 downmodulation was dynamin and eps15 
independent, inconsistent with clathrin-mediated endocytosis.  Downmodulation of CD80 
and CD86 depended on actin polymerization as well functional WASp, a protein which 
moderates actin filament formation.  Inhibitors of protein kinase C (PKC) and Src-family 
kinases, as well as Rac1 knockdown, all inhibited CD80/86 downmodulation.  TIAM, a 
Rac1 GEF activated by Src, was found to be phosphorylated in the presence of Nef, and 
expression of dominant negative TIAM reduced CD80/86 downmodulation.  Src 
knockdown also inhibited downmodulation of CD80 and CD86, but dominant active Rac 
overcame this block, indicating that Src activation is only required for Rac activation.  
However, dominant active Rac1 alone is not sufficient for downmodulation of CD80/86 
in the absence of Nef (Figure 1.8).   
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Figure 1.8. An endocytic model for CD80/86 downmodulation by Nef.  Nef binds to 
and activates an SFK, which requires Nef-induced PKC activity.  The active SFK then 
phosphorylates TIAM in an actin-remodeling-dependent manner.  Active TIAM in turn 
activates Rac1, which again induces actin remodeling.  Nef binds tightly to the 
cytoplasmic tails of CD80/86 and increases the rate of internalization from the plasma 
membrane (PM).  Nef then routes CD80/86 to Rab11+ recycling endosomes.  Finally, 
Nef activates PI3-kinase, which results in transport of CD80/86 to the TGN. 
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Finally, microscopic analysis was used to map CD80/86 trafficking in the presence of 
Nef.  CD80 or CD86 were labeled at the plasma membrane, then examined over time for 
colocalization with markers of various cellular compartments.  CD80 and CD86 initially 
colocalized with Rab11, a key regulator of recycling endosomes.  CD80/86 were 
subsequently found to colocalize with Golgi markers Rab6 and GM130, but were never 
observed in complex with ARF-6 or late endosome marker Rab7 (Figure 1.8) (28).  
Therefore, it has been proposed that HIV-1 Nef downmodulates CD80/86 by a unique 
signaling mechanism that does not rely on known Nef functional domains. 
 
1.8.4.2. Functional importance of CD80/86 downmodulation 
In an experimental system where Nef-dependent CD80 and CD86 downmodulation were 
observed, Nef also reduced the ability of murine macrophages to activate OT-1 CTLs.  
OT-1 is a transgenic mouse system in which T cells are engineered to express a TCR that 
recognizes an ovalbumin epitope in the context of the mouse H-2k
b
 MHC-I molecule. It 
is expected that MHC-I downmodulation by Nef would abrogate CTL activation.  To 
differentiate between the effects of MHC-I and CD80/86 downmodulation, the 
investigators expressed a Nef mutant capable of downmodulating CD80 and CD86, but 
not MHC-I, and found it to behave similarly to wild type Nef in the OT-1 assay, 
providing evidence that MHC-I antigen presentation is not sufficient for CTL activation, 
and that Nef inhibits an additional required signal.  A G2A myristoylation mutant of Nef, 
which is incapable of affecting intracellular trafficking, had no effect on CTL activation.  
Together, this evidence supports the conclusion that HIV-1 Nef induces downmodulation 
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of CD80/86 and thereby disrupts CTL activation by macrophages.   However, numerous 
conflicting reports are not in agreement that CD80 and CD86 are downmodulated by Nef, 
indicating that further investigation is warranted. 
 
1.9. Summary 
In conclusion, data from a number of laboratories have contributed to our current 
understanding of the mechanisms by which HIV-1 Nef affects the trafficking of cellular 
proteins to disrupt immune cell activation and anti-HIV activity.  We currently have a 
good understanding of the mechanism by which Nef affects CD4 expression, although 
the importance of this Nef function in vivo is not entirely clear.  The field is beginning to 
come to a consensus about the mechanism by which Nef downmodulates MHC-I and an 
understanding of its role in immune evasion in vitro and in vivo.  However, the extent to 
which Nef affects other proteins remains ambiguous, with conflicting data originating 
from various research groups.  A greater understanding of which targets are most 
important for Nef biology is needed.  This dissertation describes the development of tools 
to address this question, insight into the mechanisms involved in Nef-dependent 
trafficking pathways, and the development of pharmacologic inhibitors of Nef function 
for future therapeutic use. 
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Chapter 2 
HIV-1 Nef disrupts intracellular trafficking of MHC-I, CD4, 
CD8, and CD28 by distinct pathways that share common 
elements 
 
2.1 Abstract 
The Nef protein is an important HIV virulence factor that promotes the degradation of 
host proteins to augment virus production and facilitate immune evasion. The best 
characterized targets of Nef are MHC-I and CD4, but Nef has also been reported to target 
several other proteins, including CD8 , CD28, CD80, CD86, and CD1d. To compare and 
contrast the effects of Nef on each protein we constructed a panel of chimeric proteins in 
which the extracellular and transmembrane regions of MHC-I allele HLA-A2 were fused 
to the cytoplasmic tails of CD4, CD28, CD8β, CD80, CD86, and CD1d.  We found that 
Nef co-precipitated with and disrupted the expression of molecules with cytoplasmic tails 
from MHC-I HLA-A2, CD4, CD8β, and CD28, but Nef did not bind to or alter the 
expression of molecules with cytoplasmic tails from CD80, CD86, and CD1d. In 
addition, we used siRNA knockdown and co-precipitation experiments to implicate AP-1 
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as a cellular co-factor for Nef in the downmodulation of both CD28 and CD8 .   The 
interaction with AP-1 required for CD28 and CD8  differed from the AP-1 interaction 
required for MHC-I downmodulation in that it was mediated through the dileucine motif 
within Nef (LL164,165AA) and did not require the tyrosine binding pocket of the AP-1  
subunit.  In addition, we demonstrate a requirement for -COP as a cellular co-factor for 
Nef that was necessary for the degradation of targeted molecules HLA-A2, CD4, and 
CD8. These studies provide important new information on the similarities and differences 
with which Nef affects intracellular trafficking and help focus future research on the best 
potential pharmaceutical targets.  
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2.2 Introduction 
Nef is an important virulence factor for human immunodeficiency virus (HIV)-1 
pathogenesis which functions to increase viral spread and promote disease progression.  
The significance of Nef expression on disease progression is highlighted by the delayed 
progression to AIDS observed in a cohort infected with an HIV with a deletion the nef 
open reading frame and LTR (8, 26, 28, 56, 57).  Similarly, rhesus macaques infected 
with SIV Nef demonstrated low viral loads and delayed disease progression (50).  Nef is 
a 25-34kDa myristoylated early viral gene product that acts as a multifunctional adaptor 
protein, containing a number of protein-protein interaction domains.  Additionally, Nef 
has several disordered regions that confer flexibility to facilitate exposure of different 
interaction domains in response to the local environment ((34) and reviewed in (3)).  
 
 Nef has been implicated in signal transduction, intracellular trafficking, and viral 
infectivity.  One of its best studied activities is its role in promoting immune evasion 
from anti-HIV cytotoxic T lymphocytes (CTL) (22, 58, 80, 87, 95).  Nef also 
downmodulates CD4, the HIV receptor, from the plasma membrane (33) to prevent 
superinfection (5) and allow more efficient release of budding virus (53, 76).   In 
addition, Nef has been reported to downmodulate a number of other surface molecules, 
including CD8 (mediated through its  subunit), CD28, CD80, CD86, and CD1d (12-14, 
18, 19, 82, 86).  Relative to MHC-I and CD4, little is known about the mechanisms and 
the functional significance of downmodulation of these molecules by Nef. 
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We have previously demonstrated that Nef disrupts MHC-I trafficking by binding to the 
cytoplasmic tail of MHC-I in the endoplasmic reticulum or early Golgi, and this complex 
subsequently recruits adaptor protein (AP)-1 in the trans-Golgi network (64, 74, 81, 91-
93).  AP-1 then directs MHC-I into an endolysosomal pathway as opposed to the cell 
surface (79, 91-93).  In contrast, CD4 anterograde traffic to the plasma membrane is not 
inhibited in the presence of Nef.  Instead, Nef promotes CD4 internalization at the plasma 
membrane (11, 23, 61, 70, 79).  CD4 downmodulation has been shown to require AP-2 
and it has been proposed that Nef-dependent AP-2 recruitment to the cytoplasmic domain 
of CD4 at the plasma membrane promotes clathrin-dependent endocytosis (16, 45, 82).  
Our lab and others have also demonstrated that Nef utilizes a -COP-dependent pathway 
to ultimately target MHC-I and internalized CD4 to lysosomes for degradation (4, 30, 70, 
79).  
 
The other putative targets of Nef, CD28, CD8 , CD80, CD86, and CD1d, are expressed 
in a variety of immune cells, including helper T lymphocytes and CTLs, as well as 
antigen presenting cells (APCs), such as macrophage and dendritic cells (DC).  Though 
Nef is multifunctional, it is surprising that Nef would affect so many different molecular 
targets.  Therefore, we sought to directly compare the relative effect of Nef on CD28, 
CD8 , CD80, CD86, and CD1d to assess the relative importance of each target and to 
provide mechanistic insights.  Here we show that HIV-1 Nef dramatically reduces the cell 
surface expression of MHC-I, CD4, CD8  and, to a lesser degree, CD28.  We were 
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unable to detect significant downmodulation of CD80, CD86, or CD1d by HIV-1 Nef in a 
variety of cell lines or primary antigen presenting cells (APCs).  Downmodulation of 
CD8  and CD28 was partially dependant on AP-1 expression and we detected a Nef-
dependant interaction of AP-1 with the CD8  and CD28 cytoplasmic tails that relied on 
the dileucine sorting signal within Nef. Additionally, we found that Nef promoted the 
degradation of CD8  and that this function of Nef required -COP expression.   These 
new data help define the most relevant cellular targets of HIV-1 Nef and provide insights 
into the mechanism by which HIV-1 promotes disease. 
 
2.3 Results 
2.3.1 Nef targets HLA-A2, CD4, CD8 , and CD28 through their cytoplasmic tail 
domains 
Nef has been reported to downmodulate a large number of host proteins including MHC-
I, CD4, CD28, CD8 , CD80, CD86, and CD1d.  To assess the relative effects of Nef on 
these targets, we created a panel of chimeric proteins in which the extracellular and 
transmembrane regions of hemagglutinin epitope (HA) tagged HLA-A2 were fused to the 
cytoplasmic tail domain of each protein of interest (Figure 2.1).  This allowed us to use 
the same antibodies and established assays to directly compare the effect of Nef on each 
cytoplasmic tail domain.  We then measured the impact of HIV-1 and SIV Nef on the cell 
surface expression of each chimeric molecule.  We found that HLA-A2, the HLA-A2 
chimera with the CD4 cytoplasmic tail (A2/CD4), and the HLA-A2 chimera with the  
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Figure 2.1. Diagrammatic representation of chimeric molecules HLA-A2, A2/CD4, 
A2/CD8 , and A2/CD28 in CEM T cells. 
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Figure 2.2. Nef downmodulates HLA-A2, A2/CD4, A2/CD8 , and A2/CD28 in CEM 
T cells. (A) Flow cytometric analysis of CEM SS T cells expressing the indicated 
chimeric proteins and transduced with the indicated adenoviral vector. Cells were 
analyzed at 3 days post infection (dpi).  (B) Quantitation of flow cytometry experiments 
from part B.  The mean fold downmodulation +/- standard deviation is shown. n=3
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CD8  cytoplasmic tail (A2/CD8  were downmodulated by both HIV and SIV Nef 
expressed using an adenoviral vector system in a CD4
+ 
T cell line, CEM SS (3.7, 8.5, and 
4.0-fold, respectively, Figure  2.2).  HIV-1 Nef had a smaller (1.8-fold) effect on the 
HLA-A2 chimera with the CD28 cytoplasmic tail (A2/CD28), whereas SIV Nef 
downmodulated A2/CD28 to a greater extent (3-fold, Figure 2.2), as previously 
demonstrated (86).  The chimeric molecules with cytoplasmic tails from CD80, CD86, 
and CD1d (A2/CD80, A2/CD86 and A2/CD1d respectively) were not sufficient for 
downmodulation by either Nef protein (1.1, 1.1, and 1.3-fold downmodulation, 
respectively, Figure 2.2). 
 
Similar results were obtained when Nef was expressed using a retroviral vector that also 
expresses GFP from an internal ribosomal entry site (39). Again we observed strong 
downmodulation of HLA-A2, A2/CD4, and A2/CD8 , and weak downmodulation of 
A2/CD28 (Figure 2.3A and quantified in Figure 2.3B).  In addition, we again found that 
HIV-1 Nef did not significantly affect A2/CD80, A2/CD86, or A2/CD1d (Fig. 2.3A-B).  
Similar results were achieved using another T cell line (SupT1) that expressed wild type, 
endogenous CD4, CD8 (both  and  dimers), and CD28 plus exogenous HLA-A2 
(Figure 2.3C).   
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Figure 2.3. Nef downmodulates HLA-A2, A2/CD4, A2/CD8 , and A2/CD28 in T cell 
lines. (A) Flow cytometric analysis of CEM SS T cells transduced with a retroviral vector 
expressing GFP alone, or NL43 Nef and GFP reporter.  (B) Quantitation of flow 
cytometry experiments from part D.  The mean fold downmodulation of GFP
+
 cells +/- 
standard deviation is shown. n=3.  (C)  Flow cytometric analysis of SupT1 cells 
transduced with the indicated adenoviral vector. Cells were analyzed at 3 dpi.  Sup T1 
cells express endogenous CD4, CD28 and CD8.  
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2.3.2 Endogenous CD80 and CD86 are not downmodulated by Nef in Primary APCs 
Because CD80, CD86, and CD1d are normally expressed in antigen presenting cells 
(APCs), we employed the human monocytic cell lines THP-1 and U937 for further 
experiments with these molecules.  We were unable to detect significant cell surface 
expression of endogenous CD80 or CD86 in either cell line (data not shown).  Therefore 
we created stable U937 and THP-1 lines expressing the chimeric molecules.  Nef was 
introduced into undifferentiated cells using a retroviral vector and then the cells were 
stimulated with LPS and PMA to induce macrophage differentiation.  Overall, we 
observed that Nef was less active in the APC lines than in T cells, downmodulating HLA-
A2 two to three-fold in APC lines as compared to 17-fold downmodulation in CEM cells 
(Figure 2.4B).  Even so, Nef had minimal effect on the CD80 and CD86 chimeras in all 
three cell lines (Figure 2.4A-B, 0.8-2.0-fold), indicating that the cytoplasmic tails of 
CD80 and CD86 were not sufficient for downmodulation by HIV-1 Nef even in 
macrophage cell lines. In contrast we observed a decrease in MHC-I HLA-A2 surface 
expression under all conditions.  Because PMA also reduces CD4 surface expression (7), 
we were unable to assess the effect of Nef on CD4 in the PMA-treated cells. 
 
We used the same experimental approach to examine the ability of HIV-1 Nef to 
downmodulate full length endogenous CD1d in the THP-1 cell line, which also expresses 
endogenous HLA-A2.  We observed minimal downmodulation of CD1d by Nef in either 
undifferentiated or differentiated THP-1 cells (Figure 2.4C-D).  
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Figure 2.4.  NL43 Nef does not downmodulate CD80, CD86, or CD1d.   
(A) Flow cytometric analysis of U937 cells and THP-1 cells transduced with the 
indicated retroviral vector and treated as indicated with LPS, PMA or DMSO (Undiff.).   
The cells were analyzed 5 dpi. (B) Quantitation of flow cytometry experiments from part 
A.  The mean fold downmodulation +/- standard deviation is shown.  n=3.  (C)  Flow 
cytometric analysis of THP-1 cells treated as in A.  The surface expression of 
endogenous HLA-A2, CD4, and CD1d expression were measured at 5 dpi. (D) 
Quantitation of flow cytometry experiments from part C.  The mean fold 
downmodulation +/- standard deviation is shown.  n=3.   
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Figure 2.4.  NL43 Nef does not downmodulate CD80, CD86, or CD1d. 
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Figure 2.5.  NL43 Nef does not downmodulate endogenous CD80 or CD86 in 
primary antigen presenting cells. (A) Flow cytometric analysis of primary antigen 
presenting cells that were transduced with the indicated adenoviral vector. Endogenous 
HLA-A2, CD4, CD80, and CD86 expression were assessed at 3 dpi. Primary 
macrophages; GM-CSF treated prior to transduction, dendritic cells; GM-CSF, IL-4, and 
TNF-  treated prior to transduction.  (B) Quantitation of flow cytometry experiments 
from part E.  The mean fold downmodulation +/- standard deviation is shown.  n=3 
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To examine the ability of Nef to downmodulate full length CD80 and CD86, we obtained 
primary antigen presenting cells from human peripheral blood mononuclear cells.  These 
cells were stimulated with GM-CSF alone or GM-CSF, IL-4, and TNF-  to induce 
macrophage or monocyte-derived dendritic cell phenotypes, respectively (78, 96).  We 
observed no significant effect of Nef on the surface expression of endogenous CD80 and 
CD86 in either cell type (Figure 2.5A, quantified in 2.5B). As controls we demonstrated 
downmodulation of endogenous MHC-I HLA-A2 and CD4 by Nef, albeit to a lesser 
extent than in T cells (Figure 2.5A-B). 
 
2.3.3 Multiple HIV-1 Nef variants downmodulate HLA-A2, CD4, CD8 , and CD28 
All experiments thus far utilized Nef from the NL4-3 molecular clone of HIV (1).  While 
many of the known functional domains of Nef are conserved, significant sequence 
variation does occur.  Therefore, we examined whether the activity of Nef varied 
amongst HIV isolates.  Although we observed variation in the magnitude of MHC-I 
HLA-A2 downmodulation, all Nef variants tested (except YU-2) reduced HLA-A2 
surface expression dramatically (6-35-fold, Figure 2.6A-B). Similarly, all the Nef 
proteins downmodulated endogenous CD4, as well as A2/CD8 , and A2/CD28.  CD4 
was downmodulated to the greatest extent, followed by HLA-A2, then A2/CD8 .  
A2/CD28 was only moderately affected by all of the Nef variants tested.  In contrast,  
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Figure 2.6.  Nef-induced downmodulation of MHC-I, CD4, CD8 , and CD28 is 
conserved across multiple clades.  (A) Quantitation of downmodulation of the indicated 
molecule in CEM SS cells following transduction with bi-cistronic murine retroviral 
vectors expressing the indicated Nef.  The mean fold downmodulation of each molecule 
in GFP-positive cells as determined by flow cytometry is shown. n=3.  The inset displays 
the data for CD28, CD1d, CD80 and CD86 with an expanded Y axis to highlight 
differences amongst these molecules that are of a small magnitude.  The statistical 
significance was determined by two-way ANOVA analysis.  (B) Quantitation of Nef-
dependent downmodulation of the indicated molecule by each Nef variant.  The mean 
fold downmodulation in the GFP positive cells +/- standard deviation is shown. n=3.  (C)  
Relative ability of Nef variants to downmodulate each target protein, plotted as fold 
downmodulation.  YU-2 was removed as an outlier. 
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none of the Nef proteins reduced A2/CD80 or A2/CD86 surface expression more than 
1.5-fold (Figure 2.6A and inset).   
 
Interestingly, some of the Nef variants downmodulated A2/CD1d more than 1.5-fold 
(Figure 2.6A, inset).  93BR020 Nef, a clade F isolate (32), downmodulated A2/CD1d to 
the greatest extent.   Thus, certain HIV subtypes may evolve the ability to significantly 
affect CD1d trafficking, although the effect was comparatively small.   
 
Notably, Nef proteins which demonstrated higher downmodulation activity on one target 
protein did not necessarily demonstrate similarly high activity for all other targets 
examined (Fig. 2.6B). When relative Nef activities were plotted for each target molecule, 
a number of correlative observations were made (Figure 2.6C).  HLA-A2 and A2/CD8  
were negatively correlated, indicating that the ability of Nef to downmodulate these 
proteins did not seem to co-evolve.  There is a weak positive correlation between HLA-
A2 and A2/CD28, indicating that Nef sequences that contribute to the downmodulation 
of these targets may be partially shared.  Because CD4 and CD8 are analogous 
molecules, one might hypothesize that CD8  downmodulation is an evolutionary 
byproduct of CD4 downmodulation.  Significantly, however, there was no correlation 
between CD4 and A2/CD8 downmodulation (Figure 2.6C). 
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Figure 2.7.  CD4 and CD8 are downmodulated by Nef in HIV-1-infected PBMCs.   
Flow cytometric analysis of PBMCs infected with HXB ePLAP HIV +/- Nef, 
pseudotyped with HXB envelope.  Surface marker and intracellular Gag stains were 
performed at 3 dpi.   
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2.3.4 HIV-1 Nef downmodulates CD4 and CD8 in primary T lymphocytes 
CD8 can be expressed as a CD8 /  homodimer or as a CD8  heterodimer.  Because 
Nef targets CD8 only the CD8  heterodimer can be affected by Nef (82).  T 
lymphocytes, DCs, and NK cells are all CD8
+
, but the CD8  heterodimer is expressed 
exclusively in T cells.  Typically, T lymphocytes are either CD4
+
 or CD8
+
 and only the 
CD4
+
 subset can be infected by HIV. Thus, it is unclear how Nef might come in contact 
with the CD8  molecule.  Significantly, a small population of CD4
+
CD8
+
 T lymphocytes 
circulates in peripheral blood (9, 31, 66, 67, 99) and the frequency of these double 
positive cells increases in response to infection with a number of viruses, including HIV 
(42, 54, 60).  Additionally, these cells have been reported to be susceptible to infection by 
HIV (6, 20, 41, 42, 52, 94, 98).  While the role of CD4
+
CD8
+ 
double positive cells is not 
entirely clear, they are known to exhibit cytolytic activity as well as antigen-dependant 
secretion of IFN-  and IL-2.  Moreover, they are enriched for HIV-specific responses in 
chronically infected patients (40, 66, 84, 97).  Importantly, these cells are reported to 
express the CD8  heterodimer (66, 83).  Thus, this population represents a potential 
physiologic target of HIV in which Nef would encounter CD8 .   
 
To investigate the ability of HIV to infect CD4
+
CD8
+
 cells, we infected PBMCs with 
HIV HXB ePLAP (17) pseudotyped with an HIV envelope (HXB) that lacked Nef 
expression (HIVnef 
-
) so that the expression of cell surface markers would be maintained.   
As expected, we observed similar rates of infection in CD4
+
CD8
+
 and CD4
+
CD8
-
 cells 
(16 and 14% respectively, Figure 2.7, upper panel).  In contrast, when these cells were 
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infected with an HIV HXB ePLAP that expressed Nef, most of the infected cells became 
negative for both CD4 and CD8 (Figure 2.7, lower panel).  Therefore, CD4
+
CD8
+
 cells 
are a physiologically relevant target of HIV-1 and Nef actively downmodulates both CD4 
and CD8 in these cells. 
 
2.3.5 Nef recruits AP-1 to the cytoplasmic tail of CD8  and CD28 
Prior research has shown that Nef disrupts MHC-I and CD4 host protein trafficking by 
binding to sequences in their cytoplasmic tail domains (79, 91).  Here we confirmed that 
Nef co-precipitated with HLA-A2 and A2/CD4.  Moreover, we observed that Nef co-
precipitated with A2/CD8 , and A2/CD28, but not A2/Cw4, A2/CD80, A2/CD86, or 
A2/CD1d (Figure 2.8A).  A2/Cw4 is a negative control in these experiments as Nef does 
not bind to or downmodulate HLA-C (or E or F) MHC-I allotypes (21, 36, 92).  Thus, 
NL43 Nef physically associates with each of the proteins which it potently 
downmodulates in T cells.   
 
In Nef expressing cells, HLA-A2 also coprecipitates with the clathrin adaptor protein AP-
1 (when degradation is inhibited by ammonium chloride), and this interaction is required 
for Nef to disrupt MHC-I trafficking (74, 93).  Similarly, we observed AP-1 
coprecipitation with A2/CD28 and A2/CD8  (Figure 2.8B), although the interaction with 
A2/CD8  seemed weaker than that observed with HLA-A2 and A2/CD28.  In contrast,  
92 
 
 
 
 
 
 
Figure 2.8.  Nef physically associates with the cytoplasmic domains of HLA-A2, 
CD4, CD8 , and CD28 and recruits AP-1 to HLA-A2, CD8 , and CD28.  
Immunoprecipitation and western blot analysis of the indicated chimeric molecule 
expressed in CEM T cells transduced with the indicated adenoviral vector. The cells were 
harvested at 3 dpi after an overnight incubation in ammonium chloride to inhibit 
degradation.  Lysates were immunoprecipitated with an antibody directed against HLA-
A2 (BB7.2) and the presence of (HA)-HLA-A2, Nef (A) or AP-1 (B) was detected by 
western blot analysis. 
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we did not observe AP-1 coprecipitating with A2/CD4, A2/Cw4, A2/CD80, A2/CD86, or 
A2/CD1d.    
 
We also asked whether the other adaptor proteins AP-2 and AP-3 coprecipitated with the 
chimeras.  In two of five experiments we observed AP-2  recruitment to A2/CD28  
(Figure 2.9C), which would be consistent with previous reports of AP-2 involvement in         
CD28 downmodulation (82, 86).   However, we were unable to detect coprecipitation of 
any other chimeras with AP-2 or AP-3 (data not shown). 
 
2.3.6 Nef recruits AP-1 to CD8  and CD28 through its dileucine motif 
The AP proteins can utilize either Yxx  or (E/D)xxxLL motifs in cargo molecules (x 
stands for any amino acid, and indicates a hydrophobic residue).   While Nef recruits 
AP-1 to the tyrosine residue in the MHC-I cytoplasmic tail, such a sequence is not 
present in the cytoplasmic tail domains of CD28 or CD8 Interestingly, Nef also 
contains a conserved canonical dileucine motif (ExxxLL165), which has been reported to 
mediate binding to AP-1, AP-2 and AP-3 (11, 25, 29, 35, 43, 44, 55, 69).  Furthermore, 
Nef LL164,165AA  is defective at downmodulating CD8  or CD28, yet retains the ability 
to downmodulate HLA-A2 (Figure 2.9A and (82)).  Thus we hypothesized that 
recruitment of AP-1 to CD8  or CD28 might occur through this dileucine motif.  
Consistent with our hypothesis, Nef LL164,165AA  did not support coprecipitation of AP-1  
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Figure 2.9. Nef recruits AP-1 for the downmodulation of CD8  and CD28 in a 
dileucine dependant manner.  (A) Flow cytometric analysis of CEM SS T cells 
expressing the indicated chimeric protein and transduced with the indicated adenoviral 
vector.   Nef LL164,165AA is indicated as xLL.  (B) Immunoprecipitation and western blot 
analysis of the indicated chimeric molecule expressed in CEM T cells transduced with 
the indicated adenoviral vector. The cells were harvested at 3 dpi.  Lysates were 
immunoprecipitated with an antibody directed against HLA-A2 (BB7.2) and the presence 
of Nef, AP-1 subunits and MHC-I (HA) were detected by western blot analysis.  
Intervening lanes were removed, as indicated by white gap. The data are representative of 
four independent experiments.   (C) Immunoprecipitation and western blot analysis of the 
indicated chimeric molecule expressed in CEM T cells transduced with the indicated 
adenoviral vector and treated as described for part B. AP-2 co-precipitation is 
representative of two of four experiments.   
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Figure 2.9. Nef recruits AP-1 for the downmodulation of CD8  and CD28 in a 
dileucine dependant manner.   
97 
 
with A2/CD8  and A2/CD28 (Figure 2.9B lanes 4-5 and C lanes 11-12)  but did promote 
co-precipitation of AP-1 with HLA-A2 (Figure 2.9B-C).  Therefore, Nef can recruit AP-1 
to cytoplasmic tail domains using two different signals, depending upon which 
cytoplasmic tail domain Nef is bound to. 
 
In experiments where we observed AP-2 coprecipitation with the CD28 cytoplasmic tail, 
we were able to determine that the AP-2 recruitment also depended upon the dileucine 
motif in Nef (Figure 2.9C).   
 
The  subunit of heterotetrameric adaptor protein complexes recognizes tyrosine based 
motifs (10, 65) whereas an interface between the  and large subunit ( or  
recognizes dileucine motifs (15, 27, 48). For MHC-I downmodulation, Nef promotes an 
interaction between the tyrosine binding motif in the 1 subunit of AP-1 and a conserved 
tyrosine in the cytoplasmic tail of MHC-I.  An AP-1 mutant with an inactive tyrosine 
binding pocket acts as a dominant negative inhibitor of MHC-I downmodulation (74, 93).  
To confirm that downmodulation of CD8  and CD28 did not utilize the AP-1 tyrosine 
binding pocket, we tested the impact of the tyrosine binding pocket mutant (TBPM) on 
these pathways.  In contrast to its effect on MHC-I, TBPM did not significantly inhibit 
CD8  or CD28 downmodulation by Nef (Figure 2.10A-B).  Similarly, knockdown of the 
AP-1 1 subunit had no significant effect on CD8  or CD28 downmodulation by Nef 
(Figure 2.11A-B).  Importantly, depletion of the AP-1  subunit did not significantly  
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Figure 2.10. Nef recruits AP-1 for the downmodulation of CD8  and CD28 in a 
tyrosine independant manner.  (A) Flow cytometric analysis of SupT1 T cells 
transduced with an adenoviral vector expressing Nef and a retroviral vector expressing 
the indicated μ subunit of AP-1.  TBPM; tyrosine binding pocket mutant μ subunit of AP-
1, WT μ; wild type μ subunit of AP-1.  The cells were analyzed by flow at 3 dpi.  (B) 
Quantitation of flow data from part A.  The relative fold downmodulation, where the fold 
downmodulation of each molecule in the presence of Wt AP-1 is set to 100% is shown.  
Error bars represent standard deviation, *** p<0.00001,  n=3. 
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reduce AP1  expression, and AP-1  depletion had a partial destabilizing effect on AP-
1  (Figure 2.11C). Therefore, AP-1 involvement in CD8 and CD28 downmodulation 
by Nef is independent of the AP-1 tyrosine-binding activity but could still depend on AP-
1 dileucine motif binding.  
 
Based on the requirement for Nef’s dileucine motif for CD8  and CD28 downmodulation 
as well as the lack of an effect of knocking down the AP-1  subunit, we next examined 
the effect of knocking down the large subunits of the clathrin associated adaptor proteins, 
which contain in part the dileucine motif recognition site (15, 27, 48).  Knockdown was 
achieved using lentiviral vectors expressing shRNAs directed against the large subunits 
of AP-1( ), AP-2( ), AP-3( ), and -COP.  Western blot analysis confirmed that we 
efficiently and specifically reduced expression of each target (Figure 2.11D).  We found 
that knocking down AP-1  and -COP significantly reduced the downmodulation of both 
CD8  and CD28 by Nef but the effect was only partial (Figure 2.11E).  The partial 
effects we observed may be due to incomplete knockdown or Nef utilization of multiple 
adaptor proteins in redundant pathways to achieve downmodulation of CD8 and CD28.  
Additionally, AP-2  knockdown had a small but significant effect on CD28 
downmodulation, consistent with previous reports and the interaction we observed 
between CD28 and AP-2 (Figure 2.11E) (82, 86).  Surprisingly, knockdown of AP-2 had 
no significant impact on CD4 downmodulation by Nef, despite a body of evidence tying 
CD4 downmodulation to this adaptor in other cell systems (16, 45, 82).   It is possible 
101 
 
 
 
 
Figure 2.11. Nef requires AP-1 and -COP for downmodulation of CD8 and CD28.  
(A) Flow cytometric analysis of CEM SS cells expressing the indicated chimeric protein 
and transduced with lentivirus expressing shRNA and GFP and subsequently transduced 
with the indicated adenoviral vector at 3 days post lentivirus.  Flow cytometric analysis 
was performed at 3 days post adenoviral transduction.  Histograms represent GFP-
expressing cells.  (B) Quantitation of the flow data from part A.  Fold downmodulation of 
the indicated molecule in the presence of shRNA.  (C) Western blot analysis confirming 
specific knockdown of AP-1 subunits in CEM SS cells.  (D) Western blot analysis 
confirming adaptor protein knockdown in SupT1 cells.  (E)  Relative downmodulation of 
the indicated molecule in SupT1 T cells transduced with the indicated lentivirus 
expressing shRNA and GFP plus a bicistronic retrovirus expressing Nef and a PLAP 
marker gene.  shNC; negative control.   The cells were analyzed by flow at 3 days post 
retroviral transduction.   The fold downmodulation normalized to the negative control in 
cells positive for both GFP and PLAP is shown.  * p<0.05, ** p< 0.01, ***p<0.001.   
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Figure 2.11. Nef requires AP-1 and -COP for downmodulation of CD8 and CD28.  
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 CD4 downmodulation by Nef can utilize multiple adaptor proteins and the degree to 
which it does so might vary in different cell systems.  However, this possibility remains 
ambiguous because when we attempted to knockdown more than one adaptor protein 
large subunits the toxicity was too great to assess Nef function (data not shown).   
 
2.3.7 Nef increases CD28 recycling 
We were surprised to observe robust recruitment of adaptor proteins to A2/CD28 in the 
presence of Nef, because the effect of Nef on steady-state surface expression of A2/CD28 
is relatively small.  Interestingly, CD28 is internalized at a rate similar to, or even greater 
than, that of CD4 in the presence of Nef ((82) and data not shown).  To address this 
discrepancy, we performed a recycling assay in which we observed a significant increase 
in CD28 recycling in the presence of Nef (Figure 2.12).  Thus, Nef may initially induce a 
potent downmodulation of CD28 through recruitment of AP-1 and/or AP-2 in parallel or 
redundant pathways, and then a subset of CD28 is rapidly recycled to the plasma 
membrane.  Thus, the effect of Nef on CD28 may vary depending on the recycling rates 
in different cell types. 
 \
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Figure 2.12.  CD28 is recycled rapidly in Nef-expressing cells.   
Measurement of recycling in CEM T cells expressing HLA-A2 or HLA-A2/CD28 and 
transduced with the indicated adenovirus.  Cells were harvested at 3 dpi, incubated with 
150 mg/mL cycloheximide for 2 hours to inhibit protein synthesis, and stripped of 
stainable HLA-A2 by removing the 2microglobulin with an acid wash (50 mM glycine, 
100 mM NaCl pH 3.4).  The cells were then incubated at 37
◦
C in culture medium + 
cycloheximide.  Triplicate samples were removed to ice at the indicated time points, 
stained for surface HLA-A2 expression (BB7.2), and analyzed by flow.  Recycling is 
plotted as percent of steady state, where the mean fluorescence of each time point was 
divided by the mean fluorescence of cells that were not acid stripped.  n=2. 
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2.3.8 Nef utilizes -COP in CD8  and CD28 downmodulation 
We also observed that knockdown of -COP significantly reduced the effect of Nef on 
CD8  and CD28 surface expression (Figure 2.11E (SupT1 cells) and 2.13A (CEM SS  
cells)).  This is interesting because COP is required for Nef-dependant trafficking of 
HLA-A2 and CD4 to lysosomes for degradation (79). COP knockdown has different  
effects on cell surface expression of MHC-I and CD4 in Nef expressing cells.  Whereas 
COP knockdown increases cell surface levels of MHC-I in Nef-expressing cells, 
COP knockdown does not always alter CD4 surface expression in Nef expressing cells 
(Figure 2.11E and (79)).  Instead, CD4 accumulates in intracellular vesicles and is unable 
to recycle to the cell surface in some cell types (70, 79).   
Nef contains two -COP binding sites, RR17,19 and EE155,156  (70, 79).  Nef RR17,19AA is 
defective at targeting MHC-I for degradation, while Nef EE155,156AA is defective at 
targeting CD4 for degradation, and both have a partially reduced ability to co-precipitate 
with -COP (79).  When both domains are mutated (R/E), Nef is unable to efficiently 
bind -COP and is defective at promoting the degradation of either MHC-1 or CD4 (79).  
We assessed the relative contributions of these Nef domains in CD8  and CD28 
downmodulation, and found that the R/E double-mutant was defective at 
downmodulating CD8  and CD28, while each of the single mutant Nef proteins 
demonstrated intermediate defects (Figure 2.13B-C).  Similar results were observed 
whether we assayed the chimeric panel (Figure 13B) or the full length target molecules 
(Figure 2.13C). 
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Figure 2.13.  -COP is required for Nef-mediated downmodulation of HLA-
A2/CD8 .  (A) Quantitation of relative downmodulation (normalized to control) of the 
indicated molecule expressed in CEM SS cells transduced with the indicated lentivirus 
expressing shRNA and a retroviral vector expressing Nef. The cells were harvested at 3 
days post retroviral transduction.  n=3.  (B and C)  Quantitation of fold downmodulation 
of the indicated molecule expressed in (B) CEM SS cells or (C) Sup T1 cells transduced 
with a retroviral vector expressing Nef or the indicated Nef mutants. Cells with equal 
GFP expression to control for Nef levels were analyzed at 3dpi.  The mean fold 
downmodulation +/- standard deviation is shown. n=3.  * p<0.05, **p<0.01, ***p<0.001.    
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2.3.9 Combined effects of AP-1 and -COP  
To further investigate the contribution of AP-1 and -COP to A2/CD8  degradation, we 
again utilized the shRNA lentivirus system to knockdown AP-1  and -COP, both singly 
and in combination.  We observed that knockdown of either AP-1 or -COP reduced the 
ability of Nef to downmodulate HLA-A2 and A2/CD8 .  However, knocking down both 
adaptors in combination did not have a significant additional inhibitory effect on 
downmodulation (Figure 2.13A).  Thus, the effect of Nef on CD8  results from effects of 
at least two cellular trafficking factors and possibly others (82). 
 
To examine whether HIV-1 Nef promoted degradation of CD8 , we performed western 
blot analysis focusing on the mature, endoglycosidase H (endo H) resistant form of each 
molecule.  As reported previously, Nef expression reduces the amount of endo H resistant 
HLA-A2 and this degradation is reversed by knocking down AP-1 or -COP (Figure 
2.14A, left panel and quantified in Figure 2.14B).  As previously observed, knocking 
down -COP also affected the migration of MHC-I, probably by disrupting the 
trafficking of enzymes required for proper glycosylation.  -COP knockdown does not 
inhibit trafficking of HLA-A2 through the Golgi, nor does it disrupt gross Golgi structure 
(79). 
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Figure 2.14.  -COP is required for Nef-mediated degradation of HLA-A2/CD8 .  
(A)  Western blot analysis of endonuclease H (endo H)-treated lysates from the cells 
described in part A.   (B) Quantitation of endo H resistant bands. The endoH resistant 
bands (indicated by “R” in the figure)  were quantified, normalized to the loading control, 
and shNC was set to 100% remaining. *p<0.05, **p<0.01, ***p<0.001, N=3.  
109 
 
In addition, we found that knockdown of COP dramatically reduced degradation of 
A2/CD8 (Figure 2.14A, right panel and quantified in Figure 2.14B).    A small but 
statistically significant effect of knocking down AP-1 on A2/CD8 degradation was also 
noted (Figure 2.14B).  
 
2.4 Discussion 
In summary, we have found that HIV-1 Nef has three major cellular targets: MHC-I, 
CD4, and CD8. The ability of Nef to downmodulate endogenous CD8 was confirmed in 
HIV infected primary CD4
+
CD8
+
 T cells. We also report here that the effect of Nef on 
MHC-I and CD8 depended at least in part on expression of AP-1 and -COP.  In 
addition, we found that the AP-1 binding motif utilized by Nef to recruit AP-1 to 
cytoplasmic tails varied depending on which cytoplasmic tail domain Nef was bound to.  
Finally, we found that mutation of both -COP binding sites in Nef reduced the activity 
of Nef against CD8.  Thus, one explanation for the capacity of Nef to affect multiple 
targets is that it has evolved redundant mechanisms to recruit the same adaptor proteins.   
 
Downmodulation of CD8, which participates in the recognition of antigen in association 
with MHC-1 provides a second Nef-dependent mechanism by which HIV-infected cells 
could avoid CTL lysis. While CD8
+
 T cells are not generally thought to be targeted by 
HIV, there is mounting evidence that a subset of CD8
+
 T cells upregulate CD4 in 
response to activation stimuli, and that these cells demonstrate antiviral activity, thus 
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creating an infectable target cell, the inhibition of which would be beneficial to HIV (31, 
51, 52, 83, 94).  Nef might also access CD8
+
 T cells through cell-cell contacts, as was 
described to occur between infected and bystander T cells (63).  Cell-cell conduits have 
also been described between Nef expressing APCs and bystander B cells.  Moreover 
these nanotubular conduits have been shown to transmit Nef (72).  If Nef were 
transferred when CTLs contacted an infected target, the transmitted Nef could 
downmodulate CD8 and reduce the efficacy of the anti-HIV-specific CTL attack.  
Finally, there are reports of CD8-tropic HIV strains  providing another potential scenario 
in which Nef could encounter CD8 (37, 38, 59, 71, 77, 89).  
 
This study is the first to assess the contribution of AP-1 and -COP to the 
downmodulation of CD28 and CD8 .  Another group has reported a partial requirement 
for AP-2 in the downmodulation of CD4 and CD8 that we did not observe here (82).  
However, the literature is conflicting on this point; some groups report a defect in CD4 
downmodulation when AP-2 is knocked down, while other groups observe no effect (15, 
75, 82).  Additionally, co-depletion of Eps15 and AP-2 may be required to observe an 
inhibition of Nef activity against CD4 (45). Knockdown of adaptor protein subunits is 
technically difficult, as highly efficient depletion of these proteins can be lethal to cells.   
For these reasons we may have underestimated the contribution of AP-2 in CD28 and 
CD8  downmodulation by Nef in our system. AP-1- and AP-2-dependant mechanisms 
may represent parallel or redundant pathways, which Nef can utilize depending upon 
cellular localization and availability of cellular adaptors.   
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Here we have presented direct evidence that Nef can recruit AP-1 by utilizing either the 
tyrosine motif recognition site or the dileucine recognition site of AP-1, and that this is 
determined by which cytoplasmic tail domain Nef is bound to (Figure 2.15A-B).  
Previous studies found that the dileucine motif in Nef is required for glutathione-S-
transferase (GST)-Nef pull-down of AP-1 complexes from mammalian cell lysates (11, 
44) and for interactions detected in yeast two and three hybrid analyses (11, 24, 25, 29, 
35, 43, 44, 55, 69) but the dileucine motif is dispensable for  MHC-I downmodulation 
even though AP-1 is required (62).   CD4 downmodulation by Nef requires the dileucine 
motif, but does not involve AP-1 (35).  Thus, the interaction between AP-1 and the 
dileucine motif has remained unexplained.  Here we provide evidence that this interaction 
is utilized to target CD8 (and CD28).   
 
We have also identified -COP as a common factor in the downregulation and 
degradation of all three major targets of Nef: MHC-I, CD4, and CD8 .  The evidence 
presented here is consistent with a model in which Nef utilizes AP-1 or AP-2 to direct 
cellular targets into endosomal compartments, where Nef subsequently recruits -COP to 
route targets to the lysosomes for degradation as previously proposed for MHC-I and 
CD4 (Figure 2.15F).  However, the fact that the degradation of CD8 was far more 
dependent on -COP expression than on AP-1 expression indicates that -COP may also 
directly target intracellular CD8 for degradation in Nef expressing cells without the need 
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for additional adaptor proteins (Figure 2.15F).  The requirement for -COP in multiple 
Nef pathways may represent a good target for therapeutic inhibition of Nef.   
 
CD28 appears to be a unique target of Nef, in that it is downmodulated consistently by a 
panel of Nef variants, but the effect is small relative to the other targets of Nef.  The 
small effect of Nef on steady-state surface CD28 seems at odds with the observation that 
CD28 is internalized at a rate similar to that of CD4 in the presence of Nef ((82) and data 
not shown).  This discrepancy may be explained by the observation that CD28 recycling 
is significantly increased in Nef-expressing cells. SIV Nef downmodulates CD28 more 
potently than HIV-1 Nef; therefore CD28 downmodulation may be more important for 
SIV pathogenesis.  It is also possible that CD28 recycling may be regulated in some cell 
systems, and that a physiologically relevant set of conditions exists which would result in 
less recycling of CD28 and more downmodulation of CD28 by HIV-1 Nef.  
 
We were unable to reproduce data reported by another group that CD80 and CD86 were 
downmodulated by Nef.  There were some differences in the cell lines used in our study 
compared with the previous report.  The previous studies used endogenously expressed 
CD80 and CD86 in the U937 monocytic cell line.  However, even when replicating the 
published culture conditions, we were able to observe only low levels of CD80 on the cell 
surface, and no CD86 at all, leading us to believe that our clone of the U937 line is 
inherently different from that used to report downmodulation of CD80 and CD86.  This 
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may be the cause for the discrepancy between our results and others, and is the reason 
that we utilized primary macrophages and DCs as a highly relevant system for 
investigating Nef activity against these potential targets.  We were unable to detect an 
effect of Nef on CD80 or CD86 under established stimulation and culture conditions for 
primary macrophages and DCs, indicating that Nef targeting of these proteins must only 
occur under specialized circumstance that we were unable to replicate.  CD1d also 
appears to be a special case, in that all Nef isolates do not retain the ability to reduce 
surface expression of this molecule, yet one or more Nef variants may be capable of 
doing so to a limited extent.  This may be rare, evolutionarily driven by some 
infrequently occurring host factor, or may be a feature of certain HIV-1 clades.  
 
In summary, we have identified three major targets of HIV-1 Nef: MHC-I, CD4 and CD8 
and these results were generalizable to multiple Nef variants.  We also demonstrated that 
downmodulation of CD8 and CD28 required AP-1 recruitment and was dependent upon 
Nef’s dileucine motif.  This observation indicates that Nef can interact with AP-1 through 
either the tyrosine binding pocket or dileucine recognition domain of AP-1, depending 
upon which cytoplasmic tail Nef is associated with.  Finally, we discovered a role for -
COP in the downregulation and degradation of CD8, as well as MHC-I and CD4, which 
represents a convergence of the all the trafficking mechanisms utilized by Nef. 
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Figure 2.15.  Schematic representation of the two AP-1 binding sites that Nef utilizes 
when bound to the MHC-I cytoplasmic domain (A), Nef recruits AP-1 through the 
tyrosine recognition site in the AP-1  subunit (93).  In this model the three-way complex 
requires amino acid residues in both MHC-I, especially Y320, as well as in Nef, M20 in 
particular (although assays using purified proteins and a Nef-MHC-I cytoplasmic tail 
fusion protein did not demonstrate a requirement for M20) (64, 74, 81, 93).  When bound 
to the CD8 or CD28 cytoplasmic tails, Nef recruits AP-1 through the dileucine 
recognition site at the interface between the  and  subunits of AP-1 (49).  C-E) 
Schematic representation of the Nef domains involved in -COP recruitment.  Nef 
residues R17,19 are required for -COP involvement in MHC-I degradation (C) (79).  A 
diacidic motif in Nef, EE155,156, is required for -COP involvement in CD4 degradation 
(D) (30, 70, 79).  Either or both Nef domains likely participate in -COP recruitment for 
the degradation of CD8 by Nef (E).  F) Model of the trafficking pathways Nef uses to 
achieve downmodulation and degradation of target proteins.  Nef blocks anterograde 
transport in an AP-1-dependant pathway (47, 74, 85).  Nef also induces internalization of 
target molecules at the plasma membrane through an association with AP-1 or AP-2 (11, 
16, 24, 45, 61, 79, 82, 86).  These pathways likely converge at a -COP-dependant step 
(79).  Because AP-1 knockdown did not block -COP-dependent degradation of 
A2/CD8, Nef may be able to direct some targets into endolysosomal compartments by a 
pathway in which only -COP recruitment is necessary, and clathrin-associated adaptor 
proteins are dispensable.  PM stands for plasma membrane; LY indicates lysosome; LE/ 
MVB indicates late endosome or multivesicular body compartments.  
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Figure 2.15. Schematic representation of the two AP-1 binding sites that Nef utilizes 
when bound to the MHC-I cytoplasmic domain 
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2.5 Experimental methods 
2.5.1 Cell culture 
Bosc and 293T viral packaging cells were cultured in high glucose DMEM supplemented 
with 10% fetal bovine serum (FBS) and 2 mM penicillin, streptomycin, and glutamine 
(PSG). CEM-SS and SupT1 cells lines were maintained in RPMI 1640 supplemented 
with 10% FBS and 2 mM PSG.  
 
2.5.2 Preparation of T cell lines expressing HLA-A2-chimeric molecules 
Stable cell lines were made as previously described (3).  Briefly, each construct was 
introduced into CEM-SS or SupT1 cells using the Murine Stem Cell Virus (MSCV) 
retroviral vector pseudotyped with VSV-G.  A uniform population was selected by 
culturing the cells in neomycin. 
 
2.5.3 Primary T cell preparation 
 Leukopaks were obtained from the New York Blood Center. Peripheral blood 
mononuclear cells (PBMCs) were purified using ficoll gradients.  Non-adherent cells 
were stimulated with 10μg/mL phytohemaglutinin (PHA, Sigma-Aldrich) overnight and 
the next day 50 U/mL interleukin(IL)-2 was added.   
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2.5.4 Preparation of macrophages and dendritic cells 
Primary monocytes were obtained from whole PBMCs by positive selection using a 
magnetic sorting kit (EasySep Human CD14 selection kit, StemCell Technologies).  The 
CD14+ cells were induced to mature into macrophages by culturing in RPMI + 10 ng/mL 
GM-CSF (R&D Systems) for 5 days.  The CD14+ cells were induced to mature into 
dendritic cells (DC) by culturing in RPMI + 800 U/mL GM-CSF and 500 U/mL IL-
4,with the addition of 100 U/mL TNF on day 3 (all from R&D Systems).  DCs were 
stimulated 9 days in total before infection. 
 
2.5.5 DNA Constructs 
The CD80, CD1d, and CD8  cytoplasmic tails were fused to the extracellular and 
transmembrane regions of HA-tagged HLA-A2 using PCR cloning methods. HA-HLA-
A2 (1), was used as the PCR template.  The following oligonucleotide primers were used:  
HA-HLA-A2/CD8 forward primer 5’-CGGGATCCACCATGCGGGTCACGGCG-3’ 
and reverse primer 5’-
GTGGTCGCTGCTGTGATGTGGTGCTGCCGGCGGAGGAGAGCCCGGCTTCGTT
TCATGAAACAATTTTACAAATAACTCGAGCGG-3’.   HA-HLA-A2/CD80 forward 
primer 5’-CGGGATCCACCATGCGGGTCACGGCG-3’ and reverse primer 
5’AGCTGTGGTCGCTGCTGTGATGTGGAGATGCAGAGAGAGAAGGAGGAATG 
AGAGATTGAGAAGGGAAAGTGTACGCCCTGTATAACTCGAGCGG3’.  HA-
HLA-A2/CD1d forward primer 5’-CGGGATCCACCATGCGGGTCACGGCG-3’ and 
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reverse  primer 5’-
GCTGCTGTGATGTGGTCCCGGTTTAAGAGGCAAACTTCCTATCAGGGCGT 
CCTGTGACCGCTCGAGCGG-3’.  The CD28 tail was fused to HA-HLA-A2 in a two-
step cloning method.  First a 3’ fragment was created using two overlapping oligos that 
span the entire CD28 cytoplasmic tail sequence, along with a forward primer which 
appended a 15 base pair sequence which overlapped with the transmembrane region of 
HLA-A2, and a reverse primer to introduce a 3’ XhoI site.  The oligo sequences are as 
follows:  5’ oligo 5’-
AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCC 
CCGCCGCCCCGGGCCCACCCGCAAG-3’, 5’-
CGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACG 
CGACTTCGCAGCCTATCGCTCCTGA-3’, 5’-
GGTCGCTGCTGTGATGTGGAGGAGTAAGAGGAGCAGGCTC-3’ AND 5’-
TCGCAGCCTATCGCTCCTGACTCGAGGG-3’.  A second round of PCR then 
generated the HA-HLA-A2/CD28 using HA-HLA-A2 and the CD28 fragment generated 
in the first PCR reaction as templates.  The following primers were used: 5’-
CGGGATCCACCATGCGGGTCACGGCG-3’ and 
5’-TCGCAGCCTATCGCTCCTGACTCGAGGG-3’.  The full length CD86 gene was 
cloned from the Megaman human cDNA library (Stratagene) into pLITMUS29 (NEB).  
The CD86 cytoplasmic tail was fused to HA-HLA-A2 in a manner similar to CD28 
above.  A first round of PCR generated a CD86 cytoplasmic tail fragment with 15  base 
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pairs 5’ to the CD86 tail that overlap with the transmembrane region of HLA-A2 using 
full length CD86 as the template and the forward primer 5’-
gtggtcgctgctgtgatgtggaaatggaagaagaagaagc-3’ and reverse primer 5’-
aagtgatacatgtttttaactcgagcgg-3’.  A second PCR reaction was performed to create HA-
HLA-A2 with a 15 base pair 3’ region that overlapped with the 5’sequence of the CD86 
tail.   HA-HLA-A2 was the template and the primer sequences were forward primer 5’-
CGGGATCCACCATGCGGGTCACGGCG-3’ and reverse primer 5’-
GTGGTCGCTGCTGTGATGTGGAAATGGAAGAAGAAGAAGC-3’.  A third round 
of PCR, using the products of the first and second PCR reactions, resulted in the full 
length HA-HLA-A2/CD86 chimera.  The following primers were used:  forward primer 
5’-CGGGATCCACCATGCGGGTCACGGCG-3’ and reverse primer 5’-
AAGTGATACATGTTTTTAACTCGAGCGG-3’.  The PCR products were digested 
BamHI to XhoI and then ligated into the BglII and XhoI sites of MSCV2.2 (2).   The 
resultant constructs were sequenced to ensure that no mutations were introduced during 
cloning. 
 
2.5.6 Cloning of nef alleles into pMIG 
 Nef alleles were cloned into the Bgl II and Eco RI sites of pMIG vector obtained from 
Dr. Luk Van Parijs (MIT) (28). Nef alleles containing a 5’ Bam HI and 3’ Eco RI site 
were PCR-amplified from cloned HIV genomes obtained through the AIDS Research 
Reference Reagent Program, Division of AIDS, NIAID, NIH (7, 8, 12). The following 
oligonucleotide primers were used: 5’ oligonucleotides: 5’ Nef-1 5’-
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CGGGATCCACCATGGGTGGCAAGTGGTCAAAA-3’ (All except 92UG037, 
93BR029 and 92RW009) 
5’Nef-2 5’-CGGGATCCACCATGGGTAACAAGTGGTCAAAG-3’ (92UG037) 
5’Nef-4 5’-CGGGATCCACCATGGGTAGCAAGTGGTCAAAA-3’ (93BR029 and 
92RW009) 
3’ oligonucleotides: 
89.6 5’-CGGAATTCTCAGTTCTTGAAGTACTCCGGATG-3’ 
92UG037 5’-CGGAATTCTCAGCAGTCTTTGTAAAACTCCGG-3’ 
93BR020 5’-CGGAATTCTCAGTCTTGGTAGTACTCCGGATG-3’ 
NL4-3/84ZR 5’-CGGAATTCTCAGCAGTTCTTGAAGTACTCCGG-3’ 
PEYYKDC 5’-CGGAATTCTCAGCAGTCTTTGTAGTACTCCGG-3’ 
(93BR029, 92RW009, 94UG114) 
YU-2 5’-CGGAATTCTCAGTTCTTGTAGTACTCCGGATG-3’ 
All alleles were sequenced to ensure that no mutations were introduced during cloning. 
 
2.5.7 shRNA constructs 
FG12 shRNA lentiviral vectors were constructed as previously described (73, 79).  ShNC 
and construct targeting -COP were previously described (79).  The target sequence for 
shAP1  began at position 1201-
GATCCCCGCAGACTGTGCATCTGGAATTCAAGAGATTCCAGATGCACAGTCT
GCTTTTTGGAAA.  The AP2  target sequence was 
GATCCCCGTCAGAGTTCCGACAGAACTTCAAGAGAGTTCTGTCGGAACTCTG
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ACTTTTTGGAAA. The target sequence for shAP3  began at position 4180-
GATCCCCGAGAGGTTGCAGTCAGAACTTCAAGAGAGTTCTGACTGCAACCTC
TCTTTTTGGAAA 
 
2.5.8 Viral transductions 
Adenovirus was prepared by University of Michigan Gene Vector Core, and infection of 
CEM-SS cells were performed as previously described (74, 91).  Murine retroviral vector 
preparation and transduction were performed as described (68, 90, 93).  shRNA-
containing lentivirus preparation and transduction have also been described (73, 79).  
Infection of PBMCs with HIV constructs was performed as in (22).  Primary APCs were 
infected with adenovirus at MOIs titrated to generate similar Nef expression levels 
compared to what we typically obtain in CEM cells.  In these experiments, CEM cells 
were infected with an MOI of 50, primary macrophages were infected with an MOI of 
250, and primary DCs were infected with an MOI of 500. 
 
2.5.9 Western blot analyses and immunoprecipitations 
Cells were lysed in PBS 0.3% CHAPS, 0.1% SDS pH 8, 1 mM PMSF, normalized for 
total protein and separated by SDS-polyacrylamide gel electrophoresis.  Endo H (NEB) 
digestion was performed according to the manufacturer's protocol.  Immunoprecipitations 
were performed as previously described (93).  Briefly, cells were lysed in 1% digitonin 
(Wako) and normalized for total protein.  Lysates were precleared overnight with A/G 
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beads (Pierce) and isotype control antibody (BD Biosciences).  BB7.2-crosslinked A/G 
beads were used for immunoprecipitation, and were washed five times with 0.1% 
digitonin buffer prior to elution with 150 mM DTT.  
 
Samples were separated by SDS-PAGE.  HA-HLA-A2 and the chimeric proteins were 
detected using the anti-HA antibody HA.11 (1:5000; Covance).  Nef was detected with 
AG11 (1:5000), and -COP  with M3A5 (2) which were purified as described (46).  
Adaptor protein subunits were detected with anti-AP-2 , anti-AP1 and anti-AP3  (all 
1:500; BD Bioscience) or Ry/1 anti-AP1  (1:5000) (88).  The secondary antibody for 
anti-Nef, β-COP, HA, AP-2 , and anti-AP3  was HRP-rat anti-mouse IgG1 (Zymed), for 
anti-AP1 was HRP-rat anti- -μ1 was HRP-goat 
anti-rabbit (Zymed).  
 
2.5.10 Flow cytometry 
Intact cells were stained in FACS Buffer (2% FBS, 1% human serum, 1% Hepes, and 
0.025% NaN3 in PBS).  Primary cells were pre-incubated with 10% Fc-Receptor Blocker 
(Accurate Chemical and Scientific Corps) prior to primary antibody incubation.  
Chimeric molecules were detected with HA.11 (1:50; Covance) or BB7.2 (1:500).  
Endogenous proteins were detected with BB7.2 (1:500), OKT4 (1:500), OKT8 (1:500), 
all prepared by the University of Michigan Hybridoma Core and purified as previously 
described (46), or anti-CD8  5F2 (1:100; Santa Cruz), CD28.2 (1:100; Biolegend), CD80 
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(1:100; BD Pharmingen), CD86 (1:100; BD Pharmingen), CD1d (1:100; eBioscience).  
Isotype-specific secondary antibodies conjugated to PE, alexafluor 488, or alexafluor 647 
were used at 1:250 (Invitrogen). 
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Chapter 3 
 ARF-1 activity is required to recruit AP-1 to the MHC-I 
cytoplasmic tail and disrupt MHC-I trafficking in HIV-1 
infected primary T cells 
 
3.1 Abstract 
HIV-1 infected cells are partially resistant to anti-HIV cytotoxic T lymphocytes due to 
the effects of the HIV Nef protein on antigen presentation by MHC-I  and evidence has 
been accumulating that this function of Nef is important in vivo. HIV Nef disrupts  
normal expression of MHC-I by stabilizing a protein-protein interaction between the  
clathrin adaptor protein AP-1 and the MHC-I cytoplasmic tail.  There is also evidence 
that Nef activates a PI3-kinase-dependent GTPase (ARF-6) to stimulate MHC-I 
internalization. However, the relative importance of these two pathways is unclear.  Here 
we report that a GTPase required for AP-1 activity (ARF-1) was needed for Nef to 
disrupt MHC-I surface levels whereas no significant requirement for ARF-6 was 
observed in Nef expressing T cell lines and in HIV-infected primary T cells.  An ARF-1 
inhibitor blocked the ability of Nef to recruit AP-1 to the MHC-I cytoplasmic tail and a 
dominant active ARF-1 mutant stabilized the Nef-MHC-I-AP-1 complex.  These data 
support a model in which Nef and ARF-1 stabilize an interaction between MHC-I and 
AP-1 to disrupt presentation of HIV-1 epitopes to CTLs. 
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3.2 Introduction 
CD8
+
 cytotoxic T lymphocytes (CTLs) are important for the control of chronic viral 
infections.  In a virally infected cell, MHC-I molecules present peptides derived from 
viral proteins.  Once the T cell receptor (TCR) on CD8
+
 CTLs recognizes a “non-self” 
signal presented by MHC-I, the CTL releases perforins and granzymes which kill the 
virally infected cell preventing further spread of the virus (reviewed in (3)).   CTLs play 
an important role in the control of HIV infection (for review see (9)) and recent evidence 
indicates that individuals mounting a Gag-specific CTL response have improved 
parameters with regard to controlling disease (16, 24).  Despite the efficacy with which 
CTLs control viral load early in infection, anti-HIV CTLs ultimately fail to prevent 
progression of disease in most infected people.    
  
Studies performed in vitro have revealed that the HIV Nef protein protects infected cells 
from CTL-mediated lysis (8, 26, 52, 61).  Nef has been shown to protect HIV-infected 
primary T cells from CTL lysis using flow cytometric killing assays (8, 26), CTL co-
culture assays (61) and chromium release assays (52).  Although Nef limits the ability of 
CTLs to recognize and kill infected cells, it does not appear to abrogate the capacity of 
CTLs to produce inhibitory cytokines in response to infected cells (52).  Recent in vivo 
evidence supports the hypothesis that CTLs may control HIV infection in vivo primarily 
by the elaboration of inhibitory cytokines, but fail to eradicate the infection because the 
CTLs cannot efficiently lyse the infected cell source of new virions (60). 
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Nef binds directly to the cytoplasmic tail of MHC-I allotypes (58) and recruits the 
clathrin adaptor protein AP-1 to redirect MHC-I into an endolysosomal pathway from the 
trans-Golgi network (TGN) and to prevent its expression at the cell surface (41).  There 
is evidence that MHC-I delivered to endosomes via the activity of AP-1 is subsequently 
targeted for degradation via Nef binding to the COP-I coatomer, -COP (44).   
 
Nef has also been implicated in promoting internalization of MHC-I from the cell surface 
(45).  The relative contribution of internalization versus disruption of forward transport to 
overall MHC-I downmodulation varies depending on the cell type (23) and has been 
attributed to both ARF-6 (4) and AP-1 (23, 28) dependent pathways.  The relative 
importance of ARF-6 versus AP-1 has not yet been determined in studies that directly 
compared their roles. 
 
The adaptor protein AP-1 is a heterotetrameric complex that recognizes trafficking 
signals in cargo and recruits clathrin-sorting machinery to the trans-Golgi network.  AP-1 
is made up of  1, 1, , and 1 subunits, which collectively sort cargo containing Yxx  
or [D/E]xxxLL trafficking signals into the endo-lysosomal network (for review see (40)).  
MHC-I downmodulation can be inhibited by knocking down expression of the AP-1 1 
subunit (41, 44) or by overexpressing a dominant negative mutant of AP-1 1 which 
lacks a functional tyrosine-binding pocket (47, 59).  Mutation of a tyrosine residue in the 
MHC-I cytoplasmic tail disrupts binding of AP-1 to the Nef-MHC-I complex in cells (41, 
59) and in experiments using purified proteins (32, 47).  Based on these data, the AP-1 
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tyrosine-binding pocket has been proposed to interact with the MHC-I cytoplasmic tail 
tyrosine and this interaction is stabilized by Nef. 
 
Binding of adaptor proteins to trafficking signals is normally regulated by the activity of 
ADP-ribosylation factors (ARFs), which are small GTPases that control assembly and 
disassembly of intracellular trafficking complexes.  ARF activation and recruitment to 
cellular membranes is cyclical and regulated by its GTP binding state. Guanine 
nucleotide exchange factors (GEFs) promote the exchange of GTP for GDP. GTPase-
activating proteins (GAPs) support ARF catalysis of GTP and thus are important to 
inactivate ARF ((20) and reviewed in (13)).  There are a number of different ARF 
proteins expressed by cells.  ARF-1 is a clathrin regulatory protein that, upon binding 
GTP, undergoes a conformational change exposing a myristoyl group that inserts into 
membranes and subsequently stabilizes AP-1 (1, 48, 54) or COP-I coatomer (46, 54) 
binding to trafficking signals.  The ARF-1 GEF inhibitor brefeldin A (BFA) stabilizes an 
abortive ARF-GDP-bound complex (35) thus preventing ARF-1 cycling.  
 
ARF-6 is a related GTPase that regulates the recycling of cargo that has been internalized 
by clathrin-independent endocytosis (10, 38).  There is evidence that ARF-6 is required 
for Nef-dependent MHC-I downmodulation based on experiments with ARF-6 mutants 
that are “locked” in a GDP-bound, inactive state (ARF-6-T27N) or a GTP-bound, 
constitutively active state (ARF-6-Q67L) (4, 10, 38).  
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Here, we demonstrate that ARF-1 activity was required for Nef-dependent MHC-I 
trafficking via AP-1.  Co-precipitation of AP-1 with the MHC-I-Nef complex was 
specifically inhibited by BFA and stabilized by constitutively active ARF-1 Q71L (51). In 
contrast, we were unable to detect a clear requirement for ARF-6.   These data help to 
clarify the relative contributions of the two major pathways implicated in HIV immune 
evasion and highlight the AP-1/ARF-1 pathway as an important potential target for drug 
development. 
 
3.3 Results 
3.3.1 Functional ARF-1 is required for Nef to disrupt the trafficking of MHC-I 
Nef binds directly to the cytoplasmic tail of MHC-I allotypes (58) and recruits the 
clathrin adaptor protein AP-1 to redirect MHC-I into an endolysosomal pathway from the 
trans-Golgi network (TGN) and to prevent its expression at the cell surface (41).  
However, it is not known whether Nef-dependent AP-1 binding and clathrin recruitment 
bypass the normal AP-1 regulatory steps that include the GTPase, ARF-1.  To determine 
if ARF-1 activity was necessary for Nef to disrupt the transport of MHC-I to the cell 
surface, we utilized two ARF-1 mutants, ARF-1 T31N and ARF-1 Q71L.   ARF-1 T31N is 
defective because it does not exchange GDP for GTP (11).  ARF-1 Q71L is a dominant 
active form of the molecule that stably binds GTP (51). We also tested BFA, which 
inhibits the activity of ARF-1 GTP exchange factors (GEFs).   
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Figure 3.1.  ARF-1 activity is required for Nef-induced downmodulation of HLA-
A2.  (A) Flow cytometric analysis of HLA-A2, HLA-A2 A323V, and CD4 surface 
expression plus or minus Nef in cells expressing ARF-1 constructs as indicated.   Cells 
expressing ARF-1 vector control were GFP
+
 and these cells were gated on for this 
analysis.  Dark gray shaded curve, vector alone; Light gray shaded curve, adeno-Nef; 
black curve, adeno-Nef plus ARF-1 as indicated. BFA, brefeldin A. (B)  Western blot 
analysis of Myc-ARF-1 expression levels in transduced CEM T cells (C and D) 
Quantitation of part (A). The median fluorescence normalized to wild type ARF-1 is 
shown  sd, n ≥ 3.   * denotes a p-value of <0.05, ** denotes a p-value of <0.01, and *** 
denotes a p-value of <0.001.    
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We found that overexpression of wild type and T31N ARF-1 did not significantly affect 
Nef-dependent MHC-I downmodulation (Figure 3.1A and 3.2, quantified in Figure 3.1C-
D). However, the ARF-1 inhibitor, BFA, significantly increased MHC-I surface 
expression in the presence of Nef  (Figure 3.1A and quantified in Figure 3.1C-D).  The 
lack of a phenotype with overexpression of MHC-I T31N was not due to poor expression 
(Figure 3.1B) but likely resulted from the presence of endogenous wild type ARF-1 that 
was sufficient for Nef activity. CD4 downmodulation by Nef was unaffected by these 
inhibitors consistent with previously published data showing that internalization and 
degradation of CD4 are independent of the GTP-bound state of ARF-1 (Figure 3.1A and 
C) (15).   
 
In addition, we observed a striking inhibitory effect of dominant active ARF-1 (Q71L) on 
Nef-dependent MHC-I downmodulation (Figure 3.1A, quantified in Figure 3.1C).  Based 
on this result, we postulated that this mutant might inhibit MHC-I downmodulation by 
blocking the cycling of ARF-1 and thus sequestering essential trafficking machinery 
required to maintain low MHC-I surface levels.  
 
We also observed an inhibitory effect of BFA and ARF-1 (Q71L) on MHC-I surface 
expression in the absence of Nef (quantified in Figure 3.1C-D).  This is expected due to 
the known effects of these factors on protein export form the endoplasmic reticulum (27).  
Despite the inhibitory effect of these factors on MHC-I surface expression in the absence 
of Nef, both BFA and ARF-1 (Q71L) caused a significant increase in MHC-I surface 
expression in the presence of Nef (Figure 3.1).  The opposing effects observed in the  
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Figure 3.2.  Two-color flow cytometry of HLA-A2 or CD4 in CEM T cells 
transduced with either control or Nef-expressing adenovirus and ARF-1 or ARF-6 
constructs.  ARF-1 and ARF-6 open reading frames were inserted into bi-cistronic 
retroviral vectors and virus produced from these constructs was used to transduce CEM T 
cells.  GFP expression serves as an indicator of transduction efficiency and relative gene 
expression.  The percentage of cells that are GFP
+ 
is indicated within the plot.  The mean 
fluorescence intensity of MHC-I in the GFP
+
 cells is indicated below each plot. 
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Figure 3.2. Two-color flow cytometry of HLA-A2 or CD4 in CEM T cells 
transduced with either control or Nef-expressing adenovirus and ARF-1 or ARF-6 
constructs.
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absence versus the presence of Nef supports the conclusion that these inhibitors are 
specifically affecting Nef-dependent pathways. 
 
For comparison, we also included a molecule that contained a more natural AP-1 
trafficking signal, which was previously shown to bind AP-1 in the absence of Nef. This 
signal was made by substituting a valine for an alanine in the cytoplasmic tail of MHC-I 
HLA-A2 to create a Yxx  sorting signal [Y320SQV323 (HLA-A2 A323V)] (59). Compared 
to wild type MHC-I HLA-A2, this molecule has relatively low surface expression due to 
its interaction with AP-1 (59).   Interestingly, the effect of ARF-1 mutants and BFA on 
the surface expression of HLA-A2 A323V in the absence of Nef was somewhat different 
than what occurred in the presence of Nef.  The main difference was that, in the absence 
of Nef, there was a relatively small but statistically significant further reduction of HLA-
A2 A323V expression with the dominant active mutant ARF-1 Q71L (Figure 3.1C).  
Whereas in the presence of Nef, ARF-1 Q71L inhibited the Nef-dependent reduction in 
surface expression of HLA-A2 molecules (Figure 3.1A and C).  Given that HLA-A2 
A323V is a model for trafficking due to AP-1, these differences provide suggestive 
evidence that the effects of Nef on MHC-I HLA-A2 are not due to AP-1 alone and 
probably involve additional steps that are disrupted by ARF-1 Q71L. 
 
3.3.2 Functional ARF-6 is dispensable for Nef-dependent MHC-I downmodulation 
ARF-6 may also be important for Nef-dependent internalization of MHC-I based on 
evidence that dominant active ARF-6 (Q67L) inhibited internalization of MHC-I by Nef 
in HeLa cells (4). To examine the relative effect of ARF-1 and ARF-6 mutants on Nef  
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Figure 3.3.  ARF-1 but not ARF-6 activity is required for Nef-dependent HLA-A2 
and CD4 downmodulation in T cell lines.  (A) Flow cytometric analysis of HLA-A2 or 
CD4 surface expression in CEM-SS cells transduced with control or Nef-expressing 
adenovirus plus the indicated ARF-6 construct.  ARF-6 proteins were expressed via bi-
cistronic murine retroviral vectors that also expressed GFP.  Similar GFP
+
 populations 
based on FL-1 mean were analyzed for HLA-A2 or CD4.  Gray shaded curve, control 
vector; gray outlined curve, adeno-Nef; black curve, adeno-Nef plus the indicated ARF-6 
protein.  (B) Quantitation of part (A). The median fluorescence normalized to wild type 
ARF-6 is shown  sd, n=3.  (C)  Western blot of ARF-6 and Nef expression.  
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activity in our system, we generated ARF-6 constructs analogous to the ARF-1 constructs 
tested in Figure 3.1.  We found that, in contrast to the effect of ARF-1 mutants, there was 
no significant effect of ARF-6 mutants on Nef activity (Figure 3.3A-B).   As controls, we 
demonstrated that the ARF-6 mutants were expressed in the cells (Figure 3.3C).  
Additionally, we verified that the ARF-1 and ARF-6 constructs transduced the cells with 
similar efficiency (Figure 3.2).  For these experiments the ARF-1 and ARF-6 constructs 
were made identically as bi-cistronic elements that co-expressed GFP from an internal 
ribosome entry site (Figure 3.2) allowing GFP to serve both as a measure of transduction 
efficiency and as a measure of relative expression levels. 
 
ARF-6 Q67L was active in our experimental system based on its effect on MHC-I surface 
expression in the absence of Nef.  Microscopic analysis revealed intracellular 
accumulation of HLA-A2 in CEM-SS cells expressing ARF-6 Q67L, but not in cells 
expressing wild type ARF-6 or ARF-6 T27N (Figure 3.4).  This phenotype is consistent 
with previous reports that proteins that normally traffic through ARF-6 compartments are 
trapped in the presence of ARF-6 Q67L (5, 30). 
 
Previous studies have suggested that Nef activates ARF-6 via a PI3-kinase-dependent 
step.  Thus, levels of the PI3-kinase inhibitor, phosphatase and tensin homolog (PTEN), 
could influence the relative amount of ARF-6 dependent activity we observed.   Indeed, it 
has been suggested that lower expression level of PTEN in the CEM-SS cell line used in 
some of our studies may influence PI3K-induced ARF-6-dependent effects on MHC-I 
and limit our ability to detect this pathway (19).   To address this possibility, we used  
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Figure 3.4  ARF-6 Q67L disrupts HLA-A2 localization in a Nef-independent manner 
in T cell lines.  Visualization of HLA-A2 expression in CEM-SS cells transduced with 
the indicated ARF-6 construct.  ARF-6 proteins were expressed via bi-cistronic murine 
retroviral vectors that also expressed GFP.  GFP and HLA-A2 were detected by confocal 
microscopy.   
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Figure 3.5.  ARF-1 but not ARF-6 activity is required for Nef-dependent HLA-A2 
and CD4 downmodulation in PTEN-expressing T cell lines. (A) Western blot of 
PTEN or control (GAPDH) levels in the indicated cell type.  (B) Flow cytometric 
analysis of HLA-A2 surface expression in SupT1 cells transduced with control or Nef-
expressing adenovirus plus the indicated ARF-6 construct and analyzed as described in 
part A. Dark gray shaded curve, control adenovirus plus ARF as indicated;   
Light gray shaded curve, adeno-Nef plus vector; black curve, adeno-Nef   
plus ARF as indicated. (C) Quantitation of part (B). The median fluorescence normalized 
to empty vector treatment is shown  sd n=3.  Values obtained with wild type ARF-1 
were significantly different than those with ARF-1 Q71L (p< 0.01).  Values obtained with 
wild type ARF-6 were not significantly different than those with ARF-6 Q67L  (p= 0.46).   
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western blot analysis to examine the levels of PTEN expression in several cell lines, as 
well as in primary CD4
+
 T lymphocytes.  We confirmed that PTEN expression varied 
dramatically amongst cell lines and that CEM-SS cells did not express much, if any, 
PTEN (Figure 3.5A).  We also performed experiments in a cell line (the SupT1 
lymphoblastoid line) with very high PTEN expression to determine whether PTEN levels 
might be affecting our ability to detect a requirement for ARF-6 activity.  Similar to our 
observations in CEM-SS cells, we found that expression of ARF-1 Q71L significantly 
reduced HLA-A2 downmodulation by Nef, while expression of ARF-6 Q67L did not 
(Figure 3.5B-C).  As a control we again demonstrated that the ARF-1 and ARF-6 
constructs transduced the cells and expressed the bi-cistronic message to similar degrees 
(Figure 3.6). 
 
Finally, we compared the effects of ARF-1 and ARF-6 mutants in HIV-infected primary 
T lymphocytes expressing endogenous HLA-A2.  For these experiments, wild type ARF 
or its dominant active mutant was inserted directly into the envelope open reading frame 
of a GFP-expressing HIV molecular clone (Figure 3.7A, NL-GIarf).  Primary T cells 
were infected with the virus and then assayed 36 hours post-infection.  We reproducibly 
observed a two-to-three fold inhibition of Nef-dependent MHC-I downmodulation when 
the infected cells expressed the ARF-1 mutant Q71L, but not when the infected cells 
expressed the corresponding ARF-6 mutant Q67L (Figure 3.7B). These data support a 
model in which an ARF-1-dependent pathway rather than an ARF-6-dependent pathway 
is needed for Nef-dependent MHC-I downmodulation in HIV-infected primary T cells. 
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Figure 3.6.  Two color flow cytometry of GFP and HLA-A2 or CD4 staining in cells 
transduced with control or adeno-Nef.  The ARF-1 and ARF-6 constructs used in these 
experiments were made identically by inserting the open reading frames into bi-cistronic 
retroviral vectors. Virus produced from these constructs was used to transduce Sup T1 
cells.  GFP expression serves as an indicator of transduction efficiency and relative gene 
expression. 
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Further evidence that ARF-6 Q67L was active in this experimental system is its effect on 
MHC-I surface expression in the absence of Nef.  For HLA-A2, Bw4 and Bw6 MHC-I 
allotypes we observed an 18% (Figure 3.7B), 31% and 29% (data not shown) reduction in 
MHC-I expression respectively.  Over three independent experiments in which HLA-A2 
expression was measured in primary T cells expressing ARF-6 Q67L the average 
reduction in surface expression was 13% (p< 0.002).   These data are consistent with the 
inhibitory effect of ARF-6 Q67L on MHC-I recycling (5, 30).  
 
To further examine the contribution of ARF-6 to Nef-dependent MHC-I 
downmodulation, we used a lentiviral system expressing shRNA to knock down ARF-6 
expression in CEM-SS cells.  Knockdown of ARF-6 has previously been demonstrated to 
inhibit clathrin-independent endocytosis of G-protein coupled receptors (18).  We found 
that depletion of ARF-6, as confirmed by western blot, had no significant impact on 
HLA-A2 or endogenous CD4 downmodulation by Nef, as compared to negative control 
shRNA (Figure 3.8).   This observation lends additional support to the conclusion that 
ARF-6 is dispensable for Nef-induced MHC-I downmodulation in T cells.  Similar 
analysis was not possible for ARF-1, as knockdown of single Golgi ARFs does not affect 
cellular trafficking (56). 
 
3.3.3 Dominant active ARF-1 increases AP-1 recruitment to HLA-A2 A323V and the 
HLA-A2-Nef complex 
To determine the mechanism by which ARF-1 mutants affect MHC-I surface expression, 
we used co-immunoprecipitation assays to measure AP-1 binding to cargo plus or minus  
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Figure 3.7. ARF-1 but not ARF-6 activity is required for Nef-dependent endogenous 
HLA-A2 and CD4 downmodulation in HIV infected primary T cells. (A) Map of HIV 
engineered to express ARF-1, ARF-1 Q71L, ARF-6, or ARF-6 Q67L and GFP plus or 
minus Nef. (B) Flow cytometric analysis of endogenous HLA-A2 surface expression in 
primary CD4
+
 T cells infected with the indicated HIV.  Cells were harvested 36 hours 
post infection.  Numbers inside each flow plot reflect the mean fluorescence intensity of 
MHC class I in the GFP
+
 population.  Fold downmodulation of MHC class I surface 
expression derived from the nef+ and nef- populations of each HIV construct is shown 
under the bottoms panels.  Results are representative of three independent experiments. 
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expression of ARF-1 mutants.  As a positive control, we first examined AP-1 binding to a 
natural Yxx  sorting signal using HLA-A2 A323V in the absence of Nef.  As seen in 
Figure 3.9A lanes 2, 3, 4, and 5, and as previously reported (59), AP-1 co-precipitated 
with HLA-A2 A323V in the absence of Nef.  Expression of wild type (lane 3) or T31N 
ARF-1 (lane 5) did not affect AP-1 recruitment by this assay.  However expression of 
dominant active ARF-1 Q71L (lane 4) dramatically increased co-precipitation of AP-1 
with HLA-A2 A323V.  
 
Next, we used the same assay system to determine whether ARF-1 activity affected 
formation of the Nef-MHC-I-AP-1 complex.  Similar to what was observed with HLA-
A2 A323V, we found that dominant active ARF-1 Q71L dramatically increased co-
precipitation of AP-1 with HLA-A2 in Nef expressing cells.  Conversely, we found that 
treatment with BFA disrupted complex formation (Figure 3.9B lanes 10 and 11).  The 
effect of BFA was specific because it could be rescued by overexpression of ARF-1 Q71L 
as previously reported (Figure 3.9B lane 12) (62).  Similar to what we observed with 
HLA-A2 A323V, expression of ARF-1 T31N had little effect on AP-1 co-precipitation 
(Figure 3.9, lane 9), presumably because endogenous ARF-1 was sufficient for this 
purpose. 
 
We were also able to detect the presence of ARF-1 in the Nef-MHC-I-AP-1 complex 
(Figure 3.9B). ARF-1 Q71L co-precipitated readily, but both wild type and ARF-1 T31N 
could also be detected, albeit at lower efficiency.  Of note, expression of ARF-1 mutants 
and BFA treatment had no significant effect on Nef co-precipitation with HLA-A2,  
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Figure 3.8. ARF-6 knockdown does not inhibit Nef-induced MHC-I 
downmodulation. A) Flow cytometric analysis of CEM SS cells transduced with 
lentivirus expressing shRNA and GFP and subsequently transduced with the indicated 
adenoviral vector at 3 days post lentivirus.  Flow cytometric analysis was performed at 3 
days post adenoviral transduction.  B) Western blot analysis confirming specific 
knockdown of ARF-6.  C)  Quantitation of the flow data from part A.  Relative 
downmodulation of the indicated molecule.  Errors bars represent standard deviation. 
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Figure 3.9.  Dominant active ARF-1 stabilizes AP-1 binding to the Nef-MHC-I 
complex. (A) Immunoprecipitation of HLA-A2 A323V with western blot analysis of  
associated AP-1. HLA-A2 A323V was immunoprecipitated from CEM-SS cells 
transduced with a bicistronic murine retroviral vector expressing GFP and ARF-1 
proteins as indicated.  Based on GFP expression, 50-70% of the cells were transduced. 
(n=4)  (B) Immunoprecipitation of HLA-A2 with western blot analysis of associated 
proteins. HLA-A2 was immunoprecipitated from CEM-SS cells transduced with control 
or adeno-Nef and a bi-cistronic murine retroviral vector expressing GFP and ARF-1 
proteins as indicated.  Based on GFP expression 50-70% of the cells were transduced 
n=4)  
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Figure 3.9.  Dominant active ARF-1 stabilizes AP-1 binding to the Nef-MHC-I 
complex. 
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confirming previous data (58, 59) that Nef can bind to the cytoplasmic tail of HLA-A2 in 
the absence of AP-1.   
 
We also performed the reverse experiment in which we asked whether we could observe 
co-precipitation of AP-1, Nef and HLA-A2 when we immunoprecipitated ARF-1.  For 
this study we examined complexes formed both in the absence and presence of Nef.  
Indeed, we were able to detect AP-1 co-precipitating with ARF-1 Q71L (Figure 3.10).  In 
Nef-expressing cells we were also able to detect Nef co-precipitating with ARF-1 
independent of the GTP-bound state of the ARF-1 molecule (Figure 3.10 lanes 4, 5, and 
6), as previously reported (36).  Additionally, in Nef expressing cells, there was an 
enhancement in the amount of AP-1 that co-precipitated with ARF-1 Q71L (Figure 3.10, 
lane 6).  Finally, we also detected HLA-A2 co-precipitating with ARF-1 Q71L in Nef 
expressing cells.  These data suggest that ARF-1 Q71L potently stabilizes interactions 
amongst AP-1, Nef, and MHC-I HLA-A2 and that its mode of inhibition of MHC-I 
downmodulation is not disruption of complex formation but rather the formation of a 
static complex that sequesters necessary trafficking components.  Therefore we propose a 
model in which ARF-1 is necessary to form the trafficking vesicles at the trans-Golgi 
network that contain MHC-I, Nef, and AP-1  (Figure 3.11).   
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Figure 3.10. MHC-I, Nef and AP-1 co-precipitate with ARF-1 Q71L.  (A) 
Immunoprecipitation of myc-tagged ARF-1 with western blot analysis of associated 
proteins.  ARF-1 proteins were immunoprecipated from cells treated as in figure 3 part B, 
Based on GFP expression 50-70% of the cells were transduced.  (n=2)  
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3.4 Discussion 
HIV causes a persistent infection that evades eradication by anti-HIV CTLs. Viral 
persistence is mediated in part by the activity of the HIV Nef protein, which disrupts 
antigen presentation by MHC-I to CTLs. A number of cellular factors have been  
implicated in this pathway and thus it is important to clarify the relative contribution of 
each to help focus the development of inhibitors.  
 
Here we confirm a requirement for AP-1 and we provide new evidence that the small 
GTPase ARF-1 is also needed for Nef„s effects on MHC-I trafficking.  The ARF-1 
dominant active mutant, ARF-1-Q71L and the ARF-1 inhibitor, BFA both had dramatic 
effects on the formation of Nef-MHC-I–AP-1 complex and on surface MHC-I expression 
in Nef-expressing cells. Our new data, that ARF-1 is needed for Nef to recruit AP-1 to 
the MHC-I cytoplasmic tail, provide insights into what is required for complex formation 
and further elucidates how this process occurs (Figure 3.11).   
 
The effect of dominant active ARF-1 Q71L on MHC-I downmodulation may be explained 
by other studies examining COP-1 coats, which have demonstrated that when ARF-1 
Q71L is expressed, ARF-1-GTP cannot be hydrolyzed into ARF-1-GDP, resulting in a 
static coat (43, 50).   This effect compromises the cycles of recruitment and dissociation 
from membranes.   
 
Prior studies have shown that AP-1 is required for Nef-dependent trafficking and can be 
found in complexes with MHC-I and Nef in transformed T cell lines and in HIV-infected  
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Figure 3.11.  Model of Nef-dependent CD4 and MHC-I trafficking.  LY, lysosome; 
LE, late endosome; MVB, multi-vesicular body; ER, endoplasmic reticulum. 
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primary T lymphocytes (41).  Work with purified proteins has revealed that Nef directly 
contacts the MHC-I cytoplasmic tail (58) and that a Nef-MHC-I fusion protein directly 
interacts with the AP-1 subunit (32, 47). A tyrosine in the MHC-I cytoplasmic tail and 
the tyrosine binding pocket of AP-1 1 are both required for AP-1 to coprecipitate with 
HLA-A2 in Nef-expressing cells (59) and with purified proteins (32, 47).  These data 
have led to a model in which Nef disrupts MHC-I trafficking from the TGN through an 
interaction with AP-1 that re-directs MHC-I into an endolysosomal pathway instead of 
the cell surface (Figure 3.11).  In cells that demonstrate a greater degree of Nef-
dependent MHC-I internalization (e.g. HeLa), AP-1 is also required for Nef-dependent 
internalization of MHC-I (23).  
 
Nef also downmodulates the HIV receptor, CD4 to prevent viral superinfection (2) and to 
promote viral assembly and release (25, 42).   Downmodulation of CD4 and MHC-I by 
Nef occurs by distinct mechanisms and requires different Nef domains (29, 44).   Work 
from a number of laboratories has supported a model in which the separate Nef-
dependent trafficking pathways of MHC-I and CD4 ultimately converge into a common 
-COP-dependent pathway necessary for lysosomal targeting (15, 36, 44).  In this model 
(Figure 3.11), Nef promotes accelerated internalization of CD4 in an AP-2 dependent 
manner (7, 17, 21, 49) and internalized CD4 is targeted into acidic compartments (36) 
and MVBs (12, 44) for accelerated degradation. Previous research has shown that ARF-1 
is involved in COP-I coatomer recruitment to internalized Nef-CD4 complexes and is 
necessary for localization of these complexes to acidic compartments (15).  However, 
GTP binding and hydrolysis is not needed for this process (15).  
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In contrast to our results with ARF-1, we did not detect a significant requirement for 
ARF-6 activity for Nef to reduce MHC-I surface expression.  The difference in our 
results compared with prior publications from another laboratory may be related to a 
number of technical factors.   The effect of ARF-6-Q67L was reported in HeLa cells (4), 
which have been shown to traffic MHC-I differently than T cells (23).  In addition, the 
prior study (4), did not examine the effects of these mutants on steady state surface 
expression as was done here. 
 
In sum, we have further defined the mechanism by which Nef allows HIV-1 infected 
cells to evade the host immune response.  Implicating ARF-1 in downmodulation of 
MHC-I by Nef provides further support for the role of the AP-1 dependent pathway 
shown in Figure 3.11. These data help to elucidate the mechanism by which Nef 
downmodulates MHC-I and reveal further targets for pharmaceuticals that may inhibit 
immune evasion. 
 
3.5 Materials and methods 
3.5.1 Cell lines and primary cell isolation 
CEM T cells and SupT1 cells expressing HA-tagged HLA-A2 were created and 
maintained as previously published (59).   Primary T cells were purified from buffy coats 
obtained from the New York Blood Center.  Mononuclear cells were purified by ficoll-
hypaque centrifugation, and primary T lymphocytes were isolated through adherence, 
CD8 and CD56 depletion of mononuclear cells.  Following isolation, T cells were 
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stimulated with PHA at 10 g/mL (Sigma-Aldrich).  After 24 hours, 50U/mL interleukin-
2 [IL-2] was added to the culture medium.  48 hours post-IL-2 stimulation, the T 
lymphocytes were used for HIV transduction.  Donor MHC-I allotype (HLA-A2, HLA-
BW4, or HLA-BW6) was determined at the time of CD4
+
 T cell isolation using flow 
cytometric techniques. 
 
3.5.2 DNA constructs 
3.5.2.1 Construction of pMSCV IRES GFP vectors expressing ARF-1 and ARF-6  
pCB6 expressing Myc-tagged wild type or T31N ARF-1 were obtained from Didier Trono 
(Ecole Polytechnique Fédérale de Lausanne).  The arf-1 ORF was amplified by PCR 
using either wild type or T31N pCB6 Myc-ARF-1 as a template with the primers listed in 
Supplementary Table 1. MSCV Myc-ARF-1 Q71L IRES GFP was created through 
standard two-step PCR mutagenesis using wild type MSCV ARF-1 IRES GFP as a 
template with the primers listed in Supplementary Table 1. The PCR products were 
cloned into the BamHI site of MSCV IRES GFP (pMIG) (55). 
 
pXS expressing HA-tagged wild type, T27N, or Q67L ARF-6 was obtained from Julie 
Donaldson (National Institutes of Health).  ARF-6 constructs were amplified using pXS 
HA-ARF-6 as a template with the primers listed in Supplementary Table 1. The PCR 
product was cloned into Bgl II and EcoRI sites of pMIG.  
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3.5.2.2 Construction of HIV vectors expressing ARF-1 and ARF-6 
To construct HIVs that also contained both GFP and ARF ORFs, we first made a version 
of HIV (pNL-GI) in which a portion of the env ORF was replaced by a GFP IRES 
multiple cloning site cassette.  PCR was used to amplify the IRES from pNL-PI (8) and 
to add additional restriction enzyme sites downstream of the IRES. The PCR product was 
ligated into the NheI and BglII sites in the env ORF of pNL4-3-deltaE-EGFP (63) just 
downstream of GFP.  pNL-GInef 
–
 was generated by creating a frame shift within the nef 
ORF of pNL-GI by digesting with XhoI, filling-in  and re-ligating the ends.  
 
pNL-GI was then used to create HIV constructs expressing ARF-1 and ARF-6.   To 
create pNL-GIarf constructs, linker primers were designed to create a XbaI site in the 5‟ 
end and a MluI site in the 3‟ end of the amplicon during PCR amplification of the ARF-1 
and ARF-1 Q71L from MSCV ARF-1 IRES GFP and MSCV Myc-ARF-1 Q71L IRES 
GFP respectively.  Primers for this step are listed in Supplementary Table 1. Digested 
PCR products were ligated into the XbaI/MluI sites downstream of the IRES element in 
pNL-GI.  
 
Due to an internal XbaI site present in ARF-6, pNL-GI ARF-6 +/- nef and pNL-GI ARF-
6 Q67L +/- nef were engineered by designing linker primers to create a SpeI site in the 5‟ 
end, which is compatible with XbaI overhang ligation, and a MluI site in the 3‟ end of the 
amplicon during PCR amplification of the ARF-6 and ARF-6 Q67L from MSCV ARF-6 
IRES GFP and MSCV ARF-6 Q67L IRES GFP respectively.  PCR primers used are listed 
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in Supplementary Table 1.  Digested PCR products were ligated into the XbaI/MluI 
digested parental vector. All constructs were confirmed by sequencing. 
 
3.5.2.3 shRNA constructs 
FG12 shRNA lentiviral vectors were constructed as previously described (37, 44).  The 
negative control shNC construct was previously described (44).  The target sequence for 
shARF-6 began at position 247:   
GATCCCCGGTCTCATCTTCGTAGTGGTTCAAGAGACCACTACGAAGATGAGA
CCTTTTTGGAAA.   
 
3.5.3 Virus preparation and transductions.   
3.5.3.1 Retrovirus 
Retroviral supernatants were prepared as described previously (34, 55).  Bosc cells (34) 
were transfected with MSCV constructs described above, the retrovirus packaging vector 
pCL-Eco (31), and pHCMV-G (34).  Briefly, 5x10
5
 CEM or SupT1 cells were spin-
transduced with 1 ml of retroviral supernatants plus 8 g/ml polybrene at 2500 RPM for 
two hours in a tabletop centrifuge at room temperature.   
 
3.5.3.2 Adenovirus 
Replication defective adenovirus was produced by the University of Michigan Gene 
Vector Core facility.  Adenoviral transductions were performed as previously described 
(57).  Transductions were performed using 1x10
6
 cells in 1 mL of RPMI 1640 containing 
2% fetal bovine serum; 10mM HEPES; and 2mM penicillin, streptomycin, and 
glutamine.  Multiplicity of infection was 200 for CEM and 100 for SupT1 (based on 293 
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cell infectivity, which is greater than CEM infectivity).  Low serum transductions ranged 
from 4-6 hours. 
 
3.5.3.3 HIV 
HIV constructs were produced by transfecting 293 cells with each construct and 
harvesting the supernatant.  5x10
5
 PHA and IL-2 stimulated CD8-CD56-depleted T 
lymphocytes were transduced using 1 mL of supernatant with 8 g/mL polybrene using a 
spin-transduction protocol.  Primary T lymphocytes were harvested for analysis of MHC-
I downmodulation at 36 hours post transduction. 
 
3.5.4 Flow cytometry and antibodies 
Cells were stained for 20 minutes on ice in FACS buffer (PBS, 1% Human Serum, 
1%FBS, 1% HEPES, and 1% NaN3), washed, and then stained for 20 additional minutes 
in secondary antibody.  Mouse antibody to HLA-A2 antibody, BB7.2 (33) and mouse 
antibody to CD4, OKT4 (39) were purified from ascites (22) provided by the University 
of Michigan Hybridoma core facility.  Mouse antibody to PLAP antibody was obtained 
from Serotec. The secondary antibodies used were goat anti-mouse IgG2B-phycoerythrin 
(Invitrogen, 1:250) and goat anti-mouse IgG1-Alexa Fluor 647 (Invitrogen, 1:250).  
Isotype controls were obtained from BD Biosciences.  Stained cells were analyzed on a 
Becton Dickinson FACSCanto cytometer. Analysis was performed using FlowJo 
software (Tree Star Inc.).   
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3.5.5 Immunofluorescence microscopy and antibodies 
ARF-6-transduced CEM cells were adhered to glass slides with Celltak (BD 
Biosciences), fixed, permeabilized, and stained for indirect immunofluorescence as 
previously described (Roeth JBC 2004). Images were collected using a Zeiss LSM 510 
confocal microscope and processed using Deneba Canvas software. The following 
antibodies were utilized to localize proteins via microscopy: anti-HLA-A2 (BB7.2) and 
anti-GFP (3E6, Invitrogen). Secondary antibodies were obtained from Molecular Probes 
and were used at a dilution of 1:250: goat anti-mouse IgG2B-Alexa Fluor 546 and goat 
anti-mouse IgG2A-Alexa Fluor 488. 
 
3.5.6 Immunoprecipitations and western blotting 
Immunoprecipitations were performed as previously described (59).  15x10
6
 CEM cells 
were transduced with either control or Nef-expressing Adenovirus.  At 48 hours post-
adenoviral transduction, the cells were spin-transduced with either DMEM (mock) or 
MSCV ARF-1 IRES GFP viral supernatants.  At 72 hours post-adenoviral transduction, 
all cells were incubated in 20mM NH4Cl for 16 hours.  Where indicated, samples were 
also incubated in 50 M BFA for 16 hours.  Cells were then harvested and lysed in 1% 
digitonin (Wako) lysis buffer described previously (44, 59).  Lysates were normalized for 
total protein and GFP transduction rates, when appropriate, prior to immunoprecipitation.  
Input controls were 1% of the immunoprecipitated protein. After an overnight pre-clear at 
4
o
C, lysates were immunoprecipitated for either HLA-A2 (BB7.2 crosslinked beads) (59) 
or Myc-tagged ARF-1 (9e10 (14) crosslinked beads).  Immunoprecipitates were eluted 
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and analyzed by western blot as previously described (57).  Western blot antibodies used 
were anti-Nef (AG11 (6)) and anti-Myc (9e10 (14)), which were produced by the 
University of Michigan Hybridoma Core Facility and purified as previously described 
(22).  Antibodies also used for western blotting were anti-AP-1  (BD Biosciences), HA 
(HA.11, Covance), anti-PTEN (Cell Signaling Technology), anti-GAPDH (Santa Cruz 
Biotechnology), and anti-AP-1 1 (RY/1 (53)).  The secondary antibody for anti-Nef, 
anti-HA, and anti-Myc was goat anti-mouse IgG1-HRP (Zymed Laboratories Inc).  The 
secondary antibody for anti-AP-1 1 and anti-PTEN was goat anti-rabbit-HRP (Zymed 
Laboratories Inc).  The secondary antibody for AP-1  was rabbit anti-mouse-HRP 
(Zymed Laboratories Inc).   
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Chapter 4 
Cell-based high throughput screening methodology to identify 
small molecule inhibitors of HIV-1 Nef  
 
4.1 Introduction 
HIV is a worldwide epidemic, with approximately 2.6 million new infections occurring 
annually (UNAIDS, 2009).  Moreover, while treatments do exist, there is no cure for 
HIV.  Instead, HIV is a chronic infection, persisting over the lifetime of an infected 
individual.  Therefore, treatment must be also delivered over the lifetime of the patient.  
Many of the drug therapies currently available have significant toxic side effects, making 
long term adherence difficult.  Furthermore, drug resistance can arise, making additional 
viral targets important.   
 
The existing therapies for HIV target viral enzymes, including reverse transcriptase, 
protease, and integrase.  Another class of inhibitors prevents viral entry by blocking 
envelope fusion or attachment to the CCR5 coreceptor.  These drugs all target viral 
particles and inhibit viral replication.  None of these inhibitors target HIV-infected cells
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or enable the host immune system to better recognize and respond to HIV.  There are 
currently no drugs on the market or in clinical studies which target the HIV-1 Nef 
protein, despite ample evidence that Nef is critically important for viral pathogenesis and 
disease progression in both animal models and human patients.  Macaques infected with a 
Nef-deleted strain of SIV do not progress to AIDS (22).  Furthermore, a cohort of blood 
transfusion recipients who received an HIV strain with a deletion in Nef and the LTR 
demonstrate delayed disease progression or elite control of viral loads (10, 19, 24).  
These observations highlight the potential efficacy of a Nef inhibitor in HIV treatment. 
 
Traditional drug development strategies often rely on enzyme substrate modification and 
active site targeting.  These methods are not suitable for identifying a Nef inhibitor, as 
Nef has no enzymatic activity and therefore requires a different approach.  Nef is a 
structurally flexible, multifunctional adaptor protein with multiple cellular binding 
partners (13, 15-17, 21, 25).  Nef downmodulates MHC-I, allowing infected cells to 
evade detection by cytotoxic T lymphocytes (CTLs) (9, 27, 38, 41, 44), as well as the 
viral receptor CD4, preventing superinfection and increasing virion release (14, 23, 37).  
Nef also modulates the activity of kinases, such as Pak2 and Hck, and promotes T cell 
activation, which may in turn promote viral replication (1, 4, 5, 18, 31, 39, 45).  
Additionally, Nef enhances viral infectivity in vitro by a poorly understood mechanism 
that is independent of CD4 downmodulation (6, 29, 34-36).    It is likely that all of these 
Nef functions make contributions to HIV pathogenesis in vivo.  However, the ability of 
Nef to downmodulate MHC-I and evade CTL detection is a particularly tempting target 
for therapeutic intervention.  Several studies have used SIV systems to demonstrate that 
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the capacity to downmodulate MHC-I is selected for in vivo (7, 32, 40) .    In addition, it 
has recently been demonstrated that the ability of in vivo-derived Nef to down-regulate 
MHC-I predicted the resistance of HIV-1 to suppression by CTL in vitro (28) .  Taken 
together, these data demonstrate that the ability of Nef to down-regulate MHC-I in vivo is 
maintained by the need of HIV-1 to cope with the antiviral CTL response.  Therefore, 
inhibition of this Nef function early in infection may enable the host immune system to 
better counteract, or even clear, HIV-1.  While recent efforts have been applied to 
identifying Nef inhibitors, these studies have not specifically targeted the ability of Nef to 
downmodulate MHC-I. 
 
The first report to identify chemical inhibitors of Nef function used a competition ELISA 
assay to identify guanidine alkaloid analogs capable of disrupting Nef’s interactions with 
p56
lck
, p53, and actin (33).  These proteins all bind to the N-terminus of Nef, although the 
functional significance of these interactions is not clear.  Furthermore, all of the putative 
Nef inhibitors were highly cytotoxic even at submicromolar concentrations and therefore 
could not be tested for their impact on viral replication or Nef function within cells.  
These compounds have limited therapeutic value.  
 
A few studies have focused on inhibiting interactions with the polyproline, or SH3-
binding, motif in Nef.  Mutation of this domain reduces Nef’s ability to downmodulate 
MHC-I and also inhibits association of Nef with cellular Src family kinases such as Hck 
(5, 20, 21, 30, 31, 42, 45). The importance of Hck activation by Nef in HIV pathogenesis 
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is unclear, as mutation of the SH3-binding domain of Nef results in a Nef protein which 
is defective for both Hck activation and MHC-I downmodulation.  An in silico screen 
resulted in the identification of ten candidate molecules (2).  Follow-up in vitro screening 
of those compounds, as well as structural analogs, narrowed the candidates to two 
molecules capable of inhibiting Nef-SH3 interactions  in COS7 African green monkey 
kidney cells.  Neither compound demonstrated significant cytotoxicity in the COS7 cell 
line.  Inhibitor treatment did not affect CD4 downmodulation by Nef, which is 
independent of the SH3-binding domain of Nef, indicating that the inhibition was specific 
to this Nef domain.  Disappointingly, treatment of resting peripheral blood mononuclear 
cells (PBMC) with up to 25 M inhibitor, the highest concentration tested, inhibited Nef-
induced downmodulation of MHC-I A,B, and C by only 25%.   
 
Subsequent studies also focused on the SH3-binding domain of Nef, specifically looking 
for inhibitors of Nef-interactions with Src family kinases (SFK) such as Hck.  Screening 
of a 10,000 compound library enriched for kinase and protease inhibitors identified a 
compound capable of inhibiting Hck in the presence of Nef (12).  The compound, termed 
DFP-4AP, was found to inhibit Hck activation even in the absence of Nef, and therefore 
is likely not specific enough for therapeutic use.  However, analysis of DFP-4AP analogs 
lead to the discovery of DFP-AB, a molecule capable of specifically inhibited Hck 
activity in a Nef-dependant manner.  Interestingly, both DFP-4AP and DFP-AB inhibited 
HIV replication in U87MG astrocytoma cells with an IC50 in the low M range.  
Another study also identified a chemical inhibitor of Nef-induced activation of Hck 
which also partially reduced MHC-I HLA-A, B, and C downmodulation by Nef in 
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primary T lymphocytes at 8-days post HIV infection, a late time point (11).  While 
mutation of multiple prolines within the SH3-binding domain of Nef inhibit both SFK 
interactions with Nef and downmodulation of MHC-I, point mutations disrupt kinase 
activation but do not affect MHC-I downmodulation (8, 43).  It is therefore perhaps 
unsurprising that compounds which target this region of Nef have relatively small impact 
on MHC-I surface expression in the presence of Nef.  While inhibition of kinase activity 
is a tractable readout for high throughput methodology, the correlation between this Nef 
function and HIV disease progression is unclear.  
 
While targeting the polyproline motif of Nef has had limited success, another recent 
study took a different approach by simultaneously targeting multiple Nef functional 
domains in conjunction with the SH3-binding activity.  The investigators designed a 
series of soluble peptides that wrap around Nef, interacting with several domains (3).  
The SH3 domain of Hck containing six amino acid modifications that enhance affinity 
for Nef was fused to the CD4 cytoplasmic tail with a GGGG linker in the presence of an 
N-terminal lipidation signal.  This molecule was found to bind to purified Nef with a 
dissociation constant of 26 nM, the strongest interaction of a molecule with Nef ever 
reported.  Additionally, this inhibitor (termed NI3-9) inhibited CD4 and MHC-I 
downmodulation by Nef, and blocked Nef-dependant enhancement of virion infectivity in 
HeLa and Chinese hamster ovary cells, which may not recapitulate Nef activity in 
primary T lymphocytes.  The therapeutic potential of an inhibitory protein, however, is 
complicated by technical challenges in delivery, stability, and immunogenicity.  
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To our knowledge, none of the reported Nef inhibitors is being developed for therapeutic 
use.  Targeting of the SH3-binding domain of Nef makes high throughput assay 
development simpler, as kinase activation through this Nef domain is technically 
straightforward to measure.  However, the contribution of kinase activation in HIV 
pathogenesis is unclear, and for this reason is not a highly desirable target.  Inhibitors that 
target one or more Nef functions of known pathogenic importance are highly desirable.  
However, protein-based inhibitors are difficult and expensive to manufacture and deliver.  
Furthermore, compounds that inhibit Nef in vitro may not accurately predict inhibition 
within live T cells, or may simply have chemical properties that make them toxic or 
otherwise unfit for use as therapeutic agents. 
 
To this end, we have developed a high throughput assay system to screen for small 
molecule inhibitors of Nef-induced MHC-I downmodulation in T cells.  This system is of 
particular value as we assay for inhibition of an important Nef function, not a Nef 
domain.  Furthermore, we only identify molecules that inhibit Nef function within 
physiologically relevant cells.  Any chemical compounds which are cytotoxic by nature 
will be screened out in our protocol.  Here we describe the technical considerations in 
developing the assay, as well as the methods used to implement screening.  Specifically, 
we designed an assay to measure increases in MHC-I surface expression in Nef-
expressing T cells.  We adapted flow cytometric analysis for minimal sample 
manipulation in order to be logistically amenable to high throughput handling.  We also 
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optimized the assay for maximal statistical power. Preliminary findings suggest that 
molecules identified under the stringent conditions of this screen will be valid and 
effective Nef inhibitors. 
 
4.2 Methods and Results: 
4.2.1  Assay design 
In order to screen for molecules which inhibit downmodulation of MHC-I by Nef in T 
lymphocytes, we first wanted to develop a cell-based flow cytometric screening protocol 
to measure MHC-I surface expression.  A typical FACS staining protocol requires 
multiple antibody incubations and a number of rigorous washes.  These steps are not 
amenable to high throughput methodology, as minimal manipulation of sample is 
technically desirable in these systems.  Therefore, we needed to establish a FACS 
staining protocol in which we could reliably differentiate between high and low MHC-I 
surface expression, in as few steps as possible.  We tested two strategies for reducing 
sample manipulation:  condensing antibody incubations, and using dilution of the staining 
reaction to reduce background. 
 
We examined three conditions for condensing antibody incubations.  First, we tested a 
primary antibody against HLA-A2 (BB7.2) directly conjugated to Alexa Fluor-488 to 
eliminate separate primary and secondary antibody incubation steps.  As two-step 
antibody stains can amplify signal, we also tried co-incubating primary and secondary 
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antibodies, as well as sequential primary and secondary antibody incubations in the 
absence of intervening wash steps.  We used these staining protocols to compare CEM 
SS cells stably expressing exogenous HLA-A2, a common MHC-I allele, with the same 
cell line (CEM A2) transduced with an adenoviral vector expressing NL4-3 Nef.  We 
found that the directly-conjugated antibody (BB7.2-488) was most amenable to a staining 
protocol without washes, resulting in the highest signal over background (Figure 4.1A-
B).   
 
We then optimized dilution conditions in order to achieve thorough background reduction 
while keeping sample volume low.  Additionally, we further condensed the protocol by 
combining the dilution and fixation steps.  This was accomplished by including 
paraformaldehyde (PFA) in the dilution buffer.  To determine signal over background, we 
compared CEM A2 cells to parental CEM SS, incubated with BB7.2-488 and then 
subjected to a variety of dilution volumes.  We found that dilution of two- to three-fold 
resulted in high specific signal and low background, while greater dilution factors 
reduced signal without further reducing background (Figure 4.1C-D).  Thus we 
determined optimal conditions for a high throughput FACS stain, condensing a multi-step 
protocol into two simple steps which produce robust, specific signal.  
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Figure 4.1  FACS stain protocol development.  (A-B) CEM A2 cells infected with the 
indicated adenovirus were stained with the indicated antibodies.  (A) Flow cytometric 
analysis of HLA-A2 expression.  (B) Mean fluorescence intensity (MFI) plus standard 
deviation is shown, and the Z’-factor for each +/- Nef pair is displayed above the bars.  
(C-D) CEM SS and CEM A2 cells were stained with fluorophore-conjugated antibody 
and dilution with PFA was carried out at the indicated dilution factor.   (C)  Flow 
cytometric analysis of background and specific staining.  (D) The MFI is shown and the 
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signal:noise ratio, calculated as CEM A2 MFI divided by CEM SS MFI, is displayed 
above the bars. 
 
Next, we adapted this protocol to the Intellicyt high throughput sampling platform.  To 
reduce overall assay costs, we used low volume, u-bottom, 384-well plates.  Keeping 
sample volume low was desirable as this required nearly three-fold less of each reagent as 
compared to high-volume plates.  This represents a significant cost savings when 
screening more than 100,000 samples.  The u-bottom well shape was important for 
reliable sampling, as any cells settling to the bottom of the well were condensed into a 
small area for easy uptake.  The Intellicyt sampling platform consists of a sample sip, run 
by a peristaltic pump, connected by tubing to an Accuri flow cytometer.  The sip 
constantly samples so that the material from each well is separated within the tubing by a 
bubble of air which is introduced when the sample sip lifts to move to the next well.  
Therefore, samples are identified within the software as spikes in live events over time, 
separated by times with zero or low events, and thus can be assigned to specific wells.  A 
limitation of the system is that the software is only able to record 1 million events within 
each plate.  Therefore, we adjusted the density of cells that we seeded into each well such 
that we could sample sufficient cells per well without exceeding the number of data 
points we could record.  As a result, we established a powerful and cost-effective FACS 
staining protocol that could be reliably sampled with high throughput robotic equipment. 
 
4.2.2 Assay optimization 
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Once we had established a FACS staining protocol that was amenable to high throughput 
handling, it was important to assess the potential statistical power of this assay for 
screening.  An important measurement when piloting high throughput assays is the Z’-
factor.  The Z’-factor is calculated as follows:  
 
Where “s” is the standard deviation of the positive (p) and negative (n) controls, and “m” 
is the mean value of the controls.  Therefore this value relies on the magnitude of the 
difference between positive and negative controls, as well as the variability within these 
samples.  This provides a measure of the reliability with which the assay may detect 
samples with a difference of more than three standard deviations from the control 
samples.  Z’-factors fall between 0 and 1, with 1 being the ideal Z’.  Assays with Z’-
factors greater than 0.5 are considered excellent assays, while lower Z’ values indicate 
that additional considerations are warranted.  In this screen, CEM A2 cells expressing 
Nef, and therefore displaying low HLA-A2 surface expression, were the negative 
controls.  CEM A2 cells transduced with control adenovirus were the positive controls, as 
a Nef inhibitor would restore high levels of HLA-A2 surface expression (Figure 4.2A-C).  
Hence our technical goals were to minimize standard deviation and maximize the fold-
dowmodulation of HLA-A2 by Nef. 
 
In order to improve downmodulation of HLA-A2 by Nef, we optimized our adenovirus 
transductions to achieve efficient delivery of Nef.  The most obvious strategy for 
enhancing infection rate is to use a higher multiplicity of infection (MOI).  However,  
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Figure 4.2. Schematic representation of experimental controls and potential 
inhibitor results.  (A)  Positive control.  CEM A2 cells display high surface-expression 
of MHC-I in the absence of Nef.  (B)  Negative control.  Nef reduces MHC-I surface 
expression, which in turn reduces antibody binding and fluorescent signal.  (C)  A 
chemical inhibitor prevents Nef from disrupting MHC-I surface expression, resulting in 
elevated fluorescent signal.   
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adenovirus preparations, which we obtained from the University of Michigan vector core, 
are a costly reagent when required in large amounts over the course of a screen.   
    
Therefore, it was important to balance optimal infection rates with expense.  An 
additional strategy was to improve infection efficiency without using more virus.  
Adenovirus is inhibited by serum, so we typically perform these infections in low serum 
media, RPMI 1640 supplemented with 2% fetal bovine serum (FBS).  We tested whether  
eliminating serum from the infection medium altogether would enhance transduction over 
a range of MOIs.  Indeed, we found that the use of serum-free infection media resulted in 
a greater fold-reduction in HLA-A2 surface expression as compared to the 2% serum-
containing media (Figure 4.3A-B).  We also determined that an MOI of 600 resulted in 
uniform infection of the cells within the population and nearly twice as much Nef-
induced downmodulation of HLA-A2 as the lower MOIs (Figure 4.3A-B). 
 
Once we had maximized the measurable difference between our positive and negative 
controls, we investigated possible methods to reduce variability between samples.  We 
suspected that compound addition was a source of variation, as we observed high 
standard deviation in plates to which we added the DMSO solvent control versus plates 
that had no solvent or compound addition.  DMSO is the solvent for the chemical 
compounds within the test libraries and can affect HLA-A2 surface expression.  
Compound addition was performed with a robotic arm that has 384 small metal pins that 
dip into each well of plates containing the chemical libraries and rely on surface tension  
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Figure 4.3 High throughput assay optimization.  (A) Flow cytometric analysis of 
HLA-A2 expression in CEM A2 cells infected with a control adenovirus or an adenovirus 
expressing Nef at a range of MOIs in the indicated infection medium.  (B) Quantitation of 
(A) showing fold downmodulation, calculated as the mean fluorescence intensity (MFI) 
of vector transduced cells divided by the MFI of the Nef-expressing cells.  (C) 
Adenovirus-infected CEM A2 cells were either directly subjected to pintool addition of 
DMSO, or dispensed into plates containing PBS to which DMSO had been added by 
pintool.  Graph summarizing the results of high throughput sampling of each plate is 
represented by the median MFI for control vector treated or Nef-expressing cells.  Error 
bars indicate standard deviation.  Z’ values are displayed above bars.  (D) CEM A2 cells 
were transduced with adenovirus or an adenovirus expressing Nef.  At 2 dpi, the cells 
were incubated overnight at high density in low serum assay media plus DMSO solvent 
control.  Cell viability, as determined by forward scatter and side scatter profile, is 
shown.  Error bars represent standard deviation. 
 
187 
 
 
Figure 4.3 High throughput assay optimization   
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to pick up and deliver the contents of the library plates.  Therefore, the depth (ie volume) 
within the wells of the experimental plate determines the amount of solvent or compound 
delivered.  We found that pintooling solvent directly into cells and media in the 
experimental plates resulted in a high standard deviation in the concentration delivered to 
each well.  Alternatively, delivery into 4 L of PBS in each well of experimental plates 
resulted in lower standard deviations and a desirable concentration of 15-25 M for the 
compounds within the library.  A 2x cell suspension could then be delivered into plates 
already containing PBS and experimental compounds (Figure 4.3C).  In this manner, we 
were able to reduce the variation between identical samples. 
 
An additional factor to consider was potential cytotoxicity.  It was important both that the 
cells survived the assay protocol and that we avoided registering toxic chemicals as 
potential hits for extensive follow up.  With regard to the first, we examined viability of 
cells exposed to our assay protocol.  A source of potential cytotoxicity was an overnight 
incubation in low-serum media in the presence of chemical compounds or DMSO 
solvent.  The low-serum incubation was intended to avoid interference by undefined 
factors within serum.  Therefore cells were incubated with the compounds in RPMI 1640 
supplemented with 0.1% FBS.  The cells were exposed to the putative inhibitors 
overnight, or approximately 16 hours, in hopes of achieving maximal delivery and 
activity of each experimental molecule.  Cells subjected to this treatment in the presence 
of 1% DMSO tolerated this treatment well, as determined by cell viability (Figure 4.3D).  
Additionally, inclusion of a live-cell exclusion reagent, 7-Aminoactinomysin-D (7AAD), 
in the dilution buffer during the FACS stain allowed us to exclude dead or dying cells 
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from our analysis.   Therefore, we were confident that we could identify compounds that 
inhibit Nef while excluding compounds with significant toxicity in T cells.Despite 
protocol optimization, pilot experiments of the assay yielded marginal Z’ values of 0.2-
0.4.  The non-ideal Z’ values were a reflection of relatively high variation in the positive 
controls, a variation that we found to be inherent to dipping the pintool into the wells.  
The negative controls, or Nef-expressing cells, displayed very little variation.  Therefore, 
despite the low overall Z’ values, we could quite reliably identify compounds which 
increased HLA-A2 expression greater than three standard deviations as compared to 
negative controls (Figure 4.1B and 4.3C).  The high variation within the positive controls 
made elimination of false positive samples more difficult.  Hence it was necessary to 
develop a method for eliminating false positives.  
 
False positives could be the result of compounds that have intrinsic fluorescence within 
the detection channel (Figure 4.4B) or compounds that induce non-specific binding of the 
fluorophore-conjugated antibody to the cells (Figure 4.4C).  To factor out such 
compounds, we developed a counter-screen.  This involved testing the same compound 
set against CEM SS parental cells, which do not express HLA-A2, using the same 
screening protocol as that for the primary screen of CEM A2 cells.  This counter-
screened allowed us to detect any increase in fluorescence intensity that was not specific 
to increased HLA-A2 surface expression.  Any compound which registered as a hit in the 
counter-screen could be eliminated as non-specific.  Therefore, despite the non-ideal Z’ 
value for the primary screen, the stringent counter-screen allowed us to confidently 
eliminate false positives.   
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Figure 4.4. Schematic representation of possible positive sample outcomes.  A)  A 
chemical inhibitor prevents Nef from disrupting MHC-I surface expression, resulting in 
elevated fluorescent signal.  B) A test molecule with intrinsic fluorescent properties coats 
the cell surface, artificially increasing the fluorescent signal.  C) A sticky chemical 
compound induces non-specific binding of the BB7.2-AF488 antibody, resulting in 
spurious fluorescent signal.   
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4.2.3 Protocol 
We have developed a high throughput screening system with sufficient statistical power 
to reliably identify small molecules that display potent Nef inhibition in T lymphocytes.  
The detailed protocol is as follows (Figure 4.5):  First, CEM A2 cells were transduced 
with an empty adenoviral vector control or Nef-expressing adenovirus at an MOI of 600 
for six hours in serum-free RPMI 1640.  At two days post infection, the cells were 
counted and resuspended at a density of 2 million cells per mL in RPMI 1640 
supplemented with 0.2% FBS.  Experimental plates were then prepared by dispensing 4 
L PBS into each well, delivering experimental compounds, and subsequently dispensing 
4 L of cell suspension into each well.  The cells were incubated with the compounds at 
37°C for approximately 16 hours.  On day three, 2 L of a 5x antibody solution of 
BB7.2-488 (1:500) in 5x FACS buffer (10% FBS, 5% human A/B serum, 5% Hepes, and 
0.02% sodium azide in PBS) was added directly to the cells and culture media within 
each well and incubated for 30 minutes at 4°C.  After antibody incubation, each sample 
was diluted and fixed with 20 L 1.5% PFA in 1x FACS buffer (2% FBS, 1% human 
A/B serum, 1% Hepes, and 0.02% sodium azide in PBS).  After fixation, plates were 
stable at 4°C for up to one week and thus were sampled within this time frame. 
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Figure 4.5. Flow chart of the high throughput screening protocol.  CEM A2 cells 
were transduced with an adenoviral vector control or Nef-expressing adenovirus.  At two 
days post infection, the cells were seeded into 384-well plates.  Experimental plates were 
prepared by delivering experimental compounds into PBS and subsequently dispensing a 
cell suspension into each well.  The cells were incubated with the compounds for 
approximately 16 hours.  On day three, the cells were stained, fixed and then sampled.   
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4.2.4 Preliminary results 
With an optimized protocol in place, we began screening experimental compounds.  The 
initial phase consisted of screening 38,351 small molecules, including 2000 compounds 
within the Spectrum library of FDA-approved compounds, as well as Chembridge and 
Maybridge collections of drug-like compounds.  The Z-factor for this portion of the 
screen averaged to 0.25, which is a marginal value.  This screen identified 613 primary 
hits, as defined by activity greater than three standard deviations above the negative 
control samples within each plate, within the entire assay, or greater than 20% activity, 
where the average HLA-A2 staining intensity in adenovirus-treated cells is set to 100% 
activity, and that in Nef-expressing cells is set to 0%.  This represents a hit rate of 1.3% 
within the primary screen.  110 of these hits occurred in wells where fewer than 50 live 
cell events were recorded.  These compounds might be interpreted as cytotoxic, or, 
because of potential sampling error, may be considered as unsampled and thus worth 
including in a secondary screen.  These 613 compounds were tested in triplicate in a 
confirmation screen with a protocol identical to that of the primary screen.  Only 
compounds which tested as hits in at least 2 of 3 replicate wells were counted as 
confirmed hits.  To factor out false positive hits, we counter-screened the same 
compound set against CEM SS parental cells.  Any compound which registered as a hit in 
the counter-screen was eliminated as a false positive.  Of the 613 primary hits, only 1 
compound demonstrated Nef inhibition in replicate wells of the confirmation screen 
without non-specifically increasing fluorescence values in the parental cell counter-
screen.  Therefore, despite the non-ideal Z’ value for the primary screen, we were able to 
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stringently eliminate false positive and identify a small number of functionally active 
small molecule Nef inhibitors.   
 
The next test for putative Nef inhibitors is a dose response curve.  This assay also 
consists of the same protocol as the primary screen, but tests each “hit” compound at a 
range of known concentrations.  Unfortunately, our initial hit demonstrated negligible 
potency in the dose response assay.  However, we felt there was value in continuing to 
screen a broader library of chemical compounds. 
 
A phase 2 screen of 64,316 compounds within the Chemdiv 100,000 library resulted in 
1084 primary hits, defined by the same standards as phase 1.  This represents a hit rate of 
1.7% within the primary screen.  The Z’ factor for this phase of the screen averaged to 
0.45, an improvement that was likely the result of exclusion of DMSO from the positive 
control wells.  This change was necessary due to the setup of the chemical library source 
plates, not a deliberate alteration in experimental design.  In total, 113 of the hits occurred 
in low event wells.  These 1084 compounds were subjected to confirmatory and counter-
screening protocols.  Of those, 506 compounds were confirmed as active in two of three 
replicate wells, a confirmation rate of 47%, which is quite typical for high throughput 
screens.  However, all but 33 of the confirmed compounds also scored as active in the 
counter-screen, eliminating 95% of the hits as false positives.  Thus, we had a final hit 
rate of 0.05% for phase 2 of the screen.  The 33 compounds of interest will be subjected 
to dose response analysis in order to identify the most potent Nef inhibitors.  
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4.3 Discussion 
Here we have described and verified a high throughput assay system to identify chemical 
compounds that potently inhibit a critical function of Nef in live T lymphocytes in the 
absence of significant cytotoxicity.  To date we have screened 102,667 drug-like small 
molecules for their ability to inhibit downmodulation of MHC-I by HIV-1 Nef in T 
lymphocytes.  Preliminarily, we observed 1,697 primary hits, a hit rate of 1.7%.  While 
the Z’-factor measurement for the assay is non-ideal, this is a reflection of the relatively 
high variation in the positive control samples.  Conversely, the Nef-expressing negative 
control samples have a very low standard deviation (Figure 4.1). Therefore, sample wells 
with a significant increase in HLA-A2 expression as compared to the negative controls 
are unambiguous.  Hits are defined as compounds that have a signal greater than three 
standard deviations, or 20%, over the negative controls.  In addition, we have 
implemented a stringent counter-screening protocol to eliminate false positive hits.  
Therefore, we have developed a powerful system for the discovery of chemical 
compounds that inhibit an important function of Nef in T cells. 
 
We have not, as yet, identified a potent inhibitor of Nef.  We have, however, identified a 
small pool of candidate molecules for further testing.  We will also continue screening 
the chemical diversity libraries available to us through the University of Michigan Center 
for Chemical Genomics.  This includes, among others, the remainder of the Chemdiv 
library, as well as a locally assembled natural compounds library, totaling approximately 
50,000 additional chemical compounds.  Should these libraries prove insufficient, NIH-
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supported screening centers offer libraries of 300,000-500,000 small molecules for larger 
scale screening.  We fully expect to identify compounds of interest for further 
characterization. 
 
Once we have identified potent inhibitory molecules, we will perform cluster analysis in 
order to detect structural similarities.  Using this information, we will obtain structurally 
related analogs and test these for improved activity. Our most promising inhibitory 
compounds will be subjected to rigorous follow up testing.  We will first confirm that the 
inhibitor functions similarly in primary human T lymphocytes, as well as in other HIV 
targets, such as macrophages.   Importantly, we will assess the functional impact of a Nef 
inhibitor in protecting HIV-infected PBMCs from anti-HIV CTLs, similar to previously 
published assays (9).   Further work will involve elucidating the molecular mechanism of 
Nef inhibition, including mapping an interaction between the inhibitor and Nef through 
crystallography or NMR analysis.  The ability of Nef to physically associate with cellular 
binding partners, such as MHC-I, SFKs, and clathrin-associated adaptor proteins, in the 
presence of the inhibitor will also be an important line of investigation.    
 
While we are primarily interested in compounds that inhibit downmodulation of MHC-I 
by Nef, it is also interesting to determine whether other Nef functions are also inhibited.  
A compound that interferes with the effects of Nef on intracellular trafficking may also 
prevent downmodulation of other Nef targets such as CD4, CD28, and CD8.  These 
molecules are affected by Nef through distinct mechanisms, but some common cellular 
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factors are involved (26).  Furthermore, an inhibitor that had profound effects on Nef 
stability, subcellular localization, or conformation might also prevent Nef-induced kinase 
activation or enhanced HIV infectivity.  A compound which inhibits multiple Nef 
functions might have the greatest impact on HIV pathogenesis. 
While a Nef inhibitor would be a powerful laboratory tool for studying Nef function, our 
primary long term goals would be to develop such compounds for therapeutic use.  Early 
steps would involve testing the efficacy of a Nef inhibitor in animal models such as 
humanized mice and macaques.  It would be important to assess the effects of a Nef 
inhibitor on disease progression in animals with an established infection.  It is also 
interesting to hypothesize that treatment with a Nef inhibitor as a prophylactic measure 
concurrent with exposure, or very early in HIV infection, might enhance the ability of 
CTLs to recognize and target HIV-infected cells before the virus can fully establish long-
lived reservoirs.  Therefore, it will be important to measure not only HIV replication and 
disease progression in animal models, but immune cell function as well.  Depending upon 
the success of animal trials, we would then proceed to human clinical trials, with the end 
goal of bringing a Nef-targeting drug to market. 
 
With this assay, we strive to identify compounds that potently inhibit a critical function 
of Nef in live T lymphocytes in belief that such a drug would have a significant impact 
on HIV-1 pathogenesis. Inhibition of MHC-I downmodulation by Nef during acute 
infection could fundamentally impact the ability of the human immune system to identify 
and eliminate HIV-1, and perhaps increase the efficacy of vaccine-induced memory 
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responses.   This screen specifically targets this important Nef function without bias for a 
particular Nef domain and is performed in live T cells.  Thus, the nature of the assay 
excludes cytotoxic molecules and identifies compounds that are active within a 
physiologically relevant environment.  For these reasons, molecules identified in this 
screen will have significant therapeutic potential against HIV.   
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Notes 
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wrote the text of this manuscript.  Jolie Leonard supervised Kay Leopold in screening the 
102,000 compounds, the results of which are detailed as preliminary data.  
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Chapter 5 
Discussion of results and future directions 
5.1 Overview 
The data presented in the previous chapters advance our understanding of the primary 
cellular factors targeted by the HIV-1 Nef protein.  Though a variety of reports existed 
previously, there was little agreement on which proteins were targeted by Nef, or the 
mechanisms involved.  We developed tools that allowed us to directly compare the 
effects of Nef on putative target molecules. As a result, we found that HIV-1 Nef has 
three major cellular targets: MHC-I, CD4, and CD8, and, to a lesser extent, CD28.  
Moreover, we were able to demonstrate the ability of Nef to downmodulate endogenous 
CD8 in HIV infected primary CD4
+
CD8
+
 T cells. We also performed biochemical 
analyses to determine that the effect of Nef on MHC-I and CD8 depended at least in part 
on expression of cellular trafficking adaptors AP-1 and -COP.  In addition, we found 
that the AP-1 binding motif utilized by Nef to recruit AP-1 to cytoplasmic tails varied 
depending on which target protein Nef was bound to.  Thus, one explanation for the 
capacity of Nef to affect multiple targets is that it has evolved redundant mechanisms to 
recruit the same adaptor proteins.  Additionally, we provided evidence that ARF-1, but 
not ARF-6, is required for Nef-dependent MHC-I downmodulation, consistent with a 
Nef-induced block in MHC-I transport to the plasma membrane.  Finally, we described 
our ongoing efforts to identify and develop a potent Nef inhibitor for clinical application. 
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5.2 Adaptor protein involvement in Nef-dependent trafficking 
The data presented in chapter 2 is the first to assess the contribution of AP-1 and -COP 
to the downmodulation of CD28 and CD8 .  Another group has reported a partial 
requirement for AP-2 in the downmodulation of CD28 and CD8 that we were unable to 
reproduce  (53).  Knockdown of adaptor protein subunits is technically challenging, as 
highly efficient depletion of these proteins can be lethal to cells.  Additionally, co-
depletion of Eps15 and AP-2 may be required to observe an inhibition of Nef activity 
against CD4 (25).  For these reasons we may have underestimated the contribution of 
AP-2 in CD28 and CD8  downmodulation by Nef in our system.  AP-1- and AP-2-
dependant mechanisms may represent parallel or redundant pathways, which Nef can 
utilize depending upon cellular localization and availability of cellular adaptors.  
Knocking down multiple adaptor proteins in combination to look for synergistic 
inhibitory effects on downmodulation of Nef targets would clarify whether multiple 
parallel pathways exist, or whether the adaptors function within the same 
downmodulation pathway.  Our preliminary efforts to perform such experiments were 
unsuccessful due to technical issues.  As mentioned, knockdown of even one cellular 
adaptor is cytotoxic, and knocking down two adaptors further reduces cell viability.  
Additionally, this requires introducing shRNA-encoding constructs singly on successive 
days, broadening the timeline during which we must maintain live cells.  Furthermore, we 
have observed that successive viral transductions decrease in efficiency, and knockdown 
in our system requires highly efficient transduction and shRNA expression.  Therefore, a 
recently developed tool for expressing up to three shRNAs from the same plasmid might 
allow us to target up to three adaptor proteins simultaneously, at equal efficiency, and 
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perhaps within a timeframe that would allow analysis of cells prior to massive death of 
the culture (54). 
 
In chapter 2 we present direct evidence that Nef can recruit AP-1 by utilizing either the 
tyrosine motif recognition site or the dileucine recognition site of AP-1, and that this is 
determined by which cytoplasmic tail domain Nef is bound to.  Previous studies found 
that the dileucine motif in Nef is required for glutathione-S-transferase (GST)-Nef pull-
down of AP-1 complexes from mammalian cell lysates (5, 24) and for interactions 
detected in yeast two and three hybrid analyses (5, 9, 10, 12, 16, 23, 24, 32, 43) but the 
dileucine motif is dispensable for  MHC-I downmodulation even though AP-1 is required 
(36).   Conversely, CD4 downmodulation by Nef requires the dileucine motif, but does 
not involve AP-1 (16).  Thus, the interaction between AP-1 and the dileucine motif has 
remained unexplained.  Here we provide evidence that this interaction is utilized to target 
CD8, as well as CD28.  Previously, we found that mutation of residues within the 
tyrosine binding pocket of the AP-1  subunit inhibited AP-1 binding to tyrosine-based 
trafficking motifs in a dominant negative manner (60).  It is possible that mutating 
residues within the AP-1 and 2  subunits that mediate binding to dileucine motifs (A263 
and L103 in 2) may also result in a dominant negative phenotype (26).  This may 
provide an alternative approach to assessing the involvement of AP-2 in CD8 and CD28 
downmodulation by Nef.  This approach may also be a less cytotoxic method of 
comparing the relative contribution of multiple adaptor proteins to dileucine-dependent 
downmodulation of proteins targeted by Nef. 
207 
 
 
5.3 -COP is a common element in multiple Nef-induced pathways 
We have also identified -COP as a common factor required for maximal downregulation 
and degradation of all major targets of Nef: MHC-I, CD4, and CD8 and CD28.  The 
evidence presented here is consistent with a model in which Nef utilizes AP-1 or AP-2 to 
direct cellular targets into endosomal compartments, where Nef subsequently recruits -
COP to route targets to the lysosomes for degradation as previously proposed for MHC-I 
and CD4.  However, the fact that the degradation of CD8 was far more dependent on -
COP expression than on AP-1 expression indicates that -COP may also directly target 
intracellular CD8 for degradation in Nef expressing cells without the need for additional 
adaptor proteins.   
 
The requirement for -COP in multiple Nef pathways may represent a good target for 
therapeutic inhibition of Nef.  As presented in chapter 2, RNAi knockout of -COP 
partially inhibits Nef-induced downmodulation of MHC-I, CD8, and CD28.   Whether 
this level of inhibition is sufficient to restore antigen presentation by MHC-I could be 
tested by assaying for restored CTL activity against HIV-infected T cells when -COP 
expression is knocked down.  A fluorescence-resonance energy transfer (FRET) system 
could be used to screen for chemical compounds that disrupt Nef/ -COP interactions.  
However, the fact that Nef may use either of two domains to interact with -COP may 
complicate the experimental setup, as the two types of interaction may not both orient 
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protein-conjugated fluorophores in sufficient proximity to induce FRET signal.  Another 
system amenable to high throughput screening methodology would be a mammalian two-
hybrid system similar to that described by Betzi et al (3).  This system involves co-
expressing a Nef-VP16 fusion protein and a -COP-GAL4 fusion protein, where an 
interaction of Nef and -COP would result in transcriptional activation of a GAL4-
luciferase reporter construct (3, 47).  However, this system may also be subject to the 
technical issues associated with the multiple conformations of the Nef- -COP interaction.  
Therefore, using the inhibition of Nef function as an experimental readout, as described 
in chapter 4, may be a more reliable approach to identifying Nef inhibitors.  
 
5.4 CD80 and CD86  
We were unable to confirm an effect of Nef on CD80 and CD86 surface expression in 
chapter 2.  This may be a result of differences in experimental systems.  Previous 
mechanistic studies of CD80/86 downmodulation by Nef were largely conducted on 
endogenously expressed molecules in the monocytic cell line U937.  Even when 
replicating the published culture conditions, we were able to observe only low levels of 
CD80 on the cell surface, and no CD86 at all, leading us to believe that our clone of the 
U937 line is inherently different from that used to report downmodulation of CD80 and 
CD86.  Additionally, the method of Nef delivery may influence the outcome.  Chaudhury 
et al. introduced Nef into U937 cells by transfection, while we used retroviral and 
adenoviral expression systems designed to express Nef at levels similar to that observed 
with HIV infection.  Other investigators that used adenovirus to introduce Nef expression 
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also failed to observe CD80/86 downmodulation in primary dendritic cells (35). This 
discrepancy is the reason that we utilized primary human macrophages and DCs as a 
highly relevant system for investigating Nef activity against these potential targets.  It is 
also possible that the culture conditions and activation state of primary cells might 
influence Nef activity.  Studies in immature and mature DCs reported no effect of Nef on 
CD80/86 expression (35, 46, 50), while those performed in mouse DCs or human 
monocytes did observe Nef-induced CD80/86 downmodulation (6, 37).  The differences 
in experimental systems are also reflected in the magnitude of Nef-induced MHC-I 
downmodulation observed.  Chaudhury et al. report 5-10-fold reduction of MHC-I using 
a pan-MHC-I antibody which recognizes HLA-A and –B allotypes, but also allotypes that 
are not affected by Nef.  In contrast, we consistently observed only a 2-3-fold Nef-
induced reduction in HLA-A2 expression in both monocytic cell lines and primary 
antigen presenting cells.  Because we were unable to detect an effect of Nef on CD80 or 
CD86 under established stimulation and culture conditions for primary macrophages and 
DCs in which Nef was active against other targets, we conclude that if Nef targets CD80 
and CD86 it must do so under specialized circumstance that we were unable to replicate.   
 
5.5 Nef has a small effect on CD1d 
CD1d targeting by HIV-1 appears to be a special case.  In chapter 2, we observed that not 
all Nef isolates retain the ability to downmodulated CD1d, yet one or more nef alleles are 
capable of doing so.  Therefore, this function may be rare, evolutionarily driven by some 
infrequently occurring host factor, or may be a feature of certain HIV-1 clades.  
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Furthermore, the magnitude of the affect of Nef on CD1d expression is quite small, 
around 1.5-fold on average.  This observation is consistent with published reports, yet 
previous work found that this minor reduction in CD1d surface expression had a 
functional impact on NKT cell activation in vitro (6, 7, 35).  However, it is unclear what 
impact CD1d downmodulation might have on HIV-1 pathogenesis in vivo.  While CD1d 
is able to present lipid antigens from bacterial and parasitic pathogens such as 
Sphingomonas, Borrelia burgdorferi, Leishmania, and Mycobacteria (1, 14, 27, 28, 38, 
52), there is no evidence that an HIV-associated lipid antigen exists. It is also unknown 
whether CD1d-restricted NKT cells have any antiviral activity against HIV or whether 
CD1d expression influences HIV pathogenesis.  CD1d
-/-
 transgenic mice have been 
widely used to elucidate the impact of CD1d on a variety of pathogens (13, 51).  While 
mice normally cannot be infected by HIV-1, the recent development of BLT (bone 
marrow, liver, thymus) mice with humanized immune systems allows mice to be used as 
a model organism for HIV studies (11, 39).  Another useful technology is the use of 
homing endonucleases to specifically knock out genes of interest in hematopoietic 
progenitor cells, as recently developed for knock out of the HIV co-receptor, CCR5 (19).  
Combining these two technologies to create BLT mice transplanted with fetal bone 
marrow in which CD1d has been knocked out, followed by HIV infection, may shed light 
on the role CD1d plays in HIV-1 pathogenesis.   
 
Reduced CD1d expression in HIV-infected cells has also been attributed to Vpu.  
Interestingly, it has been reported that deletion of either Nef or Vpu from HIV partially 
reduced CD1d downmodulation, with the greatest inhibition occurring when both HIV-1 
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accessory proteins were deleted.  This data supports the conclusion that both Nef and 
Vpu remove CD1d from the plasma membrane through distinct mechanisms.  There is 
precedence for such functional redundancy in HIV-1 proteins, as both Nef and Vpu also 
target CD4 for degradation.  An alternative hypothesis is that either Nef or Vpu may 
retain the ability to affect CD1d expression depending upon the virus strain.  This is 
supported by the observation in chapter 2 that some, but not all, HIV-1 Nef isolates have 
the ability to downmodulate CD1d.  This scenario resembles that of the restriction factor 
BST-2/tetherin, which inhibits virus release from the plasma membrane (40, 58).  
Tetherin is antagonized by HIV-1 Vpu, while this function is performed by Nef in 
primate lentiviruses which lack Vpu, such as SIV strains that infect sooty mangabey, 
macaque, and African green monkey species (49).  A comparison of the ability of Nef 
and Vpu proteins from a variety of human and primate lentiviruses, as well as additional 
HIV-1 isolates, to remove CD1d from the cell surface would be informative. 
 
5.6 CD28 recycling may be regulated by Nef 
We did confirm that HIV-1 Nef has a moderate effect on CD28 surface expression.  
CD28 appears to be a unique target of Nef, in that this function is conserved among a 
panel of Nef variants, but the effect is small relative to the other targets of Nef.  CD28 is 
internalized at a rate similar to that of CD4 in the presence of Nef, yet displays a much 
smaller change in steady state expression (53).  This discrepancy may be explained by the 
observation in chapter 2 that CD28 recycling is significantly increased in Nef-expressing 
cells.  SIV Nef downmodulates CD28 more potently than HIV-1 Nef; therefore CD28 
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downmodulation may be more important for SIV pathogenesis.  It would be interesting to 
assess the impact of SIV Nef on CD28 recycling; presumably CD28 would be recycled to 
a lesser extent in the presence of SIV Nef than HIV-1 Nef.  It is also possible that a 
physiologically relevant set of conditions exists which would result in less recycling of 
CD28 and more downmodulation of CD28 by HIV-1 Nef.  
 
An important remaining question is the functional importance of Nef-induced CD28 
downmodulation.  CD28 is an important co-stimulatory molecule for T lymphocyte 
activation; downmodulation of CD28 could conceivably regulate the activation state of 
HIV-infected T cells.  Since all Nef domains known to be important for CD28 
downmodulation are also required for either MHC-I or CD4 downmodulation, it is not 
possible to study the pathogenesis of HIV constructs in which Nef has been mutated in 
such a way that only CD28 downmodulation is affected.  Until a Nef mutation is 
discovered which genetically separates CD28 downmodulation from other Nef functions, 
mutational analysis of CD28 may be more informative.  It is not currently known what 
residues within CD28 participate in an association with Nef and/or cellular adaptor 
proteins.  Identification of mutations that render CD28 insensitive to Nef would further 
illuminate the mechanisms by which Nef interacts with and affects cellular targets.  
Furthermore, it might be possible to “knock-in” a Nef-insensitive CD28 into an animal 
model in order to assess the importance of this Nef function in HIV replication and 
disease progression.   
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5.7 The role of Nef-induced CD8 downmodulation  
We consistently observed that multiple Nef variants induced a robust decrease in CD8 
surface expression in the presence of multiple Nef variants, yet it is not clear in what 
context Nef encounters CD8.  Downmodulation of CD8, the T cell receptor co-receptor, 
would prevent activation of CTLs, perhaps providing a second mechanism by which 
HIV-infected cells avoid CTL lysis.  However, CD8 is not expressed in cell types that are 
classically infected by HIV.  Reports of CD8-tropic HIV strains do exist, which provide a 
potential scenario for Nef coming into contact with CD8 (17, 18, 33, 44, 48, 57).  While 
this phenomenon may in fact occur, the relatively small body of evidence in support of 
this may suggest that this occurrence is rare, arguing against a strong contribution to HIV 
evolution.   
 
Another plausible scenario is the transfer of Nef through cell-cell contacts such as 
virological synapses or nanotubules.  This has already been reported to occur between 
APCs and B cells, resulting in disregulation of the humoral response without direct 
infection of B cells by HIV (45).  It is conceivable that this could similarly occur when 
CTLs contact an infected target.  Nef would be transmitted through cellular contacts and 
then downmodulate CD8 locally to prevent activation of an HIV-specific CTL.  
Preliminary attempts to demonstrate transfer of a Nef-GFP fusion protein from THP-1 
monocytic cells to SupT1 T cells were inconclusive, as the GFP protein alone was 
observed to transfer to the bystander cells (data not shown).  We also examined whether 
Nef protected primary human macrophages from lysis by non-autologous CTLs.  Again, 
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initial studies were not promising (data not shown).  However, the experiments were 
performed with an adenoviral system for expressing Nef and it is possible that other HIV 
proteins may mediate Nef transfer. 
 
There is yet another possible scenario in which HIV Nef could encounter CD8.  Usually, 
T lymphocytes are either CD4+ or CD8+, however a small population of CD4+CD8+ T 
lymphocytes does exist in peripheral blood (4, 15, 41, 42, 64).  There is evidence that 
these cells may be a subset of CD8+ T cells that upregulate CD4 in response to activation 
stimuli (15, 28, 29, 54, 58. Importantly, these cells express the CD8 heterodimer, and 
thus a CD8 molecule which would be susceptible to Nef (41, 55).  This subset of T cells 
is small, generally less than 5% of total circulating lymphocyte population.  The 
frequency of these CD4+CD8+ double positive cells has been reported to increase in 
response to infection with a number of viruses, including HIV (22, 31, 34).  Additionally, 
these cells are susceptible to infection by HIV (2, 7, 21, 22, 30, 61, 63).  While the role of 
CD4+CD8+ double positive cells is not entirely clear, they are known to exhibit antigen-
dependant IFN-  and IL-2 secretion and cytolytic activity and are enriched for HIV-
specific responses in chronically infected patients (20, 41, 56, 62).  Therefore, 
CD4+CD8+ T lymphocytes are an infectable target cell, the inhibition of which would be 
beneficial to HIV (15, 29, 30, 55, 61).  Indeed, when we infected peripheral blood 
mononuclear cells with HIV +/- Nef, we observed a marked reduction in the CD4+CD8- 
single positive cells and CD4+CD8+ double positive cells which expressed HIV-Gag, 
and a substantial population of CD4-CD8- cells which stained positive for Gag, 
indicating that both CD4 and CD8 were downmodulated by Nef.   
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Once again, CD8 downmodulation by Nef is not genetically separable from other 
functions of Nef.  This means that we cannot create a mutated HIV construct lacking only 
the ability to downmodulate CD8 and assess this virus for pathogenic defects.  However, 
studying the impact of Nef on CD4+CD8+ T lymphocyte function in vitro may shed light 
on the potential benefit of CD8 downmodulation to the virus.  Such experiments are 
complicated by the fact that once these cells express Nef, they lose their identity as CD4+ 
or CD8+, as these molecules are removed from the cell surface.  Therefore, sorting 
strategies will be important.  Positive selection of CD8+ lymphocytes would result in a 
mixed population of CD8 single-positive and CD4, CD8 double-positive cells.  We 
would then infect with population with HIV constructs, +/- Nef and pseudotyped with a 
natural HIV envelope, such that only the CD4-expressing cells could be infected.  Thus, 
the CD4-CD8- HIV Gag-expressing cells would have originated from the double-positive 
T cells, and we could test these cells for functional responses.  For example, if we 
obtained these cells from a blood donor with previous exposure to human 
cytomegalovirus (hCMV), we could examine whether Nef inhibits the ability of these 
cells to bind CMV tetramers, or four fluorophore-labeled peptide-loaded MHC-I 
complexes.  We could also co-incubate the primary cells with target cells loaded with 
CMV peptide.  We could then use multi-parameter flow cytometry assess the ability of 
the primary T cells to upregulate cytokine expression or display cytotoxic potential, as 
apparent by CD107a/Lamp1 expression at the plasma membrane.  A cleaner way to do 
this would be to positively select for CD8+ cells, followed by CD4 positive selection in 
order to isolate only the CD4+CD8+ T lymphocytes.  This may be fraught with technical 
216 
 
problems, as this population is quite small.  If we were to succeed in sorting this 
population, we would perform the experiments described for the CD8+ mixed population.  
These experiments would help elucidate the impact of Nef on CD4+CD8+ T cell activity, 
but would not provide evidence that Nef gains access to these cells in vivo. 
 
In order to explore the ability of Nef to downmodulate CD8 in vivo, we could obtain 
lymphocytes from SIV-infected primates.  Again, CD4+CD8+ T lymphocytes lose their 
identity as such if they express Nef.  Therefore, we could sort lymphocytes into CD4+, 
CD8+, and double-negative populations and use qPCR methods to detect Nef and CD8  
mRNA in the absence of CD8 protein expression.  These same methods could also be 
applied to lymphocytes acquired from HIV-infected human donors.  This would provide 
direct evidence that Nef removes CD8 from the surface of lymphocytes in vivo. 
 
5.8 Nef inhibits antigen presentation in an ARF-1-dependant manner 
We have also provided additional detail of the mechanism by which Nef affects MHC-I 
expression and addressed a controversy within the field.  In chapter 3, we observed a 
requirement for ARF-1 in Nef-induced MHC-I downmodulation, while we found ARF-6 
to be dispensable for this function.  We observed that a constitutively GTP-bound mutant 
of ARF-1 (ARF Q71L) reduced the effects of Nef on MHC-I in human T cell lines and in 
primary human T lymphocytes.  The analogous ARF-6 mutant (ARF-6 Q67L) did not 
inhibit downmodulation of MHC-I HLA-A and –B allotypes by Nef in human T cell 
lines, regardless of PTEN expression levels, as well as in primary human T lymphocytes.  
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RNAi knockdown of ARF-6 expression also had no effect on MHC-I downmodulation by 
Nef.  An ARF-1 inhibitor prevented Nef from recruiting AP-1 to the cytoplasmic tail of 
HLA-A2, while the dominant active ARF-1 mutant stabilized the Nef-AP-1-MHC-I 
complex.  This data supports a model in which Nef recruits AP-1 to the MHC-I 
cytoplasmic domain in an ARF-1-dependent manner to prevent forward transport of 
MHC-I.  Experiments using shRNA to knock down ARF-1 expression in T cells are 
ongoing in order to confirm a requirement for this molecule. However, Golgi-associated 
ARFs may be capable of substituting for one another, and ARF-1 knockdown has been 
shown to have no effect on membrane trafficking unless co-depleted with other ARF 
isoforms (59).  Therefore, it would be unsurprising if we were unable to demonstrate a 
requirement for ARF-1 in Nef-induced MHC-I downmodulation with this experimental 
strategy. 
 
5.9 Methods for the identification of a pharmacologic inhibitor of Nef 
Understanding the specific mechanisms through which Nef impairs the host immune 
response may help direct future efforts to design anti-HIV drugs.  An alternative 
approach to developing pharmacologic agents against Nef is to screen libraries of drug-
like small molecules for Nef inhibitors.  In chapter 4, we have presented preliminary 
results from a screen of over 100,000 chemical compounds from which we have 
identified a pool of 33 potential Nef inhibitors.  The next step is to test the efficacy of 
each of these active compounds over a range of concentrations.  Once we have identified 
potent inhibitory molecules, we will perform cluster analysis in order to detect structural 
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similarities.  This structure-activity relationship analysis will allow us to determine key 
chemical moieties that likely participate in Nef inhibition. Using this information, we will 
obtain structurally related analogs and test these for improved activity.    
 
Our most promising inhibitory compounds will be subjected to rigorous follow up 
testing.  We will first confirm that the inhibitor similarly disrupts Nef-induced MHC-I 
downmodulation in primary human T lymphocytes, as well as in other HIV targets, such 
as macrophages and DCs, without significant cellular toxicity.   Importantly, we will 
assess the functional impact of a Nef inhibitor in protecting HIV-infected PBMCs from 
anti-HIV CTLs in co-culture assays (8).    
 
The functional impact of a Nef inhibitor on HIV pathogenesis is of primary importance.  
However, it will also be important to elucidate the molecular mechanism of Nef 
inhibition.  First, we will use crystallography or NMR analysis to determine whether the 
inhibitor directly binds to Nef, and where, as well as how this affects the conformation of 
Nef.  We will also assess the effect of the inhibitor on Nef protein stability and 
subcellular localization.  The ability of Nef to physically associate with cellular binding 
partners, such as MHC-I and clathrin-associated adaptor proteins, in the presence of the 
inhibitor will also be an important line of investigation.  These questions can be answered 
with immunoprecipitation experiments like those conducted in chapters 2 and 3.    
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While we are primarily interested in compounds that inhibit downmodulation of MHC-I 
by Nef, it is also interesting to determine whether other Nef functions are also inhibited.  
A compound that interferes with the effects of Nef on intracellular trafficking may also 
prevent downmodulation of other Nef targets such as CD4, CD28, and CD8.  
Furthermore, an inhibitor that had profound effects on Nef stability, subcellular 
localization, or conformation might also prevent Nef-induced kinase activation or 
enhanced HIV infectivity.  Kinase activation can be detected with phospho-specific 
antibodies.  Effects on viral infectivity can be measured by producing HIV +/- Nef in T 
cell lines or primary T lymphocytes, and determining the relative efficiency with which 
equal titers of the viruses, as determined by p24 ELISA, infect a second round of target 
cells.  If a Nef inhibitor does impact this poorly understood Nef function, it would be 
interesting to determine whether the inhibitor is effective when delivered to producer 
cells or target cells.  A compound which inhibits multiple Nef functions might have the 
greatest impact on HIV pathogenesis. 
 
While a Nef inhibitor would be a powerful laboratory tool for studying Nef function, our 
long term goals are be to develop such compounds for therapeutic use.  Early steps will 
involve testing the efficacy of a Nef inhibitor in animal models such as humanized mice 
and non-human primates.  Important parameters to measure will include the time to AIDS 
progression, as well as virus titers and CD4+ T cell counts.  It will be important to assess 
the effects of a Nef inhibitor on disease progression in animals with an established 
infection, as this would resemble the most common clinical scenario.  It is also interesting 
to hypothesize that treatment with a Nef inhibitor as a prophylactic measure concurrent 
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with exposure, or very early in HIV infection, might enhance the ability of the immune 
system to recognize and target HIV-infected cells before the virus can fully establish 
long-lived reservoirs.  Therefore, it will be essential to measure not only HIV replication 
and disease progression in inhibitor-treated animals, but immune cell function as well.  
Adaptive immune responses can be measured by HIV-tetramer staining, IFN-  ELISpot, 
and intracellular cytokine staining.  Contingent upon success in animal trials, we would 
then proceed to human clinical trials with the goal of bringing a Nef-targeting drug to 
market. 
 
5.10 Concluding remarks 
The work presented in this dissertation advances our understanding of Nef, a protein 
required for maximal HIV-1 pathogenesis.  The identification of which cellular proteins 
are targeted by Nef will help direct future study of how Nef influences host immune 
responses to HIV.  Additional work is needed to determine how Nef’s functions 
contribute to HIV-1 persistence and disease progression.  In addition to a greater 
mechanistic understanding of Nef, this work represents preliminary efforts in developing 
chemical inhibitors of Nef for pharmaceutical intervention in HIV-1 pathogenesis.  
Furthermore, understanding how modulation of host proteins by Nef affects HIV-specific 
immune responses will expand the current understanding of host immune responses to 
intracellular pathogens. 
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